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Virtual colonoscopy (VC) is a minimally invasive means for identifying colorectal
polyps and colorectal lesions by insufflating a patient’s bowel, applying contrast agent via
rectal catheter, and performing multi-detector computed tomography (MDCT) scans. The
technique is recommended for colonic health screening by the American Cancer Society
but not funded by the Centers for Medicare and Medicaid Services (CMS) partially because
of potential risks from radiation exposure. To date, no in‐vivo organ dose measurements
have been performed for MDCT scans; thus, the accuracy of any current dose estimates is
currently unknown.
In this study, two TLDs were affixed to the inner lumen of standard rectal catheters
used in VC, and in-vivo rectal dose measurements were obtained within 6 VC patients. In
order to calculate rectal dose, TLD-100 powder response was characterized at diagnostic
doses such that appropriate correction factors could be determined for VC. A third-order
polynomial regression with a goodness of fit factor of R2=0.992 was constructed from this
data.
Rectal dose measurements were acquired with TLDs during simulated VC within a
modified anthropomorphic phantom configured to represent three sizes of patients
undergoing VC. The measured rectal doses decreased in an exponential manner with
increasing phantom effective diameter, with R2=0.993 for the exponential regression model
and a maximum percent coefficient of variation (%CoV) of 4.33%. In-vivo measurements
yielded rectal doses ranged from that decreased exponentially with increasing patient
iii

effective diameter, in a manner that was also favorably predicted by the size specific dose
estimate (SSDE) model for all VC patients that were of similar age, body composition, and
TLD placement. The measured rectal dose within a younger patient was favorably
predicted by the anthropomorphic phantom dose regression model due to similarities in the
percentages of highly attenuating material at the respective measurement locations and in
the placement of the TLDs. The in-vivo TLD response did not increase in %CoV with
decreasing dose, and the largest %CoV was 10.0%.
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CHAPTER 1.0: INTRODUCTION

1.1 Virtual Colonoscopy (VC)

1.1.1 VC Background
According to the Agency for Healthcare Research and Quality (AHRQ), more than
80 million Americans at average risk for colorectal cancer (CRC) should be screened, but
only half have done so by any means (1). As a result, CRC remains the second‐leading
cause of cancer deaths in the United States. Although optical colonoscopy (OC) is
considered to be the gold standard for screening, the number of qualified endoscopists is
limited and unable to meet the demands of screening, diagnosis, treatment, and
surveillance; thus, additional screening options are needed (2).
Virtual colonoscopy (VC) (also known as CT colonography (CTC)) was first
described in 1994 by Dr. David Vining as a minimally invasive means for identifying
colorectal polyps and colorectal lesions (3). The majority of patients undergoing OC could
avoid the procedure’s inherent risks of bowel injury and sedation by undergoing VC instead.
The procedure consists of #1) bowel cleansing with cathartic agents, #2) gas insufflation
with carbon dioxide, #3) computed tomography (CT) scanning of the abdomen‐pelvis in
supine and prone positions, and #4) image analysis for identification of lesions.
VC is most appropriate for the following populations: asymptomatic patients at
average-risk who are 50 years of age or younger, patients with previously known polyps or
neoplasms that have not yet been resected (in some clinical contexts), symptomatic
patients requiring diagnosis (in some clinical contexts), patients having undergone
incomplete endoscopy and requiring additional structural information, patients with
colorectal lesions deemed indeterminate by OC, and patients at high risk for OC.
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Contraindications for the use of VC typically include: patients with chronic inflammatory
bowel disease, patients at high risk for colorectal polyps or colorectal lesions, patients (in
appropriate clinical context) with various colorectal pathologies (colitis, diverticulitis, recent
surgery or perforation, or high-grade small bowel obstructions), patients requiring
evaluation for disease of the anal canal, patients with a prior history of anaphylactic
reactions to contrast agents, and patients who are pregnant (4).
VC has been proven to be an effective first‐line screening test in the average‐risk
population (5). As a result, the American Cancer Society now includes VC in its screening
guidelines (6). However, the Centers for Medicare and Medicaid Services (CMS)
concluded in 2009 that the evidence was insufficient with respect to VC’s performance in
the Medicare population and its potential harms, namely radiation risks and management of
extracolonic findings; therefore, CMS denied coverage for VC until these issues can be
resolved (7).

1.1.2 VC Procedure at MD Anderson Cancer Center
Thorough bowel cleansing and optimal distention of the colon are critical for
obtaining accurate VC results, although both are difficult to achieve reliably. As a result,
patients often undergo CT scanning in supine and prone positions to evaluate segments of
the colon that may be collapsed during one of the scans, as well as to shift residual feces
and water that may mask or simulate colonic lesions. MD Anderson VC protocols dictate
that all patients receive both prone and supine CT scans.
Stool tagging involves administering an iodine contrast agent to the colon to change
the x‐ray attenuation of residual feces and water to aid in identification of underlying polyps
(Figure 1-1). The contrast enemas are prepared by mixing 120 cc of MD‐Gastroview®
(Mallinckrodt Imaging Solutions, Hazelwood, MO) with 1000 cc of warm tap water in a
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standard double‐contrast enema bag. Patients are excluded from VC procedures if they
report a prior history of a contrast reaction to iodinated‐contrast agents.
The following outlines the steps of the VC procedure at MD Anderson Cancer
Center (after initial screening qualifies a patient for this procedure):
1. The patient undergoes bowel cleansing prior to presenting at the clinic in a
standard fashion with the oral administration of a polyethylene glycol solution.
2. The patient is placed in a supine position on a 64 channel CT scanner table
(typically the “CT9” scanner).
3. The rectal catheter assembly (Figure 1-2) is lubricated with water-soluble jelly
and inserted into the patient’s rectum. After insertion, a retention balloon on the end of the
rectal catheter is inflated to maintain a seal against the anus and prevent rectal catheter
and contrast expulsion (Figure 1-3).

Figure 1-1. Trans-axial view of VC image. Stool tagging aids detection of polyps under water.
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Figure 1-2. Rectal catheter and enema bag assembly.

Rectal Wall
Colon

Rectal Catheter Tip
Retention Balloon

Figure 1-3. Processed sagittal 3D image generated during a VC exam. The rectal catheter is
shown within the patient’s rectum (with the retention balloon inflated).
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Figure 1-4. Administration of stool‐tagging enema

4. The patient is placed in a left‐lateral decubitus position, and the enema solution
is administered under gravity pressure (Figure 1-4). The patient is then rolled to the right to
allow the enema to flow into the ascending colon, and the patient is returned to a
supine position. This maneuver only takes a few minutes to perform.
5. The rectal enema bag is lowered to a level below the patient to drain excess fluid
from the rectum.
6. The enema tubing is clamped.
7. Gas insufflation is performed using a CO2 insufflator connected to the air
insufflation port of the double‐contrast rectal catheter. At least 1.5 liters of CO2 gas
delivered at a pressure of 25 mm Hg is administered prior to the start of the supine CT
scan. If patients experience excessive discomfort at the 25 mm Hg pressure setting, the
pressure is often reduced to 20 mm Hg.
8. The patient is then placed in a supine position, and lateral and anterior-posterior
(AP) survey (or “scout”) images are acquired by the CT technologist. After the technologist
5

verifies patient positioning and specifies the scan length from these scout images, the
patient undergoes a supine CT scan according to the standard MD Anderson Cancer
Center CT technique described in Table 1-1. Following the supine scan, the patient is
rolled to the prone position, the retention balloon is deflated, and the process is repeated by
acquiring two CT scouts and a prone CT scan (using the same imaging technique).

Table 1-1. MD Anderson CT protocol for VC.
Series Description Scan Type
1

SCOUT
Supine

AP and
Lateral

2

Supine

Full Helical

3

SCOUT
Prone

AP and
Lateral

4

Prone

Full Helical

Rotation
Time (s)

0.5

0.5

Area
Mid-Sternum
to Trochanter
Diaphram to
Symphysis
Mid-Sternum
to Trochanter
Diaphram to
Symphysis

Image
Thickness
(mm)

Image
Table Speed
Pitch Interval kVp mA Delay Reconstruction
(mm/cycle)
(mm)
120

1.25

39.37

0.984

0.8

120 100
120

1.25

39.37

0.984

0.8

10
0

Standard

0

Standard

10

120 100

9. Upon completion of both CT scans, the rectal catheter is removed.
10. Each VC examination is processed and interpreted by a board certified
radiologist using computer software that is routinely used at MD Anderson Cancer Center.
Figures 1-1 and 1-3 demonstrate examples of colonic images that result from VC.

1.1.3 VC Computed Tomography (CT) Radiation Dose
One of the perceived harms of VC is the risk of radiation‐induced cancer. The
radiation dose received by patients while undergoing CT scans of any anatomy (not just
VC) has been the subject of recent high-profile media activity (8-12). A standard CT scan
of the abdomen and pelvis delivers weighted sum of organ doses (called an effective dose)
of 10‐15 milliSievert (mSv) (13). This patient risk metric is based on the linear no threshold
risk model developed from research findings from atomic bomb survivors receiving total
body mixed radiation (14). Radiation dose contributions from CT scout images are typically
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considered to be negligible compared with the dose administered by the actual CT scans
(15).
As a comparison to the dose a patient receives in CT, the average American
receives about 3 mSv of annual ubiquitous background radiation (16). Phantom
measurement estimates suggest that the average patient undergoing a VC scan with the
protocols used by MD Anderson receives an effective dose of 7 mSv and has an absolute
increased risk of developing colon cancer by 1 in 2000 (17). In an effort to mitigate
radiation risks, several recent VC studies have used low‐dose CT techniques yielding
effective doses as low as 0.8‐2.4 mSv (18, 19). However, each of these estimates of
effective dose are based on CT dose index (CTDI) values that are determined from
homogeneous acrylic phantom dose measurements and mathematical geometric models of
a standard reference person that do not represent the heterogeneous tissues or sizes of
patients that undergo VC.
Effective dose is a generic indicator relating to the risk of health detriment to a
reference patient. It is more appropriate to base risk estimates on the absorbed doses to
the organs receiving the bulk of the radiation when only a limited number of organs are
irradiated (20), as is the case in VC where only the abdomen and pelvis are irradiated. In
these circumstances, effective dose is diluted by the inclusion of many organs that receive
little or no radiation dose. A small effective dose, therefore, does not necessarily indicate a
low risk from examinations such as VC. A better alternative for quantification of risk
assessment to an individual is provided by organ dose estimates or measurements specific
to that individual (20), and such is the method preferred by epidemiologists focused on long
term risk assessment.
To date, no in‐vivo organ dose measurements have been performed for VC scans;
thus, the accuracy of any current dose estimates is currently unknown. Although MD
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Anderson VC scanning protocol suggests a 7 mSv average patient effective dose using
current methods, many uncertainties exist regarding the risk experienced by MD Anderson
patients as a result of undergoing VC exams. Therefore, the need exists to utilize available
radiation dose measurement tools to better assess the risk to a patient undergoing VC. In
spite of these quoted risk estimates, however, Brenner recently suggested that the potential
benefits of VC outweigh its potential radiation risks (17).

1.2 Thermoluminescent Dosimeters (TLDs)

1.2.1 TLD Overview
Solid state dosimeters are those solid materials that provide at least one
measurable response to radiation exposure and energy deposition within its active material
(21). The use of solid state dosimeters was first published in 1895 (22), and these
materials are believed to be the first detectors ever used to evaluate the presence of
ionizing radiation (21). Today, the most common solid state dosimeters are
thermoluminescent dosimeters (TLDs)—which are classified as solid state dosimeters that
emit a light signal when appropriately heated that is proportional to the absorbed radiation
dose within the material. Optically stimulated luminescent dosimeters (OSLDs), which emit
a light signal proportional to absorbed dose when exposed to a light of specific wavelength,
are quickly rising in popularity (23).
Over the years of development that have taken place since the introduction of
CaSO4:Mn as a thermoluminescent phosphor in 1895 (22), many TLD materials have been
introduced into the marketplace and are used today in medical applications. Lithium
fluoride (LiF), first introduced as a TLD material in 1950 by Daniels (24), was revitalized in
1961 by Cameron, et al (25) and has grown in popularity to be the most widely used TLD
material (26) because of its advantages over other TLD materials; including: high8

temperature thermoluminescence, inert qualities, insolubility, tissue equivalence, little
change in response across a wide range of doses and energies, considerable detection
capability across broad energy and dose ranges, low fading, and versatility for several
types of radiation (21, 25-29). The Harshaw Chemical Company (Cleveland, Ohio) worked
with Cameron to develop “TLD-100” (21, 27), which is the most commercially used variety
of LiF (LiF:Mg,Ti) that uses the naturally occurring isotope of Li (7.5% Li-6, 92.5% Li-7) and
includes doping with Magnesium and Titanium (26) to act as activators of the material’s
thermoluminesence (27). Common variations of this material are “TLD-600” (which uses an
enriched form of Li-6 (95.6%) to increase sensitivity to neutrons) and “TLD-700” (which
uses less than 0.1% of Li-6 such that the material becomes insensitive to neutrons) (26).
As available commercially today, TLD-100 dosimeters provide many advantages to
users; most of which are for application in personal and radiotherapeutic dosimetry. They
can be manufactured as very small chips or ground into powder to conform to the geometry
of its container. They have a very wide useful range for photon dose ranging from 50 µGy1000 Gy (26). They demonstrate little fading (5-10% per year) (21, 26, 27). They are dose
rate independent (28), can provide very good precision (as low as 0.22%(30)) and have
good accuracy (below 3% with a precision of <1% (26)) with sufficient effort and cost.
Finally, the photon effective atomic number (ZTLD-100=8.2) is very close to that of tissue
(ZTissue=7.4); which makes this material substantially tissue equivalent for most applications
(31).
In spite of these advantages, proper TLD-100 utilization to obtain optimal results
requires consideration of some inherent difficulties and disadvantages that can often be
reduced with careful execution. The shortcoming requiring the most consideration is the
lack of response uniformity between TLD-100 batches, and even within thermoluminescent
material samples taken from the same batch (26). These non-uniformities can be
accounted for by determining sensitivity corrections (in units of absorbed dose per charge9

in-air per mass) for each specific batch by using sensitivity correction standards with each
reading, by monitoring for drifts in TLD response throughout a reading session via controls,
by using well-mixed and characterized TLD-100 powder as opposed to chips, and/or by
using more than one dosimeter chip per measurement point. Other difficulties intrinsic to
quality TLD measurements, along with appropriate measures to minimize the
accompanying negative impacts, are listed in Table 1-2 (26).
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Table 1-2: Potentially negative aspects of TLD-100 and potential prophylactic actions

1

Negative aspects of TLD-100
Little uniformity between and within TLD100 batches

2

Over-response of TLD at low energies
(<100 keV) (21, 26, 28)

3

Over-response of TLD at high doses
(>1000 Gy)

4

Spurious thermoluminescence and/or
tribothermoluminescence caused by
surface trapping states creating
background light signals that impact TLD
readout (21, 26, 28)
Significantly decreased TLD precision if
adequate controls are not taken (often at
10% or more (32))

5

6
7
8

Direction of radiation field affecting TLD
response
TLD response may change with exposure
to visible or ultraviolet light
Heating rate or overall reader instability
during read-out affecting TLD response

9

Size of TL detector may influence
readings
10 Thermal history affecting energy
response of TLD

11 TLD-100 toxicity if ingested

12 Time and cost associated with TLD-100
readout
11

Corrective Actions
Determine sensitivity corrections for each
specific batch at each reading, use
controls to monitor for drifts in TLD reader
response, use well-mixed and
characterized TLD-100 powder (versus
chips), use >1 chip per measurement point
Determine the energy correction
coefficient in these low energy ranges, use
a more tissue-equivalent TLD such as
lithium borate (Li2B4O7)
Understand and adhere to the dose range
limitations of the TLD material, use a TLD
material that can appropriately respond
such as Li2B4O7:Mn
Using nitrogen gas (versus ambient air) in
the reader and use a uniform TLD powder
size

Use carefully controlled conditions, a highquality TLD reader, an experienced
technician, determine sensitivity
corrections with each reading session
using standard TLDs, use additional
control TLDs when shipping, and monitor
TLD response in a reading session with
control TLDs
Use symmetrically sized chips or powders
Keep all TLDs in a light- and temperaturesafe environment when not in use
Use carefully controlled conditions, a highquality TLD reader, an experienced
technician, and monitor TLD response in a
reading session with control TLDs
Use consistently sized dosimeters for
every reading
Anneal the TLD material, do not store the
TLDs longer than 1 week after annealing,
maintain a consistent temperature cycle
for an entire batch, minimize or eliminate
the re-use of TLD material
Appropriately train all personnel regarding
the risks and proper handling of TLD-100
material
Budget time and resources appropriately
when using TLD-100 for measurements

1.2.2 TLD Physics

Figure 1-5. Energy band diagram modified from (31) demonstrating measureable light
production as a result of exposure to radiation. In an unexcited state, electron-hole pairs
exist within the valence band of the crystal matrix. When excited by ionizing radiation,
electrons are launched into the conduction band (step 1). In the conduction energy band,
electrons may migrate in the crystal lattice (step 2) and positively-charged holes migrate
along the valance band (step 2’). Imperfections within the matrix create electron and hole
trap levels (steps 3 and 3’, respectfully). The excited TL material remains in a metastable
state until sufficient heat energy is applied to the system to release these entities back into
the conduction and valence bands, respectfully (steps 4 and 4’). These electrons and holes
recombine at luminescence centers within the crystal lattice (steps 5 and 5’) emitting light.

The theory and physics of thermoluminescence is a very complex subject with
intricacies that extend far beyond the scope of this work. On a basic level, however, the
theory of thermoluminescence can be explained with the assistance of Figure 1-5, which is
an energy band diagram that demonstrates the production of measureable light (visible or
ultraviolet) as a result of exposure to radiation. In a normal state unexcited by ionizing
radiation or temperature, electron-hole pairs exist within the valence band of the
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thermoluminescent crystal matrix. In the presence of ionizing radiation, electrons are freed
and move to the conduction band as demonstrated in step 1 of Figure 1-5. In the
conduction energy band, electrons may migrate through the crystal lattice as demonstrated
in step 2. Accordingly, positively-charged holes may also migrate along the valance band
as demonstrated in step 2’. Thermoluminescent materials rely on imperfections within the
matrix to create energy trap levels that may encumber both free electrons and holes, as
demonstrated in steps 3 and 3’ (31). Thus, after excitation the TL material remains in a
metastable state with both the holes and electrons unable to move and recombine in a deexcitation process. The doping of LiF with Mg (300 ppm) in TLD-100 accomplishes the
creation of such electron traps (26). These electron and hole traps are thermally sensitive,
and electrons and holes remain trapped until sufficient energy is applied to the system (in
the form of heat) to release these entities back into the conduction and valence bands,
respectively. The specific amount of heat required depends on the depth of the traps and
the temperature of the TLD material (31). Once released, as demonstrated in steps 4 and
4’, these electrons and holes may recombine at luminescence centers within the crystal
lattice as shown in steps 5 and 5’ and emit measurable light proportional to the excitation
received by ionizing radiation. The doping of LiF with Ti (15 ppm) in TLD-100 accomplishes
the generation of such luminescence centers (26).
The radiation dose limits of detection are a function of the TLD-100 material, the
material set-up and history, irradiation conditions, and TLD readout capabilities. Many of
these factors were discussed above and TLD readout specifics will be discussed below.
However, with regard to limitations of the TLD-100 material specifically, the upper radiation
dose limit is determined by saturation of available traps by electrons, irradiation history, and
annealing (21, 26, 31). This phenomenon is observed when TLD readings overestimate the
radiation dose due to increased sensitivity, and is known as supralinearity (because the
apparent dose response from the TLD material is no longer linear with the actual dose).
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The actual dose where this permanent damage to the material is observed is batch
dependent (for example, with slightly varying concentrations of Ti), but it is published to be
commonly pronounced at 1000 Gy (26) for TLD-100 material. The sensitivity, or linear dose
response region, of a batch of TLD-100 material can be increased (sensitized up to a factor
of five) or decreased with certain annealing techniques (26, 31, 33).
The lower-limit of the radiation dose detection capabilities of TLD-100 material vary
by batch (again, primarily based on batch composition), but is published to be 50 µGy (26).
Besides composition, the lower radiation dose limits of a batch of TLD-100 material is
(similarly to the upper radiation dose limits) observed as supralinearity (over-response). In
contrast to the upper radiation dose limit, though, this observed supralinearity is a function
of low temperature traps within the lattice (26), spurious signals caused by ambient air
being absorbed by the TLD-100 material during with the readout process (21), powder grain
size (26), and tribothermoluminescence (21) (defined below).
As a standard feature of a good TLD readout process, the composition variability is
overcome by thoroughly mixing the ground TLD powder of a batch and by characterizing
and quantifying the material to specific correction factors for every batch and every reading
session. Additionally, TLD materials are often preheated to 160°C for 10-20s (34) to
eliminate low temperature electron traps; and spurious signals are overcome by minimizing
TLD material exposure to air and by using nitrogen gas during TLD readout. Decreasing
powder grain size will decrease the relative dose response of TLD-100 material to radiation
(26) (which may lead to reduced supralinearity in the low dose region), therefore the grain
size of a batch of TLD powder should be as uniform as possible—which emphasizes the
need for careful quality control in the manufacturing of TLD-100 materials and distribution of
these powders into capsules.
Tribothermoluminescence is defined as unwanted spurious background light signals
that are related to the total surface area of the material in the form of friction (21, 26).
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These surface trapping state effects (along with ambient air gas absorption) can be partially
corrected by sufficient encapsulation of the dosimeter powder (21). Further, the influence
of tribothermoluminescence can be characterized by accomplishing TLD-100 radiation
dosimetry measurements with TLD-100 powder grains of various sizes (26). These
measures are rarely undertaken, however, as the majority of applications for TLD-100
dosimetry measurements are at cancer therapy energies and doses at which this effect is
not observed. These effects may, however, impact dose measurements obtained in low
energies and dose environments such as those encountered in diagnostic imaging and VC.
Additional measures may be required in TLD-100 dosimeter handling and in the
quantification of dose linearity and energy correction factors if using TLD-100 dosimetry in
such diagnostic applications (which can overrespond by as much as 40%) as opposed to
lithium borate (Li2B4O7:Mn), which has better tissue-equivalence properties under these
conditions (31).

1.2.3 TLD Readout Process
Although TLD-100 dosimeters can provide very precise and accurate radiation dose
measurements for a wide range of doses and energies, a proper TLD readout process
requires considerable attention to detail and substantial documentation. The mission of the
National Cancer Institute (NCI)-funded Radiologic Physics Center (RPC) at MD Anderson
Cancer (Houston, TX) is “to assure National Cancer Institute and the Cooperative Groups
that institutions participating in clinical trials deliver prescribed radiation doses that are
clinically comparable and consistent.” The RPC fulfills this mission through accurate and
consistent radiation measurement capabilities and by conducting quality assurance audits
of institutions. More specifically, the RPC’s TLD equipment, policies, and professionals
monitor the radiation dose delivered to patients in cancer therapy at sites participating in
NCI clinical trials worldwide. Thus, their TLD program is among the very best available and
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is designed to minimize and/or eliminate the potential opportunities for the TLD
uncertainties and reading errors mentioned above and to optimize measurement precision
and accuracy. They publish an overall uncertainty of 2.5% in their TLD measurement
process at radiation therapy dose and energy levels (including phantom set-up and beam
calibration) (35).
The TLD-100 material used by the RPC is grown as LiF crystals by Thermo
Scientific (Waltham, MA) and prepared for the RPC by Quantaflux, LLC (Dayton, OH).
Upon purchasing the material from Thermo Scientific, Quantaflux grinds and sifts the
crystals into a powder. Such grinding and thorough mixing is necessary to overcome both
the small inherent non-uniformities within a single LiF crystal and the non-uniformities
between the several LiF crystals contained in a TLD-100 batch sufficiently large to
accommodate the quantity of TLDs used by the RPC. Thus, appropriately prepared TLD100 powder will not have capsule-to-capsule variation in radiation response, as is the case
with TLD chips (31).
After mixing, Quantaflux loads specially-designed plastic TLD capsules (designed to
maintain a snug fit into the RPC’s large inventory of acrylic blocks and anthropomorphic
phantom inserts) to the RPC specifications (approximately 22 mg of powdered LiF per
aliquot). Upon receipt from Quantaflux, the RPC quantifies the fading, energy, and linearity
correction factors for the batch of TLD-100 material (more specific explanations of these
and other correction factors are provided below). Once the material’s radiation response
characteristics have been sufficiently quantified, they are sent (along with phantoms and
instructions) to those institutions enlisted by the NCI to conduct clinical trials.
After an institution has irradiated a TLD filled phantom as carefully instructed by the
RPC, that institution returns the block and paperwork to the RPC for analysis. When
received, analysis begins at the RPC by reading 3 “standards” TLDs (a 4 mm diameter by
15 mm length plastic capsule with a wall thickness of 1 mm containing a single aliquot of
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TLD-100 material) that have been irradiated on the Cobalt V2 machine at MD Anderson
Cancer Center. This irradiation is conducted at least 14 days prior to the reading of the
TLDs received by the institution being assessed (which are also read at least 14 days after
irradiation to stabilize the dose response within the TLD-100 material—thus reducing
potential time related variability (drift) in the dose measurements).
Irradiation of the standards TLDs is a carefully controlled process conducted by the
RPC that includes: inserting 3 TLDs into an acrylic block phantom similar to that sent to the
institutions for evaluation, positioning the TLD block on a jig attached at 80 cm source-tosurface distance (SSD) from the cobalt-60 source, and irradiating the block to 3 clicks
(4.45181 Gy as calibrated on 10/15/2005) in a 10 x 10 cm field. These standards (which
are from the same batch of TLD-100 material as those irradiated by the institution being
assessed) are used to establish the sensitivity correction factors used for the calculation of
dose to the irradiated TLDs.
Next, 3 “control” TLDs are read, which are also carefully irradiated in a controlled
process by the RPC by a different cobalt-60 source than that used to irradiate the standards
(MD Anderson’s “Cobalt C” machine). The two irradiation processes are similar, with the
primary differences being the fact that the control TLDs are irradiated on a moving carousel
attached to a jig and that the control TLDs are irradiated to 5 clicks (4.2924 Gy as calibrated
on 10/15/2005). Once the 3 standards and controls are read, the technician begins the
reading process on the measurement TLDs irradiated by an institution.
Every TLD is measured in a consistent manner to avoid uncertainties in the
readings. After the Harshaw TLD reader (ThermoFisher Scientific Corporation, Santa Fe,
NM) has warmed-up for approximately 20 minutes, an independently-certified mass of
approximately 20 mg is placed on the scale for calibration purposes. Next, a plastic block
fashioned to hold 3 TLD capsules is placed on the scale, the end of a TLD capsule that
does not contain the plug is cut and discarded, the TLD is placed in this acrylic block and
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on the scale for measurement, and the scale is again zeroed. The TLD-100 material is then
placed on the TLD reader planchette, the planchette is inserted back into the reader, and
the emptied capsule is returned to the block on the scale and the mass deficit of the
removed TLD material is recorded.
At the next full minute, the reading process is begun by pressing the “start” button
and typing the mass deficit measurement from the scale into the computer (thus
documenting the mass of the LiF powder being read). Once activated, the reader will
steadily heat the LiF to 318°C and will measure the integrated charge generated by the
stimulation of photomultiplier tubes as light is emitted from the TLD-100 material
(specifically in glow peaks IV and V (26)). This charge and mass are recorded on the
technician’s worksheet, and when the reader temperature has cooled to 110°C the
planchette is reopened and the read TLD-100 material is removed by vacuum. The
process of reading one TLD capsule should take a total of 2 minutes, and the TLD reading
process continues with the next TLD in a series. A typical TLD reading session begins with
3 standards being read, then 3 controls, then 6-8 sets of 3 measurement TLDs, then 2
controls, then 6-8 sets of 3 measurements, then 2 controls, then 6-8 sets of 3
measurements. The reading session ends with 3 controls and 3 standards being read; and
a typical reading session lasts approximately 3 hours and includes 6 standard TLDs, 10
control TLDs, and 54-72 measurement TLDs.
Once the charge and mass readings have been obtained for each of the TLDs, the
following correction factors are determined based on the properties of the TLD-100 batch
and the irradiation parameters: sensitivity (KS), fading (KF), linearity (KL), energy
dependence (KE), and f-factor (or absorbed dose to the medium as opposed to the
absorbed dose to the TLD material). Finally, the TLD dose is calculated by multiplying the
measured average charge per mass by all of the correction factors. As the effective atomic
mass of TLD-100 is similar to that of tissue, the estimated dose to tissue is easily calculated
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by applying an f-factor (if necessary). As standard protocol, the RPC provides their
radiation dose measurements to their customers as absorbed dose to muscle (with the ffactor already factored into the sensitivity correction factor).

1.2.4 TLD Correction Factors

1.2.4.1 Fading Correction Factor
The TLD fading correction factor accounts for the fact that some electrons will gain
sufficient energy at room temperature to escape from their traps, thus resulting in loss of
signal and potential uncertainties in dose measurements. For TLD-100 material, this value
is relatively small (5-10% per year) (21, 26, 27) and is most unpredictable within the first 14
days. Therefore, the RPC recommends performing TLD readout 14 or more days after
irradiation to reduce uncertainty. Per RPC protocols, TLD fading (KF) is calculated by (36):

KF = N

( a ⋅ e(

− b⋅ X )

+ c ⋅ e(

−d⋅X )

)

(1-1)

where N, a, b, c, d are values established when a TLD-100 batch is commissioned and X is
the number of days since the TLD material being read was irradiated.

1.2.4.2 Linearity Correction Factor
The TLD linearity correction factor corrects for TLD material response to dose, since
dose response is measured by the increase (or decrease) in the light per mass emitted
during readout as dose to the material increases (or decreases). For TLD-100 material, this
value is typically linear (with variations existing between batches) from approximately 200
mGy to 6 Gy (for the RPC’s B09 TLD-100 batch). Radiation dosimetry measurements
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performed for doses outside this range will require additional characterization to assess the
supralinearity characteristics of this batch and determine appropriate batch linearity
correction factors (KL) for the dose range being investigated. Per RPC protocols, KL is
calculated for doses within a commissioned dose range by (36):

KL =
m ⋅ d raw + b

(1-2)

where m and b are values established when a TLD-100 batch is commissioned and draw is
calculated from (36):

d raw= Q

mg

⋅ KS ⋅ KF

(1-3)

with Q being the integrated charge read by the TLD reader (in µC), mg being the mass of
the irradiated TLD-100 material (in mg), KS being the system sensitivity correction factor,
and KF being the fading correction factor.

1.2.4.3 Sensitivity Correction Factor
The TLD sensitivity correction factor (KS) is calculated by dividing the decaycorrected expected dose delivered to the standards by the cobalt machine by the product of
the average of the standard measurements, the fading correction factor for the standards
(which may be different from that of the TLDs being read), and the linearity correction for
the standards (using the decay-corrected expected dose as the raw dose value) as shown
by (36):
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d=
d cal ⋅ e
exp

KS =



⋅t
− ln(2)
T1 


2

(1-4)

d exp

(K F )Std ⋅ (K L )Std


 
⋅   Q
  mg  Std  Avg

( K L )Std =m ⋅ dexp + b

(1-5)

(1-6)

where dexp is the decay-corrected expected dose delivered to the standards TLDs by the
cobalt machine, dcal is the dose delivered by the cobalt source when it was calibrated, T1/2 is
the half-life of cobalt-60, t is the time elapsed between the calibration of the cobalt source
and the irradiation of the standard TLDs, (KF)Std is the fading correction factor for the
standard TLDs, (KL)Std is the linearity correction factor for the standard TLDs, and
((Q/mg)Std)Avg is the average of the six standard TLD measurements.

1.2.4.4 Energy Correction Factor
The TLD energy correction factor corrects for TL material over-response (compared
to tissue response) to the energy to which the TLD was irradiated, which can be as high as
40% in low energy (diagnostic ) applications (31) and as high as 6.5% at cancer therapy
energies (36). For TLD-100 material, this value is typically unity (with variations existing
between batches) from approximately 1 MV to 4 MV (for the RPC’s B09 TLD-100 batch as
determined at batch commissioning). Radiation dosimetry measurements performed for
energies outside this range require additional characterization to assess the energy
response characteristics of a specific TLD-100 batch for the energy range being
investigated.

1.2.4.5 f-Factor Utilization
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As standard protocol, the RPC provides their radiation dose measurements to their
customers as absorbed dose to muscle (with the appropriate f-factor already included in the
sensitivity correction factor). There are applications where it is necessary to determine an
additional factor to correct from dose to muscle to another medium reflecting the
environment in which a TLD was placed when irradiated (for example, in air or in an acrylic
phantom). In such situations, an additional f-factor (f) should be included in dose
calculations considering TLD irradiation environment by (26, 37):

 ( µen / ρ ) Environment 
f =

 ( µen / ρ ) Dosimeter 

(1-7)

where (µen/ρ)Environment is the mass absorption coefficient of the environment in which the
TLD was located (in cm2/mg), and (µen/ρ)Dosimeter is the mass absorption coefficient to which
the TLD dosimeter was calibrated (in cm2/mg). These mass absorption attenuation
coefficient values can often be obtained from data published by the National Institute of
Standards and Technology (NIST) (38).

1.2.5 TLD Dose Calculation
Finally, considering all of the correction factors presented above, the dose to a
medium can be calculated from TLD light output and mass measurements by (26, 31):

DMedium =

Q
⋅ KS ⋅ KL ⋅ KE ⋅ KF ⋅ f
mg
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(1-8)

where DMedium is the dose to a medium (in mGy), Q is the integrated charge measured from
the TLD light output of a TLD-100 sample during the reading process (in µC), mg is the
mass of the irradiated TLD-100 material (in mg), KS is the sensitivity correction factor (in
mGy*mg/µC), KL is the linearity correction factor (unitless), KE is the energy correction
factor (unitless), KF is the fading correction factor (unitless), and f is the f-factor correcting
for the medium in which the TLD was irradiated (unitless).

1.3 CT Radiation Dose Measurements

1.3.1 Background of CT Dose Measurements
Although the radiation dose received by patients while undergoing CT scans has
been the subject of recent high-profile media activity (8-12), the need to measure this entity
was realized in the very early days of computed tomography. Perry and Bridges were the
first to publish CT radiation exposure and dose measurements in 1973 using an ionization
chamber pressed in wax between a polymethyl methacrylate (PMMA) cylinder and a waterfilled soccer ball bladder taking point exposure measurements for single slice CT (39).
TLD-100 was first used to measure single slice CT exposure in 1974 (40). Among the first
to present a system for characterizing multi-slice CT dose was a group from the US Food
and Drug Administration (FDA) lead by Shope in 1981 when he introduced the concept of
CT Dose Index (CTDI) and the corresponding phantoms (41), which has evolved with
technological advances and continues to be the clinical standard for characterizing CT
scanner x-ray beam output.

1.3.2 CT Dose Index (CTDI)
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CTDI provides a convenient technique used to estimate the average absorbed dose
delivered from multiple contiguous CT irradiations (including scatter tail dose pile-up) by
subjecting the standard PMMA CTDI phantom to one axial scan; or (42):

CTDI =

1
N ⋅T

∞

∫ D( z )dz

(1-9)

−∞

where N is the number of data channels, T is the detector width sampled by each channel
(and the product N*T is therefore the total nominal x-ray beam width during the scan (37)),
and D(z) is the radiation dose profile along the z-axis (the axis parallel to the CT table).
Practically, this expression is simplified to an entity that can be realistically measured with a
commercially available 100 mm pencil ionization chamber (42):

CTDI100 =

1
N ⋅T

50 mm

∫

D( z )dz

(1-10)

−50 mm

Since the pencil ionization chamber effectively measures the integrated exposure along its
active length, this expression can be simplified to (37):

CTDI100 =

( f ⋅C ⋅ E ⋅ L)

N ⋅T

(1-11)

where f is the f-factor that converts in-air exposures to dose in air (0.87 rad/R or 8.7
mGy/R), C is the electrometer calibration factor, E is the reading provided by the
electrometer after one axial scan in the center of the CTDI phantom (in R or mR), L is the
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active length of the pencil ionization chamber (100 mm), and the product N*T is the total
nominal x-ray beam width during the scan.
However, since the dose distribution within an object (the CTDI phantom in this
case) is not uniform throughout (with increased dose being deposited superficially), the
CTDI-weighted index (CTDIw) was also created. This is obtained by taking CTDI100
measurements at the center of the CTDI phantom (CTDI100)center and by averaging CTDI100
measurements taken 1 cm below the surface at the 12, 3, 6, and 9 o’clock positions
(CTDI100)periphery , or (37):

=
CTDI w

1
2
( CTDI100 )center + ( CTDI100 ) periphery
3
3

(1-12)

It has been estimated that (CTDI100)center and (CTDI100)periphery tend to underestimate the
equilibrium dose (i.e. the true “saturation” dose at z=0, including the dose scatter tails as
the measured medium length approaches infinity (43)) by a factor of 0.6 and 0.8,
respectfully (42).
In order to account for the changes in dose deposition related to variable x-ray
beam distribution (such as with gaps or overlaps in beam coverage), the CTDI-volume
index (CTDIvol) is calculated from this CTDIw value as (37):

CTDI
=
CTDI w ⋅
vol

( N ⋅T )
I

(1-13)

where I is the table movement per rotation of the x-ray tube. For helical scans, this
expression becomes (37):
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CTDI vol =

CTDI w

pitch

(1-14)

where pitch is the table distance traveled in one complete revolution of the x-ray tube
divided by the nominal beam width, or (37):

pitch = I

( N ⋅T )

(1-15)

CTDIvol provides a useful estimate of the average radiation dose (in mGy) within a
scanned volume of PMMA for a specific scan protocol (42). These estimates are only
intended to be applied for CTDI phantoms of similar attenuation and size undergoing an
identical CT scan technique; and can only be reliably used in such circumstances. This
does not typically include human imaging since patient anatomy is heterogeneous and
exhibits varying attenuation and size properties.
A noticeable shortcoming of the CTDIvol measurement is that it does not account for
the length an object is scanned (lengthscan) (in cm). In other words, regardless of whether
an object is scanned for 20, 50, or 100 cm, the CTDIvol dose estimate remains the same
(42). Therefore, the dose length product (DLP) is calculated (in units of mGy-cm) by the
following equation (37):

=
DLP CTDI vol ⋅ lengthscan

(1-16)

It has been estimated that DLP underestimates the total energy imparted by 30% for all
scan lengths (42). Further, the units for this entity are not intuitive and therefore not very
helpful in a clinical setting to determine the dose (or perhaps more appropriately, the risk) a
26

patient receives as a result of a CT scan. Fortunately, DLP can be used to estimate the
biological effect or detriment to an individual undergoing a CT scan based on the body
region irradiated to yield an effective dose (E) (in mSv). This is calculated by (42):

E ≈ k ⋅ DLP

(1-17)

where k is a coefficient (in mSv/(mGy*cm)) published in AAPM Report 96 (shown in Table
1-3) that is specific to a patient’s age and the region of body scanned.

Table 1-3: k values published in AAPM Report 96 (42) to convert 16 cm or 32 cm diameter
head CTDI phantom-based DLP estimates to effective dose estimates. Adult head, neck, head
and neck, and pediatric patient k values were based on the 16 cm diameter phantom; while
the remaining k values were based on the 32 cm diameter phantom.

Region of Body

Head and Neck
Head
Neck
Chest
Abdomen and/or
Pelvis
Trunk

0 Years
Old
0.013
0.011
0.017
0.039
0.049

1 Year
Old
0.0085
0.0067
0.012
0.026
0.03

0.044

0.028

k (mSv/(mGy*cm)
5 Years
10 Years
Old
Old
0.0057
0.0042
0.004
0.0032
0.011
0.0079
0.018
0.013
0.02
0.015
0.019

0.014

Adult
0.0031
0.0021
0.0059
0.014
0.015
0.015

The k coefficients provided in Table 1-3 were determined by Monte Carlo
simulations on the Medical Internal Radiation Dose (MIRD) Committee’s MIRD V
anthropomorphic mathematical phantom (42, 44, 45); which has also been incorporated
into the CT dose research performed by the United Kingdom’s formerly named National
Radiological Protection Board (NRPB) (now known as Radiation Protection Division of the
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Health Protection Agency), the Imaging and Performance Assessment of CT (ImPACT)
group’s CT dose models (46-48), the Monte Carlo simulation program created by McNittGray’s group at the University of California at Los Angeles (UCLA), and many others.
Although this phantom is based on reference data published in ICRP Publication 23 (49)
and is considered among the best such models in existence (as evidenced by the fact that it
is among the most common of the mathematical phantoms used for estimating patient
dose), this phantom is based on the radiological response to only three generalized tissues
(bone, lung, and soft tissue) in 27 radiosensitive organs modeled after geometric shapes;
and therefore is limited in its ability to predict patient dose for the wide variety of patient
sizes and shapes that undergo VC.
Further, while CTDI is a good measure of CT scanner output, it is not intended to
represent the dose for patients—who present in widely varying sizes, shapes, and
attenuation (50). Since a standard CTDI phantom is only 15 cm long in the axial direction,
and a pencil ionization chamber is only 10 cm long, CTDI techniques will naturally
underestimate scatter doses experienced in typical adult anatomy by not considering the
“tails” of the z-axis dose profile (51). Additionally, CTDI is technically expressed in terms of
dose-to-air (not dose to tissue) based on its f-factor of 0.87 rad/R (or 8.7 mGy/R); so such
estimates are technically a step away from tissue dosimetry (50). The appropriate f-factor
correlating dose in a material to dose in air for a CTDI phantom has been demonstrated by
Monte Carlo modeling to vary by location within the phantom, the presence or absence of a
bowtie filter, the kVp setting, the length of the pencil ionization chamber, and by the
diameter of the CTDI phantom (51).
CTDI is so ubiquitous in CT imaging that modern CT scanners provide CTDIvol and
DLP value estimates to users, and DICOM structure reports at MD Anderson Cancer
Center additionally provide a dose report for clinicians for those scans performed since
January 2010. The term “dose report”, however, as labeled in ClinicStation is something of
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a misnomer and reported CTDIvol and DLP values are misleading because of these
limitations. Although effective dose can be calculated from these CTDIvol values and is
commonly used to quantify risk, with anthropomorphic phantom experiments showing good
agreement between cumulative organ dose measurements and these CTDI-based effective
dose values (52), during a VC scan only the abdomen and pelvis are irradiated.
Additionally, VC protocols at MD Anderson Cancer Center utilize a static CT technique
regardless of the size of the patient, which will result in more centrally located organs (like
the rectum) receiving lower doses on larger patients than on thinner patients. Since the
number of organs irradiated is low and the potential inter-patient organ dose variance may
be high, using CTDI-based effective dose estimates may under- or overestimate true
patient risk. Therefore specific organ doses are more appropriate to quantify patient risk in
such instances (20).

1.3.3 Monte Carlo Method
Monte Carlo modeling, when validated by independent phantom or in-vivo
measurements, is considered the gold standard for calculating dose to an organ from
irradiation. Monte Carlo modeling is a computationally intensive technique developed
through the 1930’s and 1940’s that has been used to study complex systems (including
those in the physical sciences, engineering, applied statistics, business,
telecommunications, and gaming fields) that have many coupled degrees of freedom,
significant uncertainty of input parameters, and complicated boundary conditions (53). As
the term “Monte Carlo” was coined in honor of the famed casino of the same name in
Monaco (54), this method relies on repeated sampling of random events (via random or
pseudo-random numbers) and probability statistics to investigate problems; thus allowing
for the examination of more complex systems than can be investigated by more
deterministic means (55). For example, calculating the interaction of a single x-ray photon
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with one or two atoms of a single tissue type within the body can be solved fairly simply;
however, solving the system of interactions for the many tissues within the body for the
relatively large number of photons emitted during a VC exam is impractical by any other
means besides Monte Carlo modeling.
For CT, this simulation procedure requires development of the CT scanner model
(as the source of the x-rays), the patient model (using the acquired images), and the x-ray
beam path (in this case, a helical geometry). ImPACT’s CTdosimetry software is probably
the most used research tool for estimating organ doses and is based on CTDI and Monte
Carlo data in a single-size patient geometry MIRD V mathematical phantom (56), but
makes several assumptions in its methodology that may result in uncertainties in dose
estimates (44). The Monte Carlo process created by McNitt-Gray’s group at the University
of California at Los Angeles (UCLA) is a well-documented and validated methodology (44,
57-62) created specifically for MDCT; but this methodology is also limited in that since it
uses patient images as the basis for its calculations, the results yielded by such simulations
are very patient specific and therefore limited in terms of patient size and organ distribution.
This Monte Carlo process is valuable, though, in that it can provide organ dose estimates
for true patient geometries. True (i.e. direct) CT point dose measurements would be ideal
to validate or benchmark such a Monte Carlo modeling procedure.

1.3.4 CT Point Dose Measurements
Direct CT dosimetry measurements using TLDs, Farmer (aka thimble) ionization
chambers, metal-oxide semiconductor field-effect transistors (MOSFET), film, diodes,
plastic scintillators, or optically stimulated luminescent dosimeters (OSLDs) (23) are often
performed in research to validate other indirect means of determining radiation dose (e.g.
CTDI, surface exposure, mathematical models, or Monte Carlo simulations). Ideally, direct
methods are preferred for radiation dose measurement (63) because they provide true
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measurements of radiation interactions in a medium. Unfortunately, these measurements
are rarely realized because they are typically considered invasive and often unsafe for use
in a patient. Therefore, various phantoms have been developed to mimic a true patient
using standard reference organ sizes and locations and by using materials that are
approximately tissue equivalent in the CT energy and dose range.
When validating an indirect dosimetry assessment tool like a mathematical (64) or
Monte Carlo (58, 63, 65, 66) model (for example) , or when estimating the dose to an organ
during a procedure (40, 64, 67-71), TLDs are typically placed on the surface of and/or
inserted into the organs of anthropomorphic phantoms and in-air exposure or organ dose
measurements are made using the CT protocol modeled. Since indirect methods/models
are typically based on approximations from (often similar) reference patient and organ
sizes, comparison results between indirect dosimetry methods (for example, between
Monte Carlo simulations and anthropomorphic phantom measurements) are often reported
to be favorably consistent with one another (65, 66) (with anthropomorphic testing being
used to benchmark and/or validate Monte Carlo modeling results). While agreement
between model and phantom measurement results is a testament to the ability of such a
model to represent the physics scenario within a given situation, such models may not in
reality provide an accurate understanding of the absorbed doses received by a patient; as
has been observed in a study comparing anthropomorphic phantom dose to cadaver dose
from identical CT protocols (72).
Non-agreement between cadaver and phantom measurements or Monte Carlo
models may be due to the fact that both simulations and phantoms are fundamentally
based on approximations to patient size, shape, and radiation response; and additionally to
the possibility that radiation dose response within a cadaver may differ from that in living
tissue or in a phantom. Therefore, although phantom measurements are valuable from
practical and risk-reward perspectives, they may not provide accurate patient organ
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absorbed dose measurements as they are based on approximations to true patient size and
in-vivo radiation dose response; and the accuracy of a Monte Carlo model that is
benchmarked against a phantom (which is inherently based on approximations) can be
questioned. Thus, in-vivo organ absorbed dose measurements are necessary to
benchmark and validate existing indirect measurement models such as phantoms or Monte
Carlo simulations.

1.3.5 MD Anderson VC Rectal Dose Estimates
VC offers an opportunity to obtain in-vivo organ dose measurements without
additional duress to a patient because a rectal catheter (to which TLDs can be affixed) is
inserted into a patient as a routine aspect of the procedure. Additionally, the centrality of
the rectum within a patient’s body decreases the likelihood that surface dose variations that
are characteristic of CT scans (61) will result in TLD point dose measurement
inconsistencies and/or errors. To date, direct in‐vivo organ dose measurements have never
been performed for internal organs during VC scans or even during MDCT scans in
general; thus, the accuracy of any indirect dose estimates is currently unknown (17-19, 73).
Further, although the average VC patient effective dose is estimated to be 7 mSv at MD
Anderson, such effective dose estimates are based on calculations from reference patients
and uniform phantoms; therefore uncertainty exists with such risk estimates (20).
Previous in-vivo CT measurements have been conducted for cone beam CT
(CBCT) by Walter, et al and Jeng, et al. Walter used a 7 mm diameter ionization chamber
inserted into patients’ rectums (74) (that was connected to an electrometer requiring input
potentials of up to ±400 V). Jeng used TLDs attached to a rectal catheter that was inserted
into the rectum (75). Using rectal dose measurements from these studies to estimate VC
rectal dose provides questionably correlated results because CBCT, not MDCT, was used
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to acquire these in-vivo dose measurements; but these studies do lend credence to this
general approach of obtaining in-vivo measurements within the rectum.
CBCT is an imaging modality typically used in dental applications and in on-board
imaging of modern linear accelerators (linacs) for image guided radiation therapy (IGRT)
(which was the application for both Walter’s and Jeng’s research). Although imaging on
CBCT devices is faster than MDCT, the image quality provided by CBCT devices is
generally inferior to that of MDCT devices. The differences between the MDCT and CBCT
modalities (and therefore opportunities for errors in dose estimation) are many, including:
VC protocols at MD Anderson requires the use of a beam width of 40 mm and many
rotations of the x-ray tube on the MDCT to obtain image data where CBCT imaging is
accomplished in one rotation of the x-ray tube and with a beam width of 450 mm. In fact,
Kim, et al. compared the modalities and concluded that under as similar technique
constraints as possible, the CTDI measurements for CBCT were 49% lower than those of
MDCT (76)—which underscores the fact that the beam dose distribution characteristics of
the two modalities are considerably different.
Since the only previous direct in-vivo rectal CT dose measurements that have been
obtained do not apply to VC or even MDCT, any VC dose predictions based on these
CBCT data are prone to error. In spite of these limitations in accuracy, by assuming CBCT
and MDCT both demonstrate a linear relationship between mAs and absorbed dose, and by
assuming the linear relationship of the two modalities are correlated, the rectal dose
received by a patient undergoing VC can be approximated from the in-vivo data published
by Walter (74) and Jeng (75) for the population of patient sizes represented in each study.
Doing so, the CT technique used in VC at MD Anderson Cancer Center yield approximate
mean rectal doses of 5.2 mGy and 4.4 mGy for each respective population of patient
habitus (patient anthropomorphic measurements were not provided by Walter (74); and
ranged in Jeng’s study (75) from 33.80 cm to 39.22 cm in patient width and from 18.70 cm
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to 23.92 cm in patient thickness). Again, these dose estimates were based on several
assumptions and therefore are prone to error.
DeMarco, et al performed Monte Carlo modeling using the UCLA code described
above on six simulated patients of varying size to determine colonic dose based on whole
body MDCT scans; obtaining colonic dose estimates ranging from 11 to 18 mGy (with an
average of 13.8 mGy) across the varying sizes at the mAs used in the MD Anderson
Cancer Center VC protocol (59). However, this estimate also has limited applicability to the
rectal dose received by patients undergoing VC at MD Anderson because the CT scanner
x-ray source model used in these calculations was based on a different scanner
manufacturer, with a different beam width, for a whole body scan (which will provide more
scatter dose to the rectum than VC), and pertained to the dose received by the entire colon
(versus just the rectum). For these reasons, the rectal dose received by patients at MD
Anderson will likely be less than this value.
Confirmation of this suspected lower rectal VC dose was obtained by simulating the
MD Anderson VC protocol using the ImPACT CT dose calculation program. Using this
protocol, an equivalent dose of 6.3 mSv is yielded for the lower large intestine of the MIRD
V mathematical phantom on which this software is based (with equivalent dose being
defined as the organ absorbed dose multiplied by the radiation quality factor, which is 1 for
photons (14), thus implying a predicted absorbed dose of 6.3 mGy). A previous study
showed that the UCLA Monte Carlo code demonstrated good agreement with ImPACT
dose estimates when applied to the same MIRD V mathematical phantom (44), therefore
the rectal dose received by patients at MD Anderson is predicted to be less than the 11 to
18 mGy range published by DeMarco (59).
Using Farmer ionization chamber measurements within the center bore of a
homogeneous CTDI body phantom exposed using the MD Anderson Cancer Center CT
technique for VC, a preliminary rectal dose estimate of 6.1 mGy was achieved. By
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mathematically subtracting 6 cm from the CTDI body phantom and applying that thickness
to the Lambert-Beer equation (Equation 3-2), an upper limit of a rectal dose estimate of
11.2 mGy was attained (for a theoretical approximate smallest diameter VC patient). An
estimated lower rectal dose limit of 0.5 mGy for a very large patient was assumed for a
patient undergoing VC at MD Anderson Cancer Center.
This 0.5-11.2 mGy dose estimate is limited, however, since a patient’s irradiated
volume during VC consists of heterogeneous tissues and since patients of different habitus
will have different proportions of self-shielding (via adipose layers, soft and hard tissues,
etc), this estimate is also subject to error. Conducting similar measurements in an
anthropomorphic phantom would likely eliminate some (but not all) of these phantom
homogeneity errors because such measurements would reflect dose to a reference patient,
but would not be able to account for random variations in organ size and position that exist
between people. Also, the largest source of variation in actual organ dose measurements
is likely that introduced by the varying sizes and shapes of patients that undergo VC. Jeng
and DeMarco published organ dose variances (resulting from differences in subject body
composition) from the mean organ dose of each study population of up to 16.2% (75) and
22.9% (59), respectfully.
In spite of all of the limitations of each of these methods for estimating the patient
rectal dose received at MD Anderson as a result of VC, all of these rectal dose estimates
are within a consistent range (0.7-14 mGy). Therefore the rectal dose received by patients
undergoing VC can reasonably be predicted to also fall within this range; but only actual
direct measurements can verify any understanding of the radiation dose administered in
such circumstances. This described difficulty in estimating the rectal dose range to be
encountered by patients while undergoing VC at MD Anderson underscores the need for invivo organ dose measurements.
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1.4 Hypothesis and Specific Aims

1.4.1 Hypothesis
Rectal dose measurements obtained in-vivo during virtual colonoscopy will have a
rectal dose coefficient of variation that will be greater than 50%; and the anthropomorphic
phantom dose measurements, CTDIvol-based dose estimates, and Farmer chamber
measurements in a CTDI body phantom will estimate rectal doses outside a 95%
confidence interval of the in-vivo patient dose measurements.

1.4.2 Specific Aims
Various options currently exist that can provide estimates of patient organ dose
received during virtual colonoscopy (VC). However, all of these techniques incorporate
indirect methods that are based on estimates from reference anatomical geometry and may
not reflect the actual organ dose received by any individual patient. Such is the case not
only for VC, but for all organ absorbed dose measurements for multi-detector computed
tomography (MDCT) examinations, where in-vivo measurements have never been feasible
to validate indirect dose measurements and estimates. Currently, most MDCT dose
estimates are based on measurements in a uniform phantom (which does not accurately
represent patient anatomy) either in the form of CTDIvol (which is based on integral dose
measurements) or point (Farmer ionization chamber) measurements. Therefore the
purpose of this research is to develop a method for obtaining in-vivo rectum dose
measurements during VC and to compare these measurements to dose estimates obtained
using the same CT scan protocols in an anthropomorphic phantom and a homogeneous
acrylic phantom that is ubiquitously used to assess CT scanner radiation output.
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1.4.2.1 Specific Aim 1: Establish TLD Linearity Correction Factors for VC Scan Parameters
on a MDCT
Using thermoluminescent dosimeters (TLDs) obtained from the National Cancer
Institute-funded Radiologic Physics Center (RPC) at MD Anderson Cancer Center, dose
linearity correction factors will be obtained at 120 kVp specific to the polyenergetic
spectrum produced by a MDCT in VC. These values will be determined by inserting one
TLD per scan in an acrylic insert rod (with a custom-made tight TLD seat) and placing the
insert rod into the center of an acrylic CTDI phantom. This phantom set-up will be used to
irradiate several TLDs using helical scans irradiating the entire length of the CTDI phantom
at varying mAs settings. This acquired absorbed dose data (in mGy) will be compiled,
compared to point dose data (in mGy) obtained via Farmer ionization chamber, and used to
calculate the TLD linearity correction factors for the conditions encountered by variously
sized patients undergoing VC at MD Anderson Cancer Center.

1.4.2.2 Specific Aim 2: Obtain Rectal Dose Measurements in an Anthropomorphic
Phantom and In-Vivo in Patients Undergoing VC with TLDs
An anthropomorphic phantom will be modified to approximate conditions during VC
in three sizes of patients; and two double chambered TLDs will be inserted into the
phantom in three iterations to assess VC rectal dose for those patients represented by each
respective phantom configuration. Additionally, in-vivo rectal dose measurements will be
acquired by affixing two TLDs to the inner lumen of 6 rectal catheters for use in 6 patient
VC studies. During a VC procedure, when a catheter is inserted into a patient’s rectum,
these affixed TLDs will acquire four measurements of the absorbed radiation dose delivered
to that patient’s rectum using the standard MD Anderson VC MDCT scan technique. 12
rectal dose measurements (in mGy) will be obtained for each of the three phantom
iterations and four rectal dose measurements will be obtained within each of the 6 patients
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using the dose linearity correction factors established for 120 kVp in Specific Aim 1; along
with the charge per mass readings, fading correction factor, and sensitivity correction factor
provided by the RPC.

1.4.2.3 Specific Aim 3: Compare In-Vivo Rectal Dose Measurements to Anthropomorphic
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements from
a Uniform Phantom
The rectal dose measurements of the three phantom configurations and in-vivo
rectal dose measurements from 6 patients will be tabulated along with patient geometry
measurements. These dose measurements will be compared to CTDIvol-based dose
estimates and point dose measurements (all in mGy) obtained from a 32 cm diameter CTDI
body phantom while irradiated with the same technique. Coefficients of variation and 95%
confidence intervals will be constructed for phantom, patient rectal dose measurements.
This data will be used to test whether the between-patient rectal dose coefficients of
variation are greater than 50% and if the anthropomorphic phantom dose measurements,
CTDIvol-based dose estimates, and the Farmer chamber dose measurement in a CTDI body
phantom are outside the 95% confidence interval of the patient dose measurements.
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CHAPTER 2.0: MATERIALS

2.1 Introduction
In order to accomplish the specific aims of this project, several items were required;
including: a GE LightSpeed VCT scanner, a CIRS ATOM adult anthropomorphic phantom,
a uniform polymethyl methacrylate (PMMA) 32 cm diameter CTDI body phantom (with
accompanying insert rods), 79 double chambered thermoluminescent dosimeter (TLD)
capsules, a custom-made PMMA CTDI insert rod with a tight TLD capsule seat, two
ionization chambers (a Radcal model 9060/10x5-0.6 Farmer chamber and a Radcal model
9060/10X5-3CT CT pencil chamber), a Radcal model 9010 electrometer, and 10 E-Z-EM
Super XL double contrast enema delivery systems.

2.2 GE LightSpeed VCT Scanner
Standard virtual colonoscopy (VC) at MD Anderson Cancer Center requires the use
of a GE LightSpeed VCT scanner (GE Healthcare, Waukesha, WI) (see Figure 2-1)
operating under the scanning protocol described in Table 1-1. This MDCT scanner model
was first introduced by GE in 2004, with VCT standing for “volume computed tomography”.
At the time of its introduction, this model was a significant upgrade from other MDCTs
available in imaging speed capabilities (advertising the capability of imaging a stationary
organ in as little as one second and a moving organ like the heart in as little as five seconds
(77)). These imaging speeds are accomplished by incorporating more data channels than
what was previously available (the GE LightSpeed VCT scanner utilized 64 data channels;
while its primary competition at the time used a maximum of either 16, 32, or 40 data
channels) and by using a very powerful x-ray tube that provided a beam width capable of
irradiating detector lengths of 40 mm (versus the more standard 20 mm detector lengths) at
fast rotation speeds (<400 ms) (78). Additionally, regardless of specified scanner
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parameter setting, this scanner always collects data at the level of the smallest detector
size (0.625 mm), which allows for the retrospective creation of CT images at varying
thicknesses. With these developments, the GE Lightspeed VCT scanner was able to
provide 73% more coverage per second (when at maximum pitch) than its CT predecessors
(78). Although several MDCT scanners have been developed between the launch of this
scanner and this writing, this scanner remains a very capable resource for accomplishing
VC.

Figure 2-1. GE LightSpeed VCT Scanner (MD Anderson Cancer Center “CT9”).

The GE LightSpeed VCT scanner has the capability to receive image data acquired
from its 0.625 mm detectors from 64 channels, and has a 70 cm bore diameter. It has six
axial nominal beam widths available (1.25 mm, 2.5 mm, 5.0 mm, 10 mm, 20 mm, and 40
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mm). Three pitch values are available for the 40 mm effective beam width used in VC
(0.516, 0.984, and 1.375). The table can move through the gantry at speeds up to 137.5
mm/sec during imaging. Additionally, the GE LightSpeed VCT scanner has dual focal spot
capabilities, where the scanner chooses the focal spot size based on the selected tube
current and voltage to balance spatial resolution (which is better with the smaller focal spot
size of 0.9 mm x 0.7 mm) and x-ray tube target heat capability (which is better with the
larger focal spot size of 1.2 mm x 1.2 mm) (79). With the capabilities provided by the GE
LightSpeed VCT scanner, a single VC prone or supine scan can be accomplished in 2.5-10
seconds (depending on the size of the patient) using standard MD Anderson VC protocols.
At the time of this writing, the Radiologic Physics section of the Department of
Imaging Physics at MD Anderson Cancer Center supported four GE LightSpeed VCT
scanners; most VC procedures at MD Anderson Cancer Center were performed on MDCT
scanner “CT9”, but were also performed on “CT5” and “CT12” as necessary for procedure
scheduling purposes. All TLD measurements used to accomplish Specific Aim 1 were
performed on “CT9” scanner and VC rectal dose measurements were performed in this
study on all three of these VCT scanners. It is not believed that the use of multiple MDCT
scanners negatively affected the accuracy of the rectal dose measurements as all four
MDCT scanners supported by the Radiologic Physics section demonstrating reasonable
consistency in computed tomography dose index (CTDI) measurements in a 32 cm CTDI
body phantom in their most recent annual surveys (with percent coefficients of variation of
2.3% for (CTDI100)center, 2.2% for (CTDI100)periphery, and 2.1% for CTDIw).

2.3 CTDI Body Phantom
The Computed Tomography Dose Index (CTDI) body phantom used for this protocol
was manufactured by the MD Anderson Cancer Center Machine Shop (Houston, TX)
according to standardized dimensions. The original design for this phantom was first
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published by Shope, et al in 1981 (41) as being a “cylindrical Plexiglas phantom 32 cm in
diameter with arrays of LiF thermoluminescent dosimeters inside the phantom”. Since the
CTDI technique pioneered by Shope has become the clinical standard for CT dose
characterization, the basic design of this phantom has changed little since it was first
introduced. The modern design for this phantom contains a bore in the center of the
phantom that is sufficiently large (1.3 cm in diameter) to insert a pencil or Farmer ionization
chamber; and at least four additional peripheral 1.3 cm diameter bores located at 90
degrees from one another at a depth of 1.0 cm from center of each bore to the phantom
surface.

Figure 2-2. 32 cm CTDI body phantom with insert rods.

The CTDI body phantom (see Figure 2-2) contains the five aforementioned bores,
along with four additional bores of the same diameter located equidistantly between each of
the peripheral bores and the center bore. These additional bores were included into the
phantom design to provide dose measurement capabilities that approximate for organ or
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fetal locations. The phantom utilizes 8 acrylic insert rods that slide into each bore that is not
being used to take measurements (i.e. the remaining bores that do not contain a
measurement device) with minimal air gap. Additionally, the CTDI body phantom is
uniformly composed of polymethyl methacrylate (PMMA), is fashioned as a 32 cm diameter
cylinder that is 15 cm thick, and weighs approximately 13.2 kg (29 lbs). Commercial
manufacturers provide CTDI body phantoms with additional features, such as an all-in-one
32 cm CTDI body, 16 cm CTDI adult head, and 10 cm CTDI pediatric head phantom.
However, such features were not necessary for this project.

2.4 CIRS ATOM Adult Anthropomorphic Phantom
In addition to the CTDI body phantom, an ATOM adult male model 701
anthropomorphic dosimetry phantom (Computerized Imaging Reference Systems, Inc
(CIRS), Norfolk, VA) (see Figure 2-3) was used to estimate the rectal dose received by
patients undergoing VC at MD Anderson Cancer Center. The ATOM phantom line was
originally developed and manufactured by ATOM Ltd (Riga, Latvia) beginning in 1985, and
CIRS assumed exclusive manufacturing privileges of this phantom in 1999 (80). The
standard ATOM model 701 adult male phantom consists of an anthropomorphic head,
torso, pelvis, and upper femurs modeled in the representation of the “standard” man as
published in ICRP 23 (49) from epoxy resins with tissue equivalent properties of adult bone
(a composition of average age-based mineral densities and known trabecular and cortical
ratios), soft tissue, lung (during held inspiration), spinal cord, cartilage (spinal discs), and
brain (81, 82). The epoxy resins representing the bone and soft tissue in this phantom
have linear attenuation coefficients that are within 1% of actual bone and water,
respectively, from 50 keV to 25 MeV; and the material representing lung tissue during
inspiration has a linear attenuation coefficient within 3% of actual lung tissue in this same
energy range (81).
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Figure 2-3. CIRS model 701 ATOM adult male phantom.

In addition to these tissue equivalent materials, adipose tissue equivalent fat layers
can be purchased from CIRS for application onto the ATOM model 701 adult male phantom
in order to accomplish dosimetry studies for larger, more realistic patients (see Figures 2-4
and 2-5). This set of fat layers consists of 10 slabs (4 cm thick by 20 cm in length) of
proprietary soft gel material (providing adipose tissue equivalence within 1% for therapy
and diagnostic energy photon beams) that has been reinforced with nylon/Lycra mesh and
hook-and-latch pads for assembly (83). The 10 fat slabs are of varying lengths and are
applied to the outer surface of the phantom abdomen in either one or two layers of four
slabs (with two additional larger slabs available to accommodate adding fat to phantom
dimensions larger than the abdomen, such as the thorax or pelvis).
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Figure 2-4. CIRS model 701 ATOM adult male phantom simulated adipose tissue kit.

A)

B)

Figure 2-5. A) ATOM phantom pelvis with first layer of simulated adipose tissue assembled;
B) ATOM pelvis with second layer of simulated adipose tissue assembled.

The adult male ATOM phantom is divided into 39 cross-sectional blocks, with each
section measuring 25 mm in thickness. The entire ATOM phantom line can be purchased
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with five millimeter diameter bores (revealed after removing custom fitted plugs)
strategically placed within 21 radiosensitive internal organs that are capable of housing TLD
capsules. Additional customized plugs are available for purchase to house other dosimetry
measurement devices such as TLD rods, chips, optically stimulated luminescent dosimeters
(OSLD), or metal oxide semiconductor field effect transistors (MOSFET). Film can also be
utilized for dosimetry by inserting appropriately sized film between phantom sections and by
taping the adjoining sections together with dark tape to prevent light penetration (81).
Overall, the adult male ATOM phantom (including the legs) measures 173 cm in
stature (5 ft, 8 in), weighs 73 kg (161 lbs), and has a thorax measuring approximately 32 cm
by 23 cm (80-82, 84-86). The standardized anthropometry, access to internal organs, and
photon beam tissue equivalence provided by the ATOM phantom have made this phantom
a popular choice for experimentation regarding image quality and radiation dose
assessment (82). Thus, the ATOM adult male phantom was a useful tool to approximate
the rectal doses received by patients undergoing VC at MD Anderson Cancer Center.

2.5 PeopleSize Software
Although the ATOM phantom provided a valuable dosimetric tool with substantial
tissue equivalence and the standardized anthropometry established in ICRP 23 (49), it was
limited in that with the additional fat slabs this phantom could only represent those patients
with one of three available pelvic circumferences. Since the VC technique utilized by MD
Anderson Cancer Center is a uniform technique that is not adjusted for patients of varying
sizes, the amount of absorbed dose received by the rectum is therefore directly related to
that patient’s habitus and body composition. Since any phantom experiment can only
provide data representative of a limited number of patient sizes, it was important to
determine which percentiles of the patient population (generalized in this study to be adults,
aged 18-64, residing in the United States) were represented by the phantom data in each
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configuration. Additionally, the fat slabs only extended 20 cm along the phantom pelvis;
where the appropriate VC scan and scatter length of a patient represented by the phantom
(and the average VC patient at MD Anderson Cancer Center) extends much further.
Therefore, additional target population anthropomorphic data was needed; specifically
regarding circumference measurements in the pelvis, abdomen and chest of a typical
patient represented by the phantom with the fat slabs attached, such that additional
attenuating material could be attached to the phantom surface in a proportionally
appropriate manner. These anthropomorphic data were acquired from PeopleSize 2008
Professional software, version 1.1, developed by Open Ergonomics Ltd (Leicestershire,
UK).
PeopleSize 2008 Pro software utilizes a simple user interface to provide customers
with data regarding anthropomorphic dimension measurements and percentiles for a
desired target population. PeopleSize 2008 provides percentiles and measurements for up
to 289 individual anatomical locations for nine nationalities (US, UK, German, Australian,
Belgian, French, Japanese, Chinese, Swedish) in up to nine adult age groups (18-64, 1825, 18-39, 25-50, 40-64, 65+, 65-74, 75+, 85+) as well as pediatric data for every year from
2-17 years and infant data for subjects under 2 years of age (87). Due to limited data
availability, complete data sets are not provided for some of these demographics in
PeopleSize 2008. At the time of this writing, this software had been incorporated into
research conducted by many industries that require ergonomic information; including
healthcare, clothing, motor vehicle, and consumer products.
The anthropomorphic data provided by PeopleSize 2008 is based on existing older
anthropomorphic survey data (acquired in dates ranging from the 1950’s to the 1990’s) that
have been scaled by size and weight to estimate modern dimensions (with bony
dimensions changing over time by a small magnitude and fatty dimensions changing over
time by a larger magnitude). The modern dimensions calculated by this software have
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been verified by comparing the predicted measurements to government-conducted surveys
(including the US Government’s most recent National Health and Nutrition Examination
Survey (NHANES), conducted from 2003-2006). Such comparisons have found that at the
most difficult dimensions to estimate (dimensions where fat is more likely to accumulate),
the software demonstrated an overall average error of 0.0% in the 5th percentile and -0.1%
in the 95th percentile; with individual landmark dimensions falling within approximately a
±3% margin (87). Thus, the PeopleSize 2008 software provided a dependable means to
determine the necessary anthropomorphic dimensions for the target patient population
represented by the respective ATOM phantom configurations used to measure simulated
VC rectal dose with thermoluminescent dosimeters (TLDs) at MD Anderson Cancer Center.

2.6 Thermoluminescent Dosimeter (TLD) Capsules
As described in Chapter 1.4.2.1, TLDs were used to acquire all in-vivo VC rectal
dose measurements. TLDs provide many benefits to users, including the capability of
being ground into powder and conformed to the geometry of its container (which provides
the added benefit of eliminating directional dependence from dose measurements).
Advantages of the TLD-100 (LiF:Mg,Ti) powder used in our measurements also include (26,
31): a wide useful linear dose range (from 50 µGy-1000 Gy), performance independent of
dose rate, small size, excellent uniformity within a batch (if appropriately prepared), quick
and convenient readout, very good precision (as low as 0.22%), low uncertainty (usually
around 2-5%, with the uncertainty published by the RPC being 2.5% for their standard setup at therapeutic doses (35)), commercial availability, and substantial tissue equivalence for
most applications.
TLD-100 material has several inherent disadvantages as well, but most of these
disadvantages can be overcome with sufficient effort. Examples of such disadvantages
include (26, 31): careful calibrations at low doses and energies (diagnostic range) due to
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supralinearity of TLD-100 response compared to tissue, the need for specific calibrations
for each batch because of batch-to-batch inconsistencies, loss of TLDs due to small size,
inconvenience associated with delayed dosimeter reading (a minimum of 14 days is
typically desirable), inconvenience and cost associated with readings performed by an
outside entity, spurious luminescence effects (which are mostly eliminated with N2 gas and
by using uniform TLD-100 powder grain size), sensitivity that is altered after large doses or
repeated doses (which is mostly eliminated with proper annealing techniques or by not
reusing material), and reader instability (which can be improved with well-trained
technicians and by control TLDs to track changes in charge measurements at uniform
doses). Ultimately, the advantages of TLD-100 were determined to outweigh these stated
disadvantages, and TLD capsules were determined to be the best method available for
measuring patient rectal dose from VC.

Figure 2-6. Double chamber TLD capsule obtained from the RPC.
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The TLDs used in this experiment were obtained from and read by the NCI-funded
Radiologic Physics Center (RPC) at MD Anderson Cancer Center (Houston, TX). The
TLDs consisted of plastic capsules containing two approximately 22 mg aliquots of ground
TLD-100 powder in a double chamber plastic capsule with a wax plug. As mentioned in
Chapter 1, the TLD-100 material was grown by Thermo Scientific (Waltham, MA); and was
ground, mixed, and packaged into plastic cylindrical capsules (4.0-4.2 mm in tapered
diameter by 15.6 mm in length) (see Figure 2-6) by Quantaflux, LLC (Dayton, OH).
When the RPC receives their order of TLDs from Quantaflux, the RPC quantifies the
fading, energy, and linearity correction factors for the batch of TLD-100 material (as
described above in Chapter 1.2.4). Once the material’s radiation response characteristics
have been sufficiently quantified, they then provide these TLDs to customers for therapy
beam quality assurance purposes. When the TLDs are returned to the RPC from their
customers, they wait at least 14 days after irradiation to reduce the uncertainty effects of
drift on the TLD charge measurement results. During readout, the mass of an aliquot of
TLD-100 powder is determined from a Mettler AT261 DeltaRange analytical balance
(Mettler-Toledo International Inc, Griefensee, Switzerland). This mass of TLD-100 material
is then placed on the planchette of a Harshaw QS 3500 TLD reader (ThermoFisher
Scientific Corporation, Santa Fe, NM) where it is heated at a constant rate to 318 degrees
Celsius. The light emitted from the TLD-100 material stimulates the reader’s photomultiplier
tubes, which is converted to a charge measurement and reported to the RPC’s TLD
technologist.
The RPC calculates a sensitivity correction factor (KS) from measurements of
Cobalt-60 irradiated standard and control TLDs. This KS value (in cGy/µC/mg) allows one
to determine the radiation dose to muscle tissue from the obtained charge and mass
readings. The RPC also calculates factors that correct for: fading (KF) using Equation 1-1:
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KF = N

( a ⋅ e(

− b⋅ X )

+ c ⋅ e(

−d⋅X )

)

(1-1)

(with coefficient values determined at commissioning of this batch of TLD-100 material to
be a=1.2815, b=0.00010885, c=0.067810, d=0.071908, N=1.3493, and X representing the
number of days between irradiation and readout); linearity (KL) (defined for doses between
200 mGy and 6000 mGy by Equation 1-2, with m=-0.00028943, b=1.08683, and draw being
defined by Equation 1-3):

KL =
m ⋅ d raw + b

(1-2)

d raw= Q

(1-3)

mg

⋅ KS ⋅ KF

and energy (KE) (defined from energies ranging from Cobalt-60 (KE=1.000) to ≥17 MV
(KE=1.065)). However, as both the rectal doses and energies encountered by patients
undergoing VC are less than the ranges for which the respective correction factors provided
by the RPC are valid, Specific Aim 1 was necessary to quantify TLD performance by
defining KL at 120 kVp (KL,120) for the range of doses encountered in VC.

2.7 Custom-Made PMMA CTDI Insert Rod
In order to accomplish Specific Aim 1 and define KL,120 for the range of doses
encountered in VC, it was necessary to provide appropriately varying doses to TLDs under
controlled conditions. Since the rectal dose and energy spectrum experienced by a patient
undergoing VC at MD Anderson Cancer Center is a function of the size of the patient and
the spectrum of the output of the MDCT scanner x-ray tube, it was determined that the
easiest way to approximate such conditions would be in a common CTDI body phantom
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(which roughly approximates the size and attenuation of a large reference patient). This
phantom was determined to be a reasonable and reproducible approximation of the beam
hardening and attenuation produced by a patient.
In order to create TLD irradiation conditions as reproducible as possible, such that
TLD placement at each irradiation condition was as consistent as possible and the MDCT
beam attenuation uniformly approximated the scatter observed in the rectum of a patient
undergoing VC, a PMMA insert rod of approximately identical external geometry as that of
the insert rods that fill the bores of the CTDI phantoms during standard CTDI phantom use
(1.27 cm diameter x 17 cm long cylinder) was designed and created by the MD Anderson
Cancer Center Machine Shop (Houston, TX) (see Figure 2-7A). This custom-made insert
rod differed from the standard CTDI insert rod in that it could be disassembled (via a tight
fitting 0.95 cm diameter x 0.32 cm deep male/female mating). Once disassembled (see
Figure 2-7B), a single TLD capsule could be inserted into a tapered 0.45 – 0.46 cm
diameter by a 0.80 cm cylindrical seat (see Figure 2-7C). Tape was attached to one side of
the insert rod (as seen in Figure 2-7) to ensure the TLD-loaded insert rod was consistently
inserted into the CTDI body phantom with the TLD located in the geometric center of the
phantom. An additional view of a TLD seated within the female side of the custom-made
insert rod is provided in Figure 2-8.
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A)

B)

C)

Figure 2-7. A) Assembled custom-made PMMA CTDI insert rod with TLD seat; B)
Disassembled custom-made insert rod; C) Disassembled custom-made insert rod with TLD in
seating.

Figure 2-8. Female side of disassembled custom-made insert rod with TLD capsule placed in
seating.
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2.8 Ionization Chambers
To accomplish Specific Aim 1 and define KL,120 for the range of doses encountered
in VC, independent dose measurements were additionally required to which TLD dose
measurements could be compared. Further, in order to identify any potential measurement
discrepancies in the event of a change in the x-ray tube within a MDCT scanner between
the time the KL,120 correction coefficients were determined and when actual
anthropomorphic phantom and in-vivo patient VC measurements were acquired, several xray beam quality factors were evaluated. These beam quality factors included the beam
half-value layer (HVL), quarter-value layer (QVL), CTDI in-air ((CTDI100)air) (88), and
weighted CTDI (CTDIw). Volume CTDI (CTDIvol) was calculated from this CTDIw value, and
these measurements were compared to the CTDIvol value displayed on the scanner
console. Each of these measurements was obtained using an electrometer and one of two
varieties of ionization chambers.
Ionization chambers operate by exploiting and measuring the effects that result
when an ionized particle moves through a gas. In their most basic form, ionization
chambers are composed of a direct current (DC) voltage source connected to positive and
negative electrodes separated by a gas (usually atmospheric air). Significant insulation
(often with measures such as a guard ring) is additionally required to protect the integrity of
the voltage bias established between the electrodes (89). When ionizing radiation (for
example a photon) enters the active volume of the ionization chamber, it interacts with the
gas within the active volume and produces an ion pair (a positive ion and a free electron) by
either the photoelectric effect, Compton scattering, or pair (or triplet) production; depending
on stochastic events and the energy of the incident photon. Secondary photons, electrons,
positrons or delta rays created by these interactions result in other ionizations occurring
within the chamber as well; and the interactions occurring within the chamber should mirror
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those occurring outside the chamber (as long as the chamber walls are sufficiently thick to
achieve electronic equilibrium) (89).
The average energy deposited by an incident photon into an active volume is
primarily a function of the binding energies of the gas within which it is interacting (90). The
number of ion pairs created by interactions initiated by an incident photon can therefore be
estimated by dividing the energy of the incident photon by the experimentally-determined
average values of energy dissipation per ion pair (also known as W-values) for a type of
incident radiation and for a species of gas. When an incident photon creates fast electrons
within the active volume of an ionization chamber filled with air (or air equivalent material),
the W-value is 33.8 eV/ion pair (89). Therefore, if a 1 MeV incident photon becomes fully
stopped within the active volume of an ionization chamber, approximately 33,000 ion pairs
will be created.
Under normal conditions in a volume of gas, these newly generated ion pairs will
quickly recombine and no net charge will result. Ionization chambers, when connected to
an electrometer, utilize a large voltage bias (±200 V to ±500 V) surrounding the active
volume to minimize or prevent such ion pair recombination. As the recombination of the ion
pairs is prevented, the respective ions migrate to the attracting electrode; and the result is a
decrease in the bias voltage. An electrometer measures and amplifies this change in the
DC voltage bias (ΔV) across a series resistor (RS) (typically between 109-1012 ohms), and
determines the saturated ion current (IS) by Equation 2-1.

I S = ∆V

(2-1)

RS

The exposure (R) in charge per unit mass (C/kg) is calculated from the saturated ion
current provided in Equation 2-1 and time of exposure as shown in Equation 2-2:
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R=

IS
⋅t
M

M = 1.293

(2-2)

kg
P T
⋅V ⋅ ⋅ 0
3
P0 T
m

(2-3)

where M is the mass of air in the active volume calculated from Equation 2-3, V is the
volume of the ionization chamber active volume (in m3), P is the air pressure in the
chamber (in mmHg), P0 is the standard air pressure (760 mmHg), T is the air temperature
in the chamber (in Kelvin (K)), T0 is the standard temperature (273.15 K), and t is the time
of exposure (in sec). Although C/kg is the SI unit for exposure, the more commonly used
value for exposure is the Roentgen (R); which is additionally calculated by the conversion:
1 R = 2.58 x 10-4 C/kg.
As an example to provide insight to the order of magnitude of the measurements
required to utilize this technology, if an ionization chamber with an active volume of 1000
cm3 is exposed at a rate of 1x10-3 R/hr at standard temperature and pressure, a saturated
ionization current of 9.27x10-14 amperes (A) would result. Such low currents underscore
the need for the above mentioned significant insulation and guard rings (to prevent leakage
of current from the respective electrodes), and for quality electrometer instrumentation.
Several models of quality ionization chambers and electrometers are commercially
available that have been designed for specific measurement purposes; including the
thimble (or Farmer) style ionization chamber, the pencil ionization chamber, and the
electrometer described below. These entities were used in Specific Aim 1 to measure
beam quality and to establish TLD response correction factors to the MDCT x-ray spectrum
experienced by patients undergoing VC at MD Anderson Cancer Center.
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2.8.1 Farmer Ionization Chamber
The first fast-responding thimble ionization chamber (cylindrical ionization chambers
incorporating two electrodes separated by insulation and a chamber of gas surrounded by
air-equivalent material and connected by wire to a feed-back amplifying electrometer) was
first introduced by Frank Farmer in 1946 (91). Before his work, ionization chambers were
both much slower and much more bulky. In honor of his work developing this detection
technology, such thimble chambers are commonly referred to Farmer chambers. Over the
years, Farmer ionization chambers have proven to be very valuable tools to medical
physicists operating in both therapy and diagnostic disciplines; and they were used in our
accomplishment of Specific Aim 1 by providing standard point exposure measurements
used to determine the KL,120 values for the TLD-100 material for the energy and to estimate
the rectal dose range received by patients undergoing VC during survey and CT imaging.
The Farmer ionization chamber used to acquire the baseline values for our TLD
exposure measurements was the Radcal model 9060/10x5-0.6 (S/N 16563) (Radcal
Corporation, Monrovia, CA). This chamber (shown in Figure 2-9A) has an active volume of
0.6 cm3, utilizes C552 air-equivalent conductive plastic walls and electrode, has an active
volume of air that is unsealed from the environment, has a 12 m low-noise triax cable,
weighs 0.28 kg, and comes with a polyacetal build-up cap (see Figure 2-9B) (92). In order
to reduce air gap within a CTDI phantom when this chamber is in place and to provide as
uniform a phantom environment as possible, the MD Anderson Cancer Center Machine
Shop (Houston, TX) created an acrylic insert rod with a cut along the length of the cylinder
to house the triax cord (see Figure 2-9C).
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A)

B)

C)

3

Figure 2-9. A) Radcal 0.6 cm 9060/10x5-0.6 Farmer-style ionization chamber; B) Radcal
Farmer ionization chamber with build-up cap attached; C) Radcal Farmer ionization chamber
with build-up cap and custom-made triax cord insert rod attached.

The active volume of the chamber is 9 mm in diameter and 21 mm in length. The
total length of the chamber is 54 mm, and the total diameter is 12 mm. The triax cord is 3
mm in diameter. This chamber can be operated in one of six modes: dose rate (recording
air kerma rates ranging from 1 mGy/min to 74 Gy/min), dose (recording total accumulated
air kerma ranging from 0.1 mGy to 6 kGy), maximum dose rate (providing the peak air
kerma in an exposure from 1 mGy/min to 74 Gy/min), auto dose (for repeated hands-off
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measurements where respective measurement parameters (exceeding a 0.6 R/min
threshold) don’t change between measurements, last dose (for determining total
accumulated air kerma at any time during a continuous exposure from 0.1 mGy to 6 kGy),
and cine mode (used for machines, like fluoroscopy, that produce exposures in pulses
greater than 0.01 mGy/pulse). The resolution provided by this ionization chamber is 1
mGy/min or 0.1 mGy. The energy dependence falls within ±5% for beams of energy
between 40 keV and 1.33 MeV when a build-up cap is incorporated; and the exposure rate
dependence operates within ±2% between the 6 mGy/min and 6 kGy/min (92). The
calibration accuracy provided by this chamber is ±4% after temperature and pressure
condition correction when using Co-60 as the calibration source. MD Anderson Cancer
Center sends all Farmer ionization chambers for calibration on a biennial basis and crosscalibration checks between similar chambers on an annual basis.

2.8.2 CTDI Pencil Ionization Chamber
In 1978, Suzuki and Suzuki from Capintec, Inc (Montvale, NJ) introduced an
expanded, pencil-shaped version of the Farmer-style ionization chamber that was capable
of measuring an integrated exposure over a distance (compared to Farmer’s chamber that
measured exposure at a point) (93). This pencil ionization chamber was created for the
expressed purpose of measuring exposures from CT scans, and this tool has found
considerable usefulness with the development of computed tomography dose index (CTDI)
as a ubiquitous method for measuring CT exposure characteristics. A pencil ionization
chamber was used to quantify several CT beam characteristics in the accomplishment of
Specific Aim 1 (including half-value layer (HVL), quarter-value layer (QVL), CTDI in-air
((CTDI100)air) (88), weighted CTDI (CTDIw), and volume CTDI (CTDIvol).
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Figure 2-10. Radcal model 9060/10X5-3CT 3 cm pencil chamber.

The pencil ionization chamber used to quantify the MDCT beam quality was a
Radcal model 9060/10X5-3CT (S/N 8696) (Radcal Corporation, Monrovia, CA). This
chamber (shown in Figure 2-10) has an active volume of 3 cm3, utilizes C552 air-equivalent
conductive plastic to compose the walls and electrode, has an active volume of air that is
unsealed from the environment, has a 2 m low-noise triax cable, weighs 0.11 kg, and
comes with a polyacetal build-up cap to create a fit with the CTDI phantom with minimal air
gap (92).
The active volume of the chamber is 3 cm3, measuring 9 mm in diameter and 100
mm in length. With the build-up cap, the diameter of the chamber becomes 12 mm and the
length is 127 mm. The total length of the chamber with the cap in place is 165 mm, and the
total diameter remains 12 mm. The triax cord is 3 mm in diameter. This chamber can be
operated in the same six modes as the Farmer chamber within the following air kerma
limits: dose rate (1 mGy/min to 15Gy/min), dose (0.01 mGy to 1.2 kGy), maximum dose
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rate (1 mGy/min to 15Gy/min), auto dose (1200 mR/min threshold), last dose (0.01 mGy to
1.2 kGy), and cine mode (greater than 1 nGy/pulse). The resolution provided by this
ionization chamber is 0.1 mGy/min or 0.01 mGy. The energy dependence operates within
±5% with beams of mean hardness ranging from 3 to 20 mm Al HVL; and the exposure rate
dependence operates within ±2% between dose rates of 0.2 mGy/s and 300 mGy/min (92).
The calibration accuracy provided by this chamber is ±4% after temperature and pressure
conditions when moderately filtered x-rays at 150 kVp and 10.2 mm Al HVL hardness are
used as the calibration source. As with the Farmer ionization chamber, calibration of all
pencil ionization chambers are performed on a biennial basis and cross-calibration checks
are performed on an annual basis.

2.8.3 Electrometer
As mentioned in the descriptions above, neither the Farmer nor the pencil ionization
chamber operates unless attached to an electrometer to provide a bias voltage to the
chamber, to receive voltage change information, to amplify and process the data, and to
provide exposure measurements to the user. A Radcal model 9010 Radiation Monitor
Controller electrometer (S/N 90-2261) (Radcal Corporation, Monrovia, CA) was used in
Specific Aim 1 to determine the exposures in each irradiation condition as detected by the
respective ionization chambers. In order to interchange ionization chambers, this
electrometer was connected in series to a Radcal 9060 converter unit (S/N 90-2292), a
Radcal 90C5-6 extension cable, and finally the ionization chamber as shown in Figure 2-11.
This converter unit allows the Radcal 9010 electrometer to be used with any Radcal 10series interchangeable ionization chamber (92).
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Extension Cord

“Enter”
“Select”
Electrometer

Converter Unit
Pencil Ionization Chamber

Figure 2-11. Radcal 9010 Radiation Monitor Controller electrometer, Radcal 90C5-6 extension
cable, Radcal 9060 converter unit, and Radcal model 10X5-3CT pencil chamber attached in
series.

The Radcal 9010 electrometer shown in Figure 2-11 provides measurement
displays and menu selections on a two-line liquid-crystal display with 16 characters per line.
Menu selections are browsed by turning the “Select” dial and by pressing the “Enter” button
when a desired setting is displayed. This electrometer operates in the modes described
above for the specific ionization chambers (dose rate, dose, maximum dose rate, auto
dose, last dose, and cine mode). The energy response and resolution for each of these
modes depend on the ionization chamber utilized.
This electrometer is powered by three 9V batteries, which provide approximately 40
hours of normal use. A “Replace Battery” message is displayed when appropriate. This
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electrometer applies a ±260 V bias to the connected ionization chamber, which requires up
to 60 seconds to stabilize when the electrometer is first turned on. As per normal start-up
procedures, this electrometer additionally performs room temperature and pressure checks;
and displays the necessary ionization chamber correction factor that has been
automatically applied to the measurement values displayed. The Radcal 9010 electrometer
boasts a measurement repeatability of ±1%, and a measurement accuracy of ±4% (92). As
with the ionization chambers described above, calibration of all electrometers are
performed on a biennial basis and cross-calibration checks are performed on an annual
basis.

2.9 Double Contrast Enema Delivery System
As mentioned in Chapter 1, standard procedure for VC at MD Anderson Cancer
Center requires the insertion of a rectal catheter into a patient for gas insufflation of the
colon and for iodinated contrast agent administration and retention. The rectal catheter and
enema system routinely used by MD Anderson Cancer Center during VC procedures is the
E-Z-EM Model 8925 Super XL Double Contrast Enema Delivery System (Bracco
Diagnostics Incorporated, Princeton, NJ). All contents of this enema delivery system are
shown in Figure 1-2 and include: a 2500 cm3 contrast agent bag, 152 cm of 12.7 mm
lumen plastic tubing, two plastic tubing clamps, a blue insufflation tube, a blue insufflation
bulb (which is not used during VC at MD Anderson Cancer Center), a retention cuff
(balloon) inflation bag (containing approximately 100 cm3 of air), 51 cm of 1.6 mm diameter
lumen plastic inflation bag tubing, and a flexible Miller™ Enema Air Tip with silicone
elastomer inflatable retention cuff (balloon) (94). All contents of this enema delivery
system are latex-free, and are used clinically as described in Chapter 1.
The Miller™ Enema Air Tip (see Figure 2-12) is the portion of the enema that is
inserted into a patient’s rectum while undergoing VC (i.e. the rectal catheter) at MD
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Anderson Cancer Center. This is also the portion of the enema delivery system to which
TLDs were attached in order to accomplish Specific Aim 2 and obtain in-vivo rectal dose
measurements in patients undergoing VC. As can be seen in Figure 2-12, the blue
insufflation tube, the large clear contrast agent tube, and the small clear balloon inflation
tube converge into the rectal catheter.

Insufflation Tube

Inferior Balloon Tie-Down
Balloon

Rectal Catheter Shaft
Balloon Inflation Tube
Contrast Tube

External (Perpendicular) Holes

Rectal
Catheter
Head

Figure 2-12. Close up view of Miller™ Enema Air Tip rectal catheter contained in the E-Z-EM
Model 8925 Super XL Double Contrast Enema Delivery System.

The entire rectal catheter wall thickness is approximately 1.8 mm. Within the interior
of the catheter (seen in Figure 2-13), the majority of the shaft volume (approximately 50%)
accommodates contrast agent flow into the patient, with the rest of the shaft volume
containing extrusions where tubes have been molded into the interior wall of the catheter to
accommodate insufflation gas flow and balloon inflation (approximately 25% for each of the
two tubes). The balloon inflation tube terminates within the shaft of the rectal catheter into
the balloon portion of the shaft just superior to the inferior balloon tie-down. The gas
insufflation tube terminates just inferior to the exterior holes on the head of the rectal
catheter (perpendicular to the central axis) and contains a port into the central contrast
agent volume to expel insufflation gas into a patient’s colon.
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Figure 2-13. Interior view of Miller™ Enema Air Tip rectal catheter.

Superior to the shaft (which measures 9.5 mm across the largest lumen diameter (i.e.
where the contrast agent flows)), the diameter opens to a maximum diameter of 13.5 mm in
the head of the rectal catheter and narrows to 6.2 mm at the superior opening. Besides the
superior opening, the rectal catheter has eight exterior elliptically-shaped holes aligned
perpendicularly to the central axis; each providing a port for insufflation gas and contrast
agent administration into the rectum and colon that is 3.0 mm in the narrow diameter and
3.9 mm in the large diameter. Each of these internal features of the rectal catheter (the
superior hole, the exterior holes, the enlarged diameter head, the shaft with the two
extrusions, and the internal insufflation gas port) must be navigated when inserting and
affixing TLDs into the head of the rectal catheter as described in Chapter 3 (and illustrated
in Figure 3-25).
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CHAPTER 3.0: METHODS

3.1 Introduction
The methods used to estimate patient rectal dose during virtual colonoscopy (VC)
are described in this chapter in order of the specific aims outlined earlier. First, in
accordance with Specific Aim 1, thermoluminescent dosimeter (TLD) linearity correction
factors were established for a range of doses at 120 kVp for a multi-detector computed
tomography (MDCT) scanner using VC scan parameters in a 32 cm CT dose index (CTDI)
body phantom. Next, in accordance with Specific Aim 2, rectal dose measurements using
TLDs were obtained in VC simulations within an anthropomorphic phantom and in-vivo
within patients undergoing VC. Finally, in accordance with Specific Aim 3, in-vivo rectal
dose measurements were compared to anthropomorphic phantom dose measurements,
CTDIvol-based dose estimates, and point dose measurements taken in a CTDI body
phantom. These specific aims were accomplished in order to test our hypotheses: in-vivo
rectal dose measurements obtained during virtual colonoscopy will have a rectal dose
coefficient of variation that will be greater than 50%; and anthropomorphic phantom rectal
dose measurements, CTDIvol-based dose estimates, and Farmer chamber measurements
in a CTDI body phantom will estimate rectal doses outside the 95% confidence interval of
the mean patient dose measurements.

3.2 Specific Aim 1: Establish TLD Linearity Correction Factors for VC Scan
Parameters on a MDCT
Although the Radiologic Physics Center (RPC) (Houston, TX) typically provides
energy and dose linearity correction coefficients to customers as a standard service, their
established correction factors pertain to those doses and energies encountered in photon or
electron cancer therapy by linear accelerator and are specifically defined for higher
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energies (a minimum of 1 MV) and doses (a minimum of 200 mGy) than those obtained by
MDCT dose to a patient’s rectum. Therefore Specific Aim 1 was deemed necessary for this
project, which provided correction factors relevant for MDCT at the energy and in the dose
range encountered in VC. Guidance, TLDs, and TLD readout for the establishment of
these coefficients were provided by staff at the RPC (under the direction of Dr. David
Followill).

3.2.1 MDCT Beam Characterization
In order to identify any discrepancies in TLD readings and actual dose
measurements in the event of a change in the MDCT x-ray tube between TLD irradiation
and anthropomorphic phantom or in-vivo patient VC measurements, several x-ray beam
quality factors were measured. These measurements were conducted in the same CT
sessions as when the TLDs were irradiated to establish the dose linearity correction factors
for VC conditions, and upon completion of all in-vivo dose measurements. Doing so
provided the additional advantage of producing data that may reduce the variability or
uncertainty between the TLD patient dose readings and future Monte Carlo rectal dose
calculations because the equivalent source model of some Monte Carlo codes relies on this
beam data to develop the virtual CT scanner that delivers the dose to the patient in the
simulation (60). These measured beam factors included the half-value layer (HVL),
quarter-value layer (QVL), CTDI in-air measured with a 100 mm pencil chamber
((CTDI100)air) (88), weighted CTDI (CTDIw), and volume CTDI (CTDIvol) for the MD Anderson
Cancer Center VC technique on the institution’s “CT9” GE LightSpeed VCT scanner; as
well as HVL and QVL measurements on the “CT5” and “CT12” GE LightSpeed VCT
scanners to demonstrate consistency in x-ray tube output between the three MDCT
scanners utilized for VC.

67

3.2.1.1 HVL and QVL Measurement
The HVL and QVL measurements were made using the method described by
Mathieu, et al (95) incorporating the Lambert W function (the multivalued inverse of
Equation 3-1) as a more generalized form of the Lambert-Beer equation (Equation 3-2)
such that it becomes appropriate for the polyenergetic spectrums encountered in CT:

z = W (z ) ⋅ eW ( z )

(3-1)

I = I 0 ⋅ e − µ ⋅x

(3-2)

where z is a complex number (96), I is the intensity of the filtered photon beam (measured
as exposure in mR), I0 is the intensity of the unfiltered photon beam (mR), µ is the linear
attenuation of the filtering material (in mm-1), and x is the thickness of the attenuating
material (in mm) . Mathieu used these equations, along with an empirical model for a mean
linear attenuation coefficient ( µ ) for the polyenergetic photon spectrum in narrow-beam
geometry (Equation 3-3) as the basis to derive Equation 3-4 and Equation 3-5 to interpolate
the HVL and QVL, respectively:
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(3-4)

(3-5)

where µ represents the mean attenuation coefficient of the polyenergetic photon beam,
and λ and µ0 are unknown coefficients whose values are simplified to Equation 3-6 and
Equation 3-7, respectively, by Lambert W interpolation.
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Equations 3-6 and 3-7 are based on attenuated exposure measurements  x1 ,
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I
 ; where x1 and x2 are two thickness of aluminum 1100 alloy (in mm), and 1 and
I0


I2
each represent the respective ratios of the exposure measurements made using x1 and
I0
x2 thickness of Al 1100 alloy filtration to the exposure measurements made with no filtration.
The value of the technique proposed by Mathieu is its demonstrated ability to
accurately interpolate x-ray beam hardness values (such a HVL or QVL, which describe the
thickness in millimeters of aluminum 1100 alloy (mm Al) necessary to reduce the intensity
of an attenuated beam to one half or one quarter of its unattenuated value, respectively)
using only one unfiltered and two filtered beam intensity measurements (each of which are
acquired with different thicknesses of aluminum alloy filtration). This technique is
contrasted with the more traditional technique, where HVL and QVL have been measured
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taking several measurements with increasing aluminum thicknesses until the radiation
intensity measurements were less than half of the unattenuated intensity; and the HVL was
interpolated (using either linear or semi-logarithmic interpolation methods) between the two
thicknesses that yielded slightly less and slightly more than half exposure value filtration.
Thus, to measure both HVL and QVL required a minimum of five (and typically many more)
exposure measurements traditionally and only three with Lambert W interpolation. Mathieu
showed that by attempting to obtain both HVL and QVL with only three total exposure
measurements with a pencil ionization chamber on a CT scanner at 120 kVp, the
interpolated HVL and QVL values will only be within 5% of the nearest measurable HVL
thickness 22% and 23% of the time, respectively, when using linear interpolation; and 76%
and 84% of the time, respectively, when using semi-logarithmic interpolation. Under the
same conditions, the Lambert W interpolation method yielded HVL and QVL values within
5% of the nearest measureable thickness in 100% of the measurements (95).
To obtain the HVL and QVL measurements, two thicknesses of aluminum 1100
alloy were measured with electronic calipers, and the average of eight measurements at
different points on each of the aluminum plates was determined to be the average thickness
of each Al 1100 plate. Next, the Radcal pencil ionization chamber described in Chapter 2
was secured inside the center bore of a CTDI head phantom using paper towels to prevent
chamber movement within the phantom resulting from CT scanner table movement during
chamber alignment to the scanner isocenter, and the CTDI phantom was set onto the headholder attachment and was affixed to theGE LightSpeed VCT scanner table. The pencil
chamber was positioned within the center bore of the CTDI head phantom such that in-air
measurements could be acquired. The Radcal pencil ionization chamber was connected to
the Radcal electrometer by triaxial cable, and the electrometer was set to acquire
measurements in auto dose mode (in units of mR). After the ionization chamber/phantom
assembly was secured to the scanner head-holder attachment with tape, the table was
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moved such that the center of the active volume of the pencil chamber was located at
isocenter. The CT scanner was then set to the zero position ((0,0,0) in the frontal, sagittal,
and axial planes) (see Figure 3-1).

Figure 3-1. Using a CTDI head phantom on the head-holder attachment to place the pencil
ionization chamber at isocenter of the CT scanner bore for in-air measurements.

With the pencil ionization chamber in-air at isocenter, the CT scanner was placed in
service mode, and the x-ray tube was set to remain stationary through a scan (i.e. such that
it did not rotate when the tube was on) at the bottom position of the gantry (in the 180
degree position) (see Figure 3-2). The scanner was otherwise set such that the x-ray tube
irradiated the ionization chamber to the same technique as that used by MD Anderson
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Cancer Center for VC described in Table 1-1: 120 kVp, 100 mA, the default trigger rate of
984 Hz, large (body) bowtie filter, small focal spot, effective beam width of 40 mm, and the
default calibration vector setting of “full”. Exposure times of one second were used for
these exposures to achieve a total of 100 mAs as opposed to the 0.5 second rotation head
time described in Table 1-1 (yielding 50 mAs) because VC at MD Anderson Cancer Center
utilizes two CT scans (one each with the patient in a prone and in a supine position). Since
each scan provides 50 mAs of exposure to the patient, and since dose is linearly related to
mAs (37), these two exposures were combined into one 100 mAs exposure for the purpose
of these beam quality measurements.

Beam Collimator
Mylar Window

Figure 3-2. X-ray tube held stationary at the 180 degree (bottom) position of the CT scanner.

Exposure measurements were acquired for three separate scans, and the average
of the three exposures (in mR) was determined to be the I0 value (see Figure 3-3). One of
the measured sheets of Al 1100 alloy (x1 = 6.36 mm thick) was then set on the gantry over
the Mylar window and exposure measurements were again acquired for three scans (with
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the average being considered the I1 value). Finally, a second 13.48 mm thick sheet of Al
1100 alloy was added to the beam filtering, providing a total filter thickness of x2 = 19.84
mm. Exposure measurements were acquired for three scans in this third configuration (see
Figure 3-4), and the average of these measurements was determined to be the I2 value.
With all of the measurements complete, the HVL and QVL values of the MDCT scanner
were determined for 120 kVp using the VC protocol using Equations 3-4, 3-5, 3-6 and 3-7.

Figure 3-3. Configuration used to measure the unattenuated exposure (I0).
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Figure 3-4. Configuration used to measure the x1 and x2 attenuated exposures (I1 and I2).

3.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination
With the CT scanner in normal image acquisition mode (i.e. such that the x-ray tube
rotated when on), and the pencil ionization chamber located in air at isocenter (as was the
case for the HVL and QVL measurements displayed in Figure 3-1 above), the CT scanner
was set to the following technique to approximate (for CTDI measurement purposes)
irradiation conditions experienced in VC at MD Anderson Cancer Center: axial scan, 0.5
sec per rotation of the x-ray tube, an effective beam width of 40 mm, 120 kVp, 200 mA,
standard reconstruction algorithm, large (body) bowtie filter, large body scan field of view
(SFOV) and 50 cm display field of view (DFOV). In a manner similar to the scan technique
utilized in the beam HVL and QVL measurements, 100 mAs was used to acquire these
CTDI measurements to simulate the combined dose received by patients undergoing VC
from the prone and supine CT scans. Exposure measurements were acquired (in mR) for
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three scans using this technique, the average of these exposure measurements was
calculated, and the (CTDI100)air was calculated using Equation 1-11:

CTDI100,air = ( f ⋅ C ⋅ E ⋅ L )

(N ⋅ T )

(1-11)

where f = 0.0087 mGy/mR, C = 1 (the actual temperature and pressure correction factor of
0.99 was factored into the exposure reading provided by the electrometer, therefore C=1
was used), E was the average of the three exposure measurements (in mR), L was the
length of the pencil chamber (L = 100 mm), N was the number of data channels, T was the
detector width sampled by each channel, and the product N*T was the nominal beam width
(N*T = 40 mm). In order to establish the linearity of the MDCT scanner output with mAs,
(CTDI100)air measurements were acquired using this technique in 10 mAs increments from
20 mAs (40 mA) to 170 mAs (340 mA). The results of these linearity measurements gave
us confidence these measurements would also be linear within the center bore of a CTDI
body phantom.
The final step of characterizing the beam quality was to determine the CTDIw in the
32 cm CTDI body phantom with the MD Anderson Cancer Center VC protocol. To do this,
the CT table padding was peeled back, and the head-holder attachment was removed.
Next, the phantom was placed on the unpadded MDCT scanner table and positioned by
laser alignment such that the gantry isocenter was located at the phantom’s center bore
and such that the other bores were located at the 12, 3, 6, and 9 o’clock positions. The
scanner was zeroed (0,0,0) to the center (in the frontal, sagittal, and axial planes) of the
phantom according to the laser alignments, and the phantom was secured in place with
tape. The standard acrylic insert rods were inserted into the 8 peripheral bores of the CTDI
body phantom and the pencil chamber was inserted into the center bore such that the
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marked center of the ionization chamber corresponded with the center of the phantom (and
the scanner landmark (zero) point) (see Figure 3-5).

Figure 3-5. Configuration used to measure the exposure in the center bore of the CTDI body
phantom, which was used to calculate (CTDI100)c.

The electrometer was used in the auto dose measurement mode (in mR) and the
scanner was set to the following technique to represent VC conditions at MD Anderson
Cancer Center (axial scan, 0.5 sec per rotation of the x-ray tube, nominal beam width of 40
mm, 120 kVp, 200 mA (totaling 100 mAs to represent combined patient dose from the
prone and supine CT scans), standard reconstruction, large (body) bowtie filter, large body
SFOV, and 50 cm DFOV. Exposure measurements were acquired (in mR) for three scans.
The average of these measurements was calculated and this average exposure value was
used to calculate the CTDI100 value for the center bore (CTDI100)c) using Equation 1-11 and
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the same values for f, C, L, and N*T as those previously used to calculate the CTDI100,air
values.

Figure 3-6. Configuration used to measure the exposure in the 12 o’clock bore of the CTDI
body phantom, which was used to calculate (CTDI100)12. A similar configuration was used to
measure the respective exposures in the determination of (CTDI100)3, (CTDI100)6, and (CTDI100)9.

Next, the pencil ionization chamber was removed from the center bore and placed in
the peripheral bore in the 12:00 position of the phantom (and the insert rod that formerly
occupied that bore was placed in the center bore) (see Figure 3-6). The process used to
measure the three exposure measurements with the pencil ionization chamber in the
determination of (CTDI100)c was repeated, yielding the CTDI100 value for the 12 o’clock bore
position ((CTDI100)12). Similarly, the process was repeated for the peripheral bores located
in the 3, 6, and 9 o’clock positions, and the CTDI values for these positions were also
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determined ((CTDI100)3, (CTDI100)6, and (CTDI100)9, respectively). These four peripheral
CTDI100 values were averaged to obtain the (CTDI100)periphery value used in Equation 1-12 to
calculate CTDIw. Volume CTDI (CTDIvol) was calculated from this CTDIw value using
Equation 1-14, and this measurement was compared to the CTDIvol value displayed on the
scanner console to verify consistency.

=
CTDI w

1
2
( CTDI100 )center + ( CTDI100 ) periphery
3
3

(1-12)

CTDI w

(1-14)

CTDI vol =

pitch

3.2.2 Determination of TLD Dose Linearity Correction Coefficients for Virtual Colonoscopy

3.2.2.1 TLD Irradiation at Exposures Received by Patients Undergoing Virtual Colonoscopy
The Farmer style ionization chamber was attached to the electrometer and was
placed in the phantom’s center bore (with the standard PMMA insert rods placed in the 8
remaining peripheral bores) (see Figure 3-7). The build-up caps were attached to the
proximal (wired) end and to the distal (active volume) end of the Farmer chamber (as
shown in Figure 2-9) such that the entire bore volume was occupied with minimal air gap.
The CTDI body phantom was positioned at isocenter in the “CT9” GE LightSpeed VCT
scanner table. The Farmer ionization chamber was aligned within the center bore such that
the active volume was at the center (0,0,0 coordinate) of the phantom as shown in Figure 37.

78

Figure 3-7. Configuration used to measure the exposure in the center bore of the CTDI body
phantom with the Farmer ionization chamber.

A posterior-anterior (PA) survey (i.e. scout) image was obtained of the phantom
assembly at 120 kVp and 10 mA. A helical scan was specified to be conducted from 75
mm superior to 75.4 mm inferior to the landmarked (0,0,0) coordinate (i.e. through the
length of the CTDI phantom). The CT scanner was set to standard MD Anderson VC
protocols: full helical scan mode with 0.5 sec rotation time, 1.25 mm image thickness,
39.37 mm/rotation table speed, 0.984 pitch, 0.8 mm interval, 120 kVp, 100 mA, 0 sec delay,
and standard reconstruction algorithm.
The ionization chamber exposure was measured and recorded for two scans under
the specified CT technique for a total photon output of 100 mAs per x-ray tube rotation
(representing the cumulated exposure acquired from both the prone and supine 50 mAs
scans in VC). In addition to exposure, the scan time (in sec), the scanner estimate of
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CTDIvol (in mGy), and the scanner estimate of dose length product (DLP) (in mGy*cm) were
recorded for each scan for reference purposes. This process was repeated three times,
and the average of the three iterations of two summed exposure measurements was
determined to be the exposure value used for comparison with the TLD doses. The
exposures from the PA scout scans were not measured or documented as this dose is
known to be small, is often considered negligible compared to that provided by the actual
CT scan (15), and is not displayed on the scanner console (thus no benchmark for
comparison is available). The dose contributions to each patient from the PA and lateral
scout scans was estimated as described in Chapter 3.3.2.7.
Next, one double-chambered TLD capsule was inserted into the seating cut in the
center of the custom-designed insert rod (fabricated by the MD Anderson Cancer Center
Machine Shop and shown in Figures 2-7 and 2-8). The Farmer ionization chamber was
replaced within the CTDI body phantom with the TLD-loaded insert rod, and the TLD was
placed in the center (in the frontal, sagittal, and axial planes) of the CTDI body phantom
(with the CT scanner still landmarked to this location as (0,0,0)) (see Figure 3-8). The
phantom was then irradiated with the TLD embedded within its center using the same CT
technique settings as those previously used to irradiate the Farmer ionization chamber
(including the use of two helical scans in each measurement). After a TLD was irradiated,
the TLD-loaded insert rod was removed from the phantom and the irradiated TLD capsule
was taped to a piece of paper and the paper was carefully labeled to document the study
number assigned to that TLD and the conditions under which each TLD was irradiated.
After the two CT scans representative of the two supine and prone scans received
by a patient undergoing VC had been accomplished, the TLD-loaded insert rod was loaded
with a second unirradiated TLD capsule within the customized insert rod. The newly
assembled TLD-loaded insert rod was identically placed back within the CTDI body
phantom, and the second TLD was irradiated in the same manner as the Farmer ionization
80

chamber and the first TLD. TLD readout results from the RPC were provided on the same
sheet of paper as that on which the irradiated TLDs were labeled to minimize opportunities
for incorrect results to be reported for a specific scan technique.

Custom-Made Insert Rod
with TLD Seat in Position
within the Phantom

Figure 3-8. Configuration used to measure the dose in the center bore of the CTDI body
phantom with a TLD inserted into the custom-made insert rod.

In order to obtain the TLD dose linearity response for the spectrum of rectal doses
expected to be encountered in the range of sizes of VC patients, this technique was
repeated at approximately 0.5 mGy increments from the lowest expected dose to the
highest expected dose. Since it is well-known that dose is linearly proportional to mAs (37),
the scan technique was increased in 10 mAs increments from the estimated lowest rectal
dose (described in Chapter 1.3.5) of 0.5 mGy (0.7 mGy was measured at 20 mAs) to the
estimated upper rectal dose of 11.2 (10.8 mGy at 170 mAs) to achieve the approximate 0.5
mGy dose increments desired. For the lowest dose levels, where the Farmer chamber
could not detect exposure in the center of the CTDI body phantom, exposure values were
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extrapolated based on the linearity of the CTDI values at the mid- and upper range dose
levels. These extrapolations were based on the principle of x-ray tube linearity observed in
the CTDI100,air measurements.
In order to ensure KL,120 values pertaining to the lowest doses were sufficiently
quantified, four TLDs (each with two aliquots of TLD-100 powder) were used to measure
doses at 20, 30, 40, and 50 mAs. The doses administered at the mid- and upper-range
tube currents (in 10 mAs increments from 60 mAs to 170 mAs) were each measured with
two TLDs (each also containing two aliquots of TLD-100 powder). Thus, a total of 16 doses
were measured (along with 5 background TLDs) for a total of 45 TLDs being used to
determine the KL,120 values for this TLD batch under VC conditions. As each TLD capsule
contained two separate chambers filled with TLD-100 material, either eight or four total TLD
measurements were therefore obtained at the low and mid/high-dose ranges, respectively.
The TLDs were read by the RPC a minimum of 14 days after irradiation in order to reduce
uncertainties caused by fading and drift.

3.2.2.2 TLD Readout and Dose Linearity Correction Factor Calculation
The RPC conducted the TLD read-out process as described in Chapters 1.2.3 and
2.4, and provided the following data for each TLD: charge reading (Q) (in µC), aliquot TLD
mass (mg) (in mg), sensitivity (KS) (i.e. dose to muscle in cGy/µC/mg, which was converted
to mGy/µC/mg for the order of magnitude of rectal doses received by patients undergoing
VC) (see Equation 1-5 for details on KS determination), and fading correction factor (KF)
(unitless) (see Equation 1-1). In order to calculate the dose to the acrylic phantom using
the method outlined in Equation 1-8, the f-factor for acrylic (fAcrylic = 0.78 rad/R) was divided
by the f-factor for muscle/soft tissue (fMuscle = 0.94 rad/R) (42) in a manner similar to that
described by Equation 1-7. Thus, TLD dose to the CTDI body phantom was calculated by
Equation 3-8:
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DMedium =

f Acrylic
Q
⋅ K S ⋅ K L ,120 ⋅ K F ⋅
mg
f Muscle

(3-8)

where KL,120 is the dose linearity correction factor for the GE LightSpeed VCT spectrum at
120 kVp (unitless). TLD response may not be linear at diagnostic energies or in the dose
range experienced by patients undergoing VC (25, 26), therefore the two correction
coefficients cannot be determined independently without additional information being
available regarding TLD-100 batch response to this energy or dose range. Therefore, the
dose linearity correction factor could only be defined for the desired range of doses for each
desired energy spectrum. However, it was only necessary for this protocol to define the
dose linearity correction factor at 120 kVp because that is the only energy specified by MD
Anderson Cancer Center VC protocols. Defining KL at additional energies was therefore
determined to be outside the scope of this project.
In order to calculate values of KL,120 appropriate for VC, the exposure measurements
obtained by the Farmer ionization chamber (in mR) had to be converted to dose in the
acrylic CTDI body phantom (in mGy). These calculations were made using the appropriate
conversion factors (100 rad = 1 Gy, 1000 mGy = 1 Gy, 1000 mR = 1R) and an f-factor of
fAcrylic= 0.78 rad/R (42). The Farmer ionization chamber measurement represented an
accumulated dose to the center point within the CTDI body phantom as a result of the direct
photon beam and from scatter through the phantom. The average dose of the three Farmer
ionization chamber exposure measurements for each mAs setting was calculated and
estimated to be the true dose within the medium (DMedium) for that specific protocol. Using
this value as a standard by which to compare the dose response within the TLDs, KL,120 was
calculated by rearranging Equation 3-8 into Equation 3-9:

83

K L ,120 =

DMedium
f Acrylic
Q
⋅ KS ⋅ KF ⋅
mg
f Muscle

(3-9)

where Q is the TLD charge reading (in µC), mg is the aliquot TLD mass (in mg), KS is the
TLD sensitivity correction factor (in mGy/µC/mg), KF is the fading correction factor
(unitless), fMuscle = 0.94 rad/R, and fAcrylic= 0.78 rad/R. These resultant KL,120 values were
used to establish a third-order polynomial regression curve using Excel software (Microsoft
Corporation, Redmond, WA) based on apparent TLD dose measurements (i.e. TLD dose
measurements not corrected by KL,120 values). This regression equation was used to
calculate anthropomorphic phantom and in-vivo patient rectal dose from apparent TLD dose
measurements in VC at MD Anderson Cancer Center in Specific Aim 2.

3.3 Specific Aim 2: Obtain Rectal Dose Measurements in an Anthropomorphic
Phantom and In-Vivo in Patients Undergoing VC with TLDs
With Specific Aim 1 accomplished, both the MDCT beam quality and the TLD
response had been established for the dose range and energy spectrum received by a
patient’s rectum when undergoing virtual colonoscopy (VC). Before obtaining in-vivo rectal
dose measurements in patients undergoing VC at MD Anderson Cancer Center, rectal dose
measurements were acquired with thermoluminescent dosimeters (TLDs) (provided by the
Radiologic Physics Center (RPC), Houston, TX) within an anthropomorphic phantom.
Performing these measurements allowed for the identification of any potential problems in
in-vivo measurements through “practice” measurements and allowed for an assessment of
the accuracy of measurements acquired in a phantom compared to in-vivo measurements.
MD Anderson Cancer Center Institutional Review Board (IRB) approval was obtained to
perform in-vivo rectal radiation dose measurements for patients undergoing VC. IRB
84

approval was granted for this study to affix two TLDs to the inner diameter of the standard
rectal catheters used in 10 patient VC studies at MD Anderson Cancer Center, but data for
only 6 of these patients were available at the time of the writing.

3.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic Phantom
In order to conduct simulated VC measurements in an anthropomorphic phantom,
an ATOM model 701 adult male phantom (Computerized Imaging Reference Systems, Inc
(CIRS), Norfolk, VA) was modified by placing a circular cut into the pelvis of the phantom to
simulate an insufflated rectum during VC. This simulation also included modification of a
rectal catheter tip that is used in VC and creation of a plug to lift the rectal catheter tip away
from the posterior wall of the simulated insufflated rectum within the phantom. In order to
increase the relevance of the results obtained from measurements within this phantom that
was designed according to standardized geometric dimensions (that may not reflect the
anatomy of many actual patients), additional simulations were performed with layers of
simulated adipose tissue added to the surface of the anthropomorphic phantom such that
rectal dose determination could be made to simulate patients of larger habitus.

3.3.1.1 Modifications to the Anthropomorphic Phantom
Measurement of the Miller™ rectal catheter contained within the E-Z-EM model
8925 Super XL Enema System (Bracco Diagnostics Incorporated, Princeton, NJ) revealed
that the tip of the rectal catheter (where the TLDs were placed in this experiment) was
approximately 25 mm in length. This length correlated well with the 25 mm length of each
section of the ATOM phantom. Therefore it was determined that although rectal and
colonic insufflation during VC extends for the entire length of these organs, irradiation
conditions where these point measurements would be taken with the TLDs could be
adequately replicated by only cutting a bore representative of an insufflated rectum into one
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25 mm section of the ATOM phantom. Doing so also minimized potential damage to the
ATOM phantom that may have been detrimental to future dosimetric or imaging
experiments.
Selection of the phantom section to be cut was determined through analysis of
supine CT images obtained from 29 randomly selected VC exams previously performed at
MD Anderson Cancer Center from 9/22/2009 to 9/10/2010. In each of these supine CT
image sets, the images containing the superior, center, and inferior portions of each rectal
catheter head were evaluated with respect to reference anatomical bony landmarks
(femoral heads, femurs, acetabulum, coccyx, pubic bone, ischia). These same bony
landmarks were observed on the ATOM phantom, and the section of the phantom that most
closely corresponded to the average location of the rectal catheter head (and therefore the
average location of the TLDs) was determined. Among the 29 exams evaluated, the TLDs
would have been placed in the anatomical location approximately corresponding to ATOM
phantom section 33 in 9 patients, in section 34 in 15 patients, and in section 35 in 5
patients (see Figure 3-9). As the mean, median, and mode of this distribution all equaled or
rounded to section 34, this ATOM phantom section was determined to contain the average
location of the rectal catheter head during VC at MD Anderson Cancer Center.

Figure 3-9. Representative images of patients with a mean TLD location corresponding to
section 33, section 34, and section 35, respectively, of the ATOM phantom
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Figure 3-10. Illustration of maximum rectal diameter measurements at the superior, central,
and inferior TLD locations

Determination was also made regarding the size of the insufflated rectum at the
location corresponding to the placement of the TLDs in this study. This measurement was
important in order to resolve the size of the cut to make within section 34 of the ATOM
phantom. This estimation was made using two different methods. The first method for
determining the size of the insufflated rectum incorporated measurements of the largest
diameter of the rectum in the supine scan image that corresponded to the superior, central,
and inferior borders where the TLDs would be located within a patient (see Figure 3-10).
These measurements were made using the tools available in Philips iSite Enterprise patient
archiving and communication system (PACS) (Philips Healthcare, Andover, MA). The
largest rectal diameter in an exam was chosen to be the reference measurement obtained
because it was the easiest dimension to determine in each rectum (which varied widely in
size and shape of insufflation within the population of VC patients analyzed). The average
maximum rectal diameter measurement at the superior portion of the TLDs was 59.6 mm,
the average of the diameter measurements at the center of the TLDs was 69.3 mm, and the
average of the diameter measurements at the inferior portion of the TLDs was 59.4 mm.
The average of these three diameters was 62.8 mm, which represented the average
insufflated rectal diameter as concluded by our first method.

87

The second approach for determining the size of rectal insufflation involved
estimating the average diameter of the rectum after insufflation while accounting for
potential differences in these measurements based on rectal catheter head placement
within the surrounding anatomy and based on the size of the patient. Of the 15 patients
that had their respective rectal catheter heads placed in the anatomical position that
corresponded to section 34 of the ATOM phantom, six of these patients were approximately
the same size as the ATOM phantom. This was based on estimating the cross sectional
shape of each patient and the phantom to be an oval (at the approximate center image
where TLDs would be located), by measuring the short and long radii (rshort and rlong,
respectively) of each patient, and by calculating the estimated cross sectional area (Area)
of each of the 15 patients (see Figure 3-11) using Equation 3-10:

Area = π ⋅ rshort ⋅ rlong

(3-10)

Figure 3-11. Illustration of the approximation of the cross-sectional area of a patient, the
ATOM phantom, and the cross-sectional area of the patient’s insufflated rectum, respectively,
at the mean TLD location

Using this method, the cross sectional area of the ATOM phantom was estimated to
be 550 cm2, and the average cross sectional area of the six patients was estimated to be
554 cm2 (within 1%). Next, the area of the insufflated rectum of each of these six patients
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was also estimated to be an oval and the area of each insufflated rectum was also
approximated using Equation 3-10. The six rectal cross sectional areas were averaged to
obtain a cross sectional area of 33.5 cm2. Normalizing this area by the difference between
the average patient cross sectional area and the phantom cross sectional area, an average
insufflated rectal cross sectional area was calculated to be 33.2 cm2 for a patient of
approximately equal cross sectional size to the ATOM phantom. This area was determined
to be equivalent to a circle 65.0 mm in diameter, which showed good agreement with the
62.8 mm average diameter estimate obtained from the first measurement technique.
Averaging these two diameters yielded a circle of approximately 64 mm in diameter, which
was determined to be the most appropriate diameter for the circular cut that was placed in
the phantom to represent an insufflated rectum around the TLDs.

Figure 3-12. Illustration of the determination of the location of an insufflated rectum within
the axial plane of a patient by establishing reference coordinate axes and acquiring rectumto-surface distance measurements along the reference coordinate axes, respectively

With the ATOM phantom section selected and the size of the simulated insufflated
rectum calculated, it was appropriate to determine proper placement of the cut within the
phantom slice. This was accomplished by measuring the distance of the insufflated rectum
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to the surface of each patient in both the x and y directions. In these measurements, the
reference x- and y- coordinate systems were established with respect to the locations of the
femoral heads in each patient (because not all patients’ femoral heads were lying parallel to
the CT scanner table and were therefore slightly tilted within the scan) such that the
reference x-coordinate in each patient was parallel to an imaginary axis through the femoral
heads. The center of each reference coordinate axes was established to be the
approximate center of the insufflated rectum, and the distance measurements from the
rectal wall to a patient’s skin were taken along this reference coordinate axis. This
measurement process is illustrated in Figure 3-12.
These rectal wall measurements within the six patients that most closely were
represented by the ATOM phantom showed that the average insufflated rectum lied slightly
to a patient’s left by an average of 6.6 mm, and towards a patient’s posterior surface by an
average of 57.5 mm. Transposing the anticipated 64 mm diameter circular cut onto the
phantom using these dimensions proved problematic, however, because such a cut within
the phantom would have cut through the phantom’s coccyx; which would not be a realistic
scenario for VC gas insufflation. Therefore, the location of the 64 mm diameter circular cut
within section 34 of the ATOM phantom was modified to be the approximate center in the
lateral direction, and 5 mm anterior to the coccyx (which provided a representative posterior
rectum positioning similar to that demonstrated in the actual patient measurements) (see
Figure 3-13).
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Figure 3-13. ATOM 701 adult male phantom section 34 before modification to include
simulated insufflated rectum.

The circular cut into section 34 of the ATOM phantom that simulated the insufflated
patient rectum was made by the MD Anderson Cancer Center Machine Shop (Houston,
TX). The cut was designed to be circular to make the cutting process easier. Much of the
removed phantom plug was spared such that it could be reinserted into the bore to
accommodate future dosimetric and imaging studies. Where some phantom material was
lost during the cutting process (based on the width of the cutting tool), the plug was
supplemented with a sleeve composed of solid water material to reestablish a functionally
tight fit when the plug was inserted into the phantom. Figure 3-14 shows section 34 of the
ATOM phantom both with the simulated insufflated rectum and with the plug in place.
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A)

B)

Figure 3-14. A) ATOM 701 adult male phantom section 34 after modification to include
simulated insufflated rectum; B) ATOM phantom section 34 with plug for non-VC studies.

3.3.1.2 Modifications to the Rectal Catheter
With the ATOM phantom appropriately configured to accommodate simulations of
rectal dose measurements during VC at MD Anderson Cancer Center, it was necessary to
modify a rectal catheter such that it could be placed within the assembled ATOM phantom.
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This was accomplished by simply excising the superior 24 mm of a rectal catheter head
from the rest of the rectal catheter as shown in Figure 3-15. Since a review of the 29
previous supine VC scans revealed that the rectal catheter rests at various locations within
the insufflated rectum and rarely against the posterior portion of the rectum (as would be
the case if the catheter tip was simply placed into the insufflated rectal cavity shown in
Figure 3-14A), a low-density Styrofoam plug was fabricated to lift the modified rectal
catheter tip away from the simulated rectal catheter wall to more closely represent VC
conditions (shown in Figure 3-16).

Modified Rectal
Catheter

TLD

Figure 3-15. Miller™ Enema Air Tip rectal catheter modified for insertion into ATOM phantom
section 34 for simulated VC.
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ATOM Phantom Slice 34

Modified Rectal
Catheter

Low Density
Styrofoam Plug

Figure 3-16. Low density Styrofoam plug designed for insertion into the phantom simulated
insufflated rectum to lift the rectal catheter tip away from the phantom posterior rectal wall
during simulated VC.

3.3.1.3 Anthropomorphic Phantom Assembly
Once the ATOM phantom had been modified to represent VC conditions at MD
Anderson Cancer Center, the phantom was assembled such that the sections were
properly aligned and ordered from section 1 at the top of the phantom head descending to
section 39 at the upper thigh. For convenience during phantom irradiation, the phantom
was assembled such that several sections were attached to each other by tape and/or
nylon straps according to anatomical grouping: the shoulders/thorax/abdomen (sections
10-29), the pelvis (sections 30-37), and the upper legs (sections 38-39). The phantom
head (sections 1-9) was not utilized because its presence would have only contributed
minimally to the rectal scatter dose and because of the difficulties associated in positioning
this portion of the phantom to adjoin to the rest of the phantom torso when the adipose
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tissue layers were attached. Since the ATOM phantom legs were not available to simulate
the additional scatter dose that would be present in a real patient, the CTDI body phantom
and an additional anthropomorphic abdomen and pelvis phantom designed for imaging
studies (manufacturer unknown) was attached to sections 38-39 as shown in Figure 3-18
below to approximate such scatter dose contribution to the rectum from a patient’s legs.

3.3.1.4 Phantom Measurements and Determination of Population Percentages
Represented
With the phantom assembled, anthropomorphic measurements were acquired to
determine the percentage of the population represented by the phantom. A limitation of any
anthropomorphic phantom is the fact that, although they are designed and fabricated to
represent a standardized “typical” human in composition and dimension (in accordance with
ICRP 23 (49) in the case of the ATOM phantom (81, 82)), they are limited in that the results
rendered from dose measurements obtained in these phantoms only can be considered
accurate for patients of approximately equal size and body composition as the phantom.
Therefore, it was important to determine the percentage of the population that was
represented by the ATOM phantom.
A limit to the validity of anthropomorphic phantom geometry measurements in their
correlation to measurements obtained in actual patients undergoing VC exists in that the
phantom is constructed of rigid epoxy resin materials fashioned after a standing patient,
and actual patients are composed of materials that shift depending on whether that patient
is lying either on their dorsal or ventral surfaces during VC. True patient dimensions
demonstrate depth measurements that decrease and breadth measurements that increase,
compared to when standing erect, when a patient is laying on their dorsal or ventral
surfaces. Therefore, measurements that quantified dimensions involving patient breadth or
depth were determined to be inappropriate for comparison between patient and phantom
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dimensions. Patient circumference measurements can also vary based on patient position
(specifically regarding whether a patient is standing or lying), especially in the buttocks
region on most patients (as well as in other regions in obese patients) where folds in the
skin can make true circumference measurements difficult to achieve and where the
distribution of excess weight can shift along the axial direction of a large patient. The
changes in patient circumference with patient position, however, are not as significant as
changes in patient breadth or depth; therefore circumference measurements were
determined to be most appropriate for comparison between true patient measurements and
phantom measurements.
PeopleSize 2008 Professional software (version 1.1) (Open Ergonomics Ltd,
Leicestershire, UK) was used to determine the percentage of US adults (aged 18-64)
represented by the ATOM phantom. This software provided anthropomorphic data for six
trunk circumferential measurements, including: chest circumference at the armpits (axillae),
waist circumference at the midpoint, abdominal waist circumference, mid-hip
circumference, hip circumference around the buttocks, and maximum hip circumference.
The locations on the ATOM phantom corresponding to each of these locations are shown in
Figure 3-17. The results of these measurements, and the percentile of the US adults aged
18-64 represented by these measurements, are shown in Table 3-1.
In order to expand the applicability of measurements obtained in the
anthropomorphic phantom to patients of different habitus, CIRS has manufactured
additional layers of adipose tissue-equivalent material in order to conduct dosimetry studies
for obese patients using the ATOM phantom. These “fat slabs” were designed to be
applied to the outer surface of the phantom in up to two layers as described in Chapter 2.
These fat slabs provided the capability to perform dosimetry studies with the ATOM
phantom for patients of three sizes.
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1) Chest circumference at the armpits (axillae)
2) Waist circumference at the midpoint
3) Abdominal waist circumference
4) Mid-hip circumference
5) Hip circumference around the buttocks
6) Maximum hip circumference

Figure 3-17. Locations of circumference measurements on the ATOM phantom, including: 1)
chest circumference at the armpits (axillae), 2) waist circumference at the midpoint, 3)
abdominal waist circumference, 4) mid-hip circumference, 5) hip circumference around the
buttocks, and 6) maximum hip circumference.

Table 3-1. CIRS ATOM phantom circumference measurements and corresponding percentage
of US adults aged 18-64 represented.

ATOM
Circumference
(mm)
940
815
850
890
890
920
884

Measurement
Chest circumference at armpits (axillae)
Waist circumference, at the mid point
Waist circumference, abdominal
Mid-hip circumference
Hip circumference, around buttocks
Hip circumference, maximum
Average

Percentile of US
Adults (18-64 Years)
(%)
20
23
27
9
4
5
15

The adipose tissue-equivalent phantom fat slabs were positioned onto the ATOM
phantom pelvis in a manner similar to that shown in Figure 2-5A such that the fat slabs
attenuated the primary CT beam before being measured by the TLDs within the modified
rectal catheter placed in the phantom’s rectum. The fat slabs were assembled onto the
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ATOM phantom by first attaching the hook and latch ends of the large “1B” and “1D” slabs
such that the labels were facing the same direction. Next, these attached slabs were slid
over the lateral portions of the previously assembled ATOM pelvis (sections 30-37) with
slab “1B” being placed over the phantom’s left side. Slab “1A” was then slid under the hook
and latch assembly against the posterior side of the phantom such that the widest surface
was in contact with the phantom. The first layer of fat slabs was complete when slab “1E”
was similarly slid under the hook and latch assembly on the anterior side of the phantom.
Anthropomorphic measurements were then performed on the fatter ATOM phantom to
determine the percentage of US adults aged 18-64 that were represented by this habitus.

Table 3-2. Circumference measurements of the first layer of CIRS adipose tissue slabs after
attachment to the ATOM phantom pelvis and the corresponding percentage of US adults aged
18-64 represented.

Measurement
Mid-hip circumference
Hip circumference, around buttocks
Hip circumference, maximum
Average

Fat Layer 1 + ATOM
Circumference
(mm)
1170
1175
1180
1175

Percentile of US
Adults (18-64 Years)
(%)
92
87
81
87

As mentioned in Chapter 2, these fat slabs only provide 20 cm of phantom surface
coverage. Therefore only three of the six circumference measurements acquired for the
ATOM phantom torso were able to be acquired for the two additional phantom
configurations, including: mid-hip circumference, hip circumference around the buttocks,
and maximum hip circumference. The results of these measurements and the percentiles of
US adults aged 18-64 represented by these dimensions are provided in Table 3-2.
Averaging the percentiles of US adults aged 18-64 represented by these three
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circumference measurements yielded an approximation that the 87th percentile was
represented by the phantom configuration with the first layer of fat slabs attached to the
pelvis.

Table 3-3. Circumference and thickness of supplemental fat material to add to
th

anthropomorphic regions of the ATOM phantom corresponding to the 87 percentile of US
adults aged 18-64.
th

Anthropomorphic Region

87 Percentile
of US Adults
(18-64 yr)
Circumference
(mm)

Supplemental
Circumference
to be Added to
Phantom
(mm)

Supplemental
Thickness to
be Added to
Phantom
(mm)

1155
1135
1135
1142

215
320
285
273

34
51
45
44

Chest circumference at armpits (axillae)
Waist circumference, at the mid point
Waist circumference, abdominal
Average

Using this phantom configuration to approximate the rectal dose received by a
patient undergoing VC at MD Anderson Cancer Center was problematic because where the
fat slabs only extended 20 cm along the phantom’s pelvis, an appropriate VC scan of a
person whose torso length equaled that of the phantom would have been much longer.
Therefore, in order to appropriately represent the conditions experienced by a patient
undergoing VC, additional application of adipose tissue-equivalent material to the external
surface of the ATOM phantom was necessary. The amount of additional fat material
necessary to represent a patient in the 87th percentile of US adults aged 18-64 was
determined by calculating the 87th percentile measurements of the three additional
circumferences measured for the ATOM phantom without the fat slabs in place (but which
were not measureable due to the short length of the fat slabs). These three additional
circumferences included: chest circumference at armpits (axillae), waist circumference at
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the midpoint, and abdominal waist circumference. The results of these circumference
values provided by PeopleSize 2008 Pro, the amount of fat circumference required to be
added, and the amount of additional fat required to be added to the ATOM phantom to
achieve these circumferences are provided in Table 3-3.
Upon completion of the analysis required for the ATOM phantom with the first fat
layer attached, the second fat layer was added to the exterior of the first fat layer in a
manner similar to that shown in Figure 2-5B. This was accomplished by first attaching the
hook and latch pads located at the ends of the large “2B” and “2D” slabs such that the
labels were facing the same direction. Next, these attached slabs were slid over the lateral
portions of the previously assembled 87th percentile ATOM pelvis (sections 30-37) with slab
“2B” being placed over the phantom’s left side. Slab “2A” was then slid under the hook and
latch assembly on the posterior side of the phantom such that the widest surface was in
contact with the first fat layer. The second layer of fat slabs was complete when slab “2E”
was similarly slid under the hook and latch assembly on the anterior side of the phantom.
The same three pelvis circumference measurements as were performed on the first layer of
fat slabs when attached to the ATOM phantom were then performed on the phantom with
the second fat layer attached to determine in PeopleSize 2008 Pro software the percentage
of US adults aged 18-64 this third habitus represented. These measurements and
percentiles are provided in Table 3-4, and the average of these measurements was
approximated to be representative of the 99th percentile of US adults aged 18-64 years.
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Table 3-4. Circumference measurements of the second layer of CIRS adipose tissue slabs
after attachment to the ATOM phantom pelvis, and the corresponding percentage of US
adults aged 18-64 represented by this phantom configuration.

Measurement
Mid-hip circumference
Hip circumference, around buttocks
Hip circumference, maximum
Average

Fat Layer 2 + ATOM
Circumference
(mm)
1410
1435
1465
1437

Percentile of US
Adults (18-64 Years)
(%)
99.9
99.5
99.99
≈99

In a manner similar to that performed for the first fat layer, the average amount of
additional fat material was determined with PeopleSize 2008 Pro that was required to be
added to: the phantom chest circumference at the armpits (axillae), the waist
circumference at the midpoint, and the abdominal waist circumference; such that the
phantom configuration represented the 99th percentile of US adults aged 18-64. These 99th
percentile circumferences, the amount of additional circumference, and the amount of
additional thickness to add to the built-up phantom (with the first fat layer and supplemental
fat material) are provided in Table 3-5. Obtaining 99th percentile patient measurements was
useful for this study because such measurements should represent minimum rectal dose
limits (due to maximum attenuation by surrounding fatty tissue), which insured that the
lower limits of administered rectal doses would be detectable with the TLDs in this study.
We did not expect to perform many (if any) in-vivo measurements in patients large enough
to be considered within the 99th percentile of US adults aged 18-64.
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Table 3-5. Circumference and thickness of supplemental fat material to add to
anthropomorphic regions of the CIRS ATOM phantom (with the first layer of supplemental fat
th

already in place), corresponding to the 99 percentile of US adults aged 18-64.
th

Anthropomorphic Region

99 Percentile
of US Adults
(18-64 yr)
Circumference
(mm)

Supplemental
Circumference
to be Added to
Phantom
(mm)

Supplemental
Thickness to
be Added to
Phantom
(mm)

Chest circumference at armpits (axillae)
Waist circumference, at the mid point
Waist circumference, abdominal
Average

1352
1481
1469
1434

197
346
334
292

31
55
53
47

With the amount of supplemental fat material to be added to the chest
circumference at the phantom’s armpits (axillae), to the phantom’s waist circumference at
the midpoint, and to the phantom’s abdominal waist circumference calculated for the two
larger phantom configurations, the issue of appropriate selection of supplemental fat
material to utilize became a relevant decision. It was determined that the most practical,
workable, and cost effective material that could be implemented to create a realistic scatter
medium was pig adipose material in the form of lard. Therefore 207 pounds of lard were
purchased and repackaged into 8 space-saver plastic luggage bags (ITW Space Bag®,
San Diego, CA) and two zipper-style resealable two-gallon bags that could be molded into
shape and sealed after forcing air out of the bags. As an added precaution against soiling
the CT scanner or phantom with this adipose material, a plastic sheet was placed between
the CT scanner table and the phantom assembly. Each two-gallon bag was filled with 2-3
pounds of lard material, each medium-sized plastic luggage bag was filled with 15-18
pounds, and each large-sized luggage bag was filled with 30-35 pounds such that the
appropriate thickness of fat material (shown in Tables 3-3 and 3-5) could be added to the
exterior of the ATOM phantom at the appropriate locations both superior and inferior to the
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CIRS fat tissue layers (over the thorax/abdomen and leg regions of the phantom). During
the simulated VC procedures with the ATOM phantom, the bags of adipose tissue were
secured in place around the appropriate phantom circumferences with duct tape.

3.3.1.5 Virtual Colonoscopy Simulation in an Anthropomorphic Phantom
Before acquiring any TLD measurements during simulated VC in the ATOM
phantom, the “CT9” GE VCT scanner at MD Anderson Cancer Center was evaluated to
determine the beam half-value layer (HVL), quarter-value layer (QVL), weighted computed
tomography dose index (CTDIw), volume CTDI (CTDIvol), and 100 cm in-air CTDI
(CTDI100,air) as described in Chapter 3.2.1. These beam quality measurements were
obtained for comparison purposes with those beam quality measurements that were
acquired when the TLDs were irradiated during the calibration procedure (Specific Aim 1).
HVL and QVL measurements were also performed upon the completion of in-vivo dose
measurements on all three GE VCT scanners upon which measurements were performed
to verify the consistency of the beam output of the x-ray tubes. Once the x-ray tube beam
quality had been initially characterized by each of these entities on the “CT9” scanner, the
ATOM phantom was prepared for simulated rectal dose measurements during VC.
Before placing the ATOM phantom onto the CT scanner, a plastic sheet was placed
onto the table to reduce the risk of the simulated adipose material soiling the scanner.
Next, each of the previously established ATOM phantom regions were placed onto the
scanner table and assembled such that the respective regions (i.e. thorax and abdomen,
pelvis, upper legs/leg simulation medium) abutted to one another. The 15th percentile
configuration phantom was placed on the scanner table such that it was lying in a supine
position and no additional fat slabs were attached (see Figure 3-18). The MDCT scanner
was then landmarked to the (0,0,0) coordinate at the center of the phantom in the coronal
plane (which had previously been marked on the phantom with tape), in the approximate
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center of the phantom in the sagittal plane, and in the center of phantom section 34 in the
axial plane (87.5 mm from the inferior edge of the phantom pelvis region). A piece of tape
was placed on the scanner table in the axial direction at section 34 and a mark was placed
on the tape along the laser marking the axial plane for consistency in alignment between
the phantom and the CT scanner in the repeated scans. A posterior-anterior (PA) scout
image of the assembled phantom was acquired at 120 kVp and 10 mA to determine the
superior and inferior borders of the VC scan, which corresponded superiorly with section 18
at the base of the lungs and inferiorly at section 36 at the ischium. This scan length was
based on the same landmarks used to determine scan length of actual patients undergoing
VC at MD Anderson Cancer Center.

VC Scan Length

Thorax and Abdomen
Region

Leg
Region

Pelvis
Region

TLD
Location

CTDI
Phantom

Anthropomorphic Abdomen
and Pelvis Phantom

Figure 3-18. Phantom assembly utilized in simulated VC rectal dose assessment.

With the scan length established, the strap connecting the pelvic region of the
phantom was disconnected, and section 34 was removed from the rest of the pelvis
assembly. The custom-cut insufflated rectum plug was then removed from the phantom
section and the Styrofoam plug was inserted into the bore. The modified rectal catheter tip
104

was then inserted into the Styrofoam plug, and two double-chambered TLDs (obtained from
the RPC) were inserted into the modified rectal catheter tip. The TLDs were not attached to
the rectal catheter wall or subjected to extensive quality assurance (QA) measures to
ensure patient safety (as would be the case for in-vivo measurements) because such steps
were unnecessary within the inanimate phantom.
When the two TLDs had been inserted into the modified rectal catheter, the ATOM
phantom pelvis was reassembled, the strap holding the region together was refastened,
and the entire ATOM phantom was carefully reassembled by aligning the marks on the
scanner table and section 34 such that the phantom was in the same position as during the
acquisition of the scout image. The MDCT scanner was then set to MD Anderson Cancer
Center VC scan protocols: full helical scan mode with 0.5 sec rotation time, 1.25 mm image
thickness, 39.37 mm/rotation table speed, 0.984 pitch, 0.8 mm image interval, 120 kVp, 100
mA, 0 sec delay, and standard reconstruction algorithm. The phantom was then irradiated
in the supine position using this CT scan technique. Since CT dose is well known to be
linearly proportional to mAs (37), and since this experiment was not concerned with
obtaining the diagnostic benefits described in Chapter 1.1.2 that are associated with
acquiring both supine and prone CT scans in VC, the ATOM phantom was not rolled over to
a prone position but rather simply irradiated a second time with the same technique to
simulate the prone scan.
Once the two double chambered TLDs had been irradiated with both supine VC
scans, the pelvic region of the phantom was again disassembled and section 34 was
removed. The two TLDs were then extracted from this phantom section and were taped to
a sheet of paper that was carefully labeled with TLD identification information and the
irradiation conditions of the TLDs. Next, a second set of two double chambered TLDs were
inserted into the modified rectal catheter and the phantom was reassembled. The phantom
was identically placed on the MDCT scanner using the alignment lasers and marks placed
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on both the table and the phantom (see Figure 3-19); and the phantom was irradiated using
the same MD Anderson Cancer Center method used to irradiate the previous TLDs. When
the second set of TLDs had been irradiated, they were replaced with a third set of two
double chambered TLDs within the ATOM phantom.

Figure 3-19. Placement of the anthropomorphic phantom on the MDCT scanner such that a
mark designating the location of the TLDs within the phantom align via laser with a mark
placed on the scanner table

After a total of three sets of two double chambered TLDs had been irradiated within
the initial (15th percentile) ATOM phantom configuration (i.e. without the additional fat slabs
and supplemental fat material), a fourth set of TLDs were inserted into the phantom and the
first fat layer was added to the external circumference of the pelvis. For alignment
purposes, a mark was placed on the surface of the fat slab that was 87.5 mm from the
inferior edge of the phantom pelvis region to correspond to the center of phantom section
34. Next, a medium-sized space-saving bag containing lard was placed on the CT scanner
table abutting to both the inferior and superior ends of the pelvis fat slabs (see Figure 3106

20A). The superior and inferior portions of the phantom were then placed on top of the
bags filled with lard and were each covered with a second medium-sized bag. The two
lard-filled bags were abutted around the respective lateral portions of the phantom and
were attached at that end with two pieces of duct tape (see Figure 3-20B). The bags of
adipose tissue were then wrapped around the respective portions of the phantom and were
connected by two more pieces of duct tape on the opposite lateral portion of the phantom
(see Figure 3-20D). On the phantom thorax and abdomen, the two bags were too short to
connect on the opposite side; so an additional zipper-style two-gallon bag containing 2-3
additional pounds of adipose tissue was placed between the respective space-saver bags
(see Figure 3-20C).
With the superior and inferior portions of the lard wrapped around the phantom,
significant efforts were made to ensure the connecting regions of the phantom correctly
abutted to one another. At times, this required placing towels and pillows under portions of
the adipose material to correctly position the phantom. Once the regions of the phantom
were adequately adjoined, the adipose tissue within the bags surrounding the phantom
were then manipulated by hand such that the lard within the combined bags was
approximately 51 mm thick at the abdomen and tapered down to approximately 34 mm
thick at the abdomen in accordance with Table 3-3.
The adipose material attached to the leg region of the phantom was manipulated by
hand to be an approximately uniform 40 mm throughout because this thickness equaled
that of the fat slabs manufactured by CIRS (and anthropometric data for upper leg
circumference was not available in PeopleSize 2008 Pro software). It should be noted,
though, that manipulation of the fat to desired thickness was inexact and even after
extensive efforts, certain portions remained thicker than others (for example, the central
portions of the lard-filled bags supporting the phantom weight were unavoidably thinner
than the lateral portions of those bags due to the effects of gravity).
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A)

B)

Medium-Sized Bag
of Adipose Tissue

Support Towel

C)

D)

Zipper-Style Bag of
Adipose Tissue

Figure 3-20. A) Placement of the phantom onto a medium-sized bag filled with adipose tissue
th

to represent the 87 percentile of US adults aged 18-64; B) Attachment of two abutting
adipose tissue-filled bags with duct tape at the lateral portion of phantom; C) The use of a
zipper-style two-gallon bag filled with adipose tissue to connect opposing bags surrounding
the phantom thorax and abdomen; D) Attachment of the abutting adipose tissue-filled bags
with duct tape at the opposite lateral portion of phantom after pulling the bags tightly around
the phantom.
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Figure 3-21. ATOM phantom assembled to represent the 87 percentile of US adults aged 1864 for simulated VC.

When the respective regions had been supplemented with sufficient adipose
material to represent the 87th percentile of US adults aged 18-64 (the percentile
corresponding to the pelvic circumference attained when the first fat layer was added to the
ATOM phantom pelvis), the phantom was reassembled (see Figure 3-21) onto the MDCT
scanner such that the mark placed on the pelvic fat slab at phantom section 34 aligned with
the mark placed on the scanner table. This phantom configuration was then irradiated
twice (both times with the phantom in the supine position) using the MD Anderson Cancer
Center CT scan technique for VC provided above. The pelvis region of the phantom was
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then rolled away from the rest of the phantom assembly, disassembled, the TLDs within
section 34 were replaced with two more double chambered TLDs, the phantom
configuration was reassembled, and the process was repeated such that a total of three
measurement sets of two double chambered TLDs were acquired in the 87th percentile
phantom configuration.
Upon the completion of measurements acquired to represent the rectal dose
received by the 87th percentile of US adults aged 18-64 while undergoing VC, the phantom
was modified to accommodate for measurements representing the dose received by the
99th percentile (the percentile corresponding to the pelvic circumference attained when the
second fat layer was additionally added to the ATOM phantom pelvis) during VC. This was
accomplished by disassembling the entire phantom used to represent the 87th percentile
and by placing two double chambered TLDs into the ATOM phantom pelvis. Next, the
second fat layer was added to the ATOM phantom pelvis and the pelvis assembly was
placed on the CT scanner table.
In order to ensure consistency in phantom placement between iterations and
configurations, a piece of tape was placed on the external surface of the second pelvic fat
slab and a line was placed on the tape 87.5 mm from the inferior surface of the pelvic
region. This line represented the location of the center of ATOM phantom section 34 and
the location of the TLDs, and the pelvis assembly was adjusted on the scanner table such
that this line was in alignment to the line previously placed on the scanner table. A largesized bag of lard was then placed onto the CT scanner table both superiorly and inferiorly to
the phantom pelvis such that both bags abutted to the second fat slab layer encompassing
the phantom pelvis. A medium-sized bag of lard was additionally placed on top of each
large-sized bag, and the 87th percentile phantom configuration was assembled using these
medium-sized bags on top of the large-sized adipose tissue bags.
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Once the 87th percentile phantom configuration had been reassembled, a second
large-sized bag of adipose tissue was placed on top of the superior and inferior regions of
the 87th percentile phantom configuration, and the two large-sized bags were attached at
one lateral portion of each region of the phantom by two pieces of duct tape. In a manner
similar to that used to assemble the 87th percentile configuration, the large-sized bags were
then pulled tightly around the phantom and secured at the opposite lateral side of the
phantom by two additional pieces of duct tape (incorporating an additional zipper-style twogallon bag of adipose tissue to connect the large-sized bags on the thorax/abdomen portion
of the phantom). In a manner also similar to that incorporated to assemble the 87th
percentile phantom configuration, considerable care was taken to ensure the adjoining
portions of the ATOM phantom were correctly mated to one another by using additional
towels and pillows to prop up portions of the phantom as appropriate.
When the ATOM phantom was correctly aligned, the bags of adipose tissue were
adjusted to ensure they abutted to the pelvic fat slabs, and then the lard within the largesized bags were manipulated by hand such that the abdominal thickness of lard was
approximately 54 mm thick and tapered to approximately 31 mm thick at the chest (in
accordance with Table 3-5).

As with the 87th percentile phantom configuration, the large-

sized bags of lard surrounding the leg portion of the phantom assembly were additionally
manipulated to be approximately 40 mm thick throughout. Such hand manipulation of the
adipose tissue within the bags was inexact, and portions of the respective bags unavoidably
accumulated more lard (i.e. the lateral portions of the bags) than other portions (i.e. the
portion of the bags supporting the weight of the phantom).

111

th

Figure 3-22. ATOM phantom assembled to represent the 99 percentile of US adults aged 1864 for simulated VC.

Figure 3-22 shows the final phantom assembly used to represent the body habitus
of the 99th percentile of US adults aged 18-64. In order to acquire multiple measurements
within a phantom configuration, the pelvic region of the phantom was rolled away from the
rest of the phantom assembly (see Figure 3-23), disassembled, irradiated TLDs were
harvested and replaced with unirradiated TLDs within the ATOM phantom pelvis, and the
entire phantom was reassembled for each measurement set. This process became very
time consuming and required patience. As was the case with the two previous phantom
configurations simulating VC using the MD Anderson Cancer Center protocol, the three
measurement sets of two double chambered TLD measurements were acquired for the
phantom configuration simulating the rectal dose received by the 99th percentile of US
adults aged 18-64 undergoing VC.
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Figure 3-23. Disassembly of 99 percentile phantom configuration for repeated TLD
measurements during simulated VC; with the two layers of CIRS simulated phantom fat
disattached from the ATOM phantom pelvis region (held in-tact during simulated VC by the
black nylon strap shown).

Simulation of in-vivo rectal dose measurements in an ATOM phantom was
completed after the three sets of two double chambered TLDs were irradiated within the
phantom configuration simulating the 99th percentile of US adults aged 18-64. In total,
three sets of two double chambered TLD measurements were accomplished for three
phantom configurations equaling 12 TLD dose measurements per habitus for a total of 36
TLD measurements with the ATOM phantom. The RPC conducted the TLD read-out
process a minimum of 14 days after irradiation as described in Chapters 1.2.3 and 2.4.

3.3.1.6 Simulated Virtual Colonoscopy Data Analysis
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The results provided by the RPC included the following data for each TLD: charge
reading (Q) (in µC), aliquot TLD mass (mg) (in mg), sensitivity (KS) (i.e. dose to muscle in
cGy/µC/mg, which was converted to mGy/µC/mg for the order of magnitude of rectal doses
received by patients undergoing VC) (using Equation 1-5), and fading correction factor (KF)
(unitless) which was adjusted according to Equation 1-1 to account for the time delay
between TLD irradiation and readout. The linearity and energy correction factors (KL,120)
used to calculate dose for these measurements were those established in Specific Aim 1.
These dose measurements were used to fit a regression model estimating rectal dose
based on a patient’s effective diameter; and 95% confidence intervals and an R2 goodness
of fit coefficient were calculated for this regression analysis. The average of the 12 dose
measurements at each simulated habitus was determined to be the dose received by a
specific patient habitus, and these average dose values were used to accomplish Specific
Aim 3 in comparing the TLD dose measurements to CTDIvol-based size specific dose
estimate (SSDE) and Farmer chamber dose measurements taken in a uniform CTDI body
phantom.

3.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy
MD Anderson Cancer Center Institutional Review Board (IRB) approval was
obtained to perform in-vivo rectal radiation dose measurements for patients undergoing VC.
IRB approval was granted for this study to affix two TLDs to the inner diameter of the
standard rectal catheters used in 10 patient VC studies at MD Anderson Cancer Center. At
the time of this writing, however, data was only available for six VC patient measurements,
and therefore data will only be presented in this work for those six patients. As mentioned
above, each of the TLDs used in this study contained two measurement chambers; and
therefore four total rectal radiation dose measurements were obtained for each patient. Per
standard VC procedure, the rectal catheters were not used for more than one patient (which
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significantly reduced the opportunity for infection in patients as a result of participation in
this study); therefore 6 different rectal catheters were used in this study.
The only deviation from the standard MD Anderson Cancer Center protocol for VC
(described in Chapter 1.1.2) introduced by this study was the measurement of the radiation
dose received by the rectum by affixing the two small TLDs inside the same rectal catheter
used as a part of the standard VC procedure. Four measurements were obtained per
patient of the accumulated dose administered to that patient’s rectum from four scout
images and both prone and supine CT scans. In order to reduce the chances of TLD-100
material coming in direct contact with patients, of TLDs becoming dislodged from the rectal
catheter, or of patients or researchers receiving an infection as a result of participation in
this study, a quality assurance (QA) system was established covering five stages of quality
control (QC). These QC steps were implemented into the TLD/catheter assembly and VC
processes.

3.3.2.1 QC Step 1: Testing TLD Capsules for Leakage
The first stage of QC was designed to ensure that the plastic encapsulating the
TLDs remained watertight while in a patient. These measures were important because
although LiF toxicity data shows that initial GI symptoms may appear with quantities of LiF
ingestion as low as 120 mg (97) (and this amount is greater than the total amount of LiF
used per patient in this study), irritation of the mucosal cells of the rectum and large
intestine may result from contact with LiF (97-99). However, as the tissues of the rectum
and distal portions of the large intestine only permit trace amounts of most materials to be
absorbed (98), it was determined that there was little risk of notable side effects in the very
unlikely event that LiF escaped encapsulation.
In order to ensure the integrity of the TLD encapsulation, the following steps were
accomplished for each TLD/rectal catheter assembly:
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1. Two double chamber TLDs obtained from the Radiologic Physics Center (RPC) were
visually inspected with a magnifying glass to ensure there were no cracks in the plastic
capsule and that the wax plug was firmly in place.
2. The TLDs were submersed in a tap water bath within a small container for a period no
less than 24 hours (see Figure 3-24).
3. After at least 24 hours had passed, LiF powder within the TLD capsule was carefully
examined for any condensation or nonuniformities. As LiF is hygroscopic (97), it readily
absorbs water within its environment and should provide visually obvious signs of any
such water intake. The appearance of the TLD capsule was compared to that of a
control TLD that had not been submerged.
4. Any TLD that would have absorbed water would be deemed to have an insufficient seal
for this project and therefore returned to the RPC.

Figure 3-24. QA test #1: Place TLDs in a water bath for 24 hours.

3.3.2.2 Attaching TLDs to the Rectal Catheter
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Once the integrity of the TLD plastic encapsulation was established, two doublechambered TLDs were inserted into the inner lumen of the rectal catheter and secured by
Silicone II (General Electric Corporation, Huntersville, NC) silicone glue and suture string
(Tyco Healthcare, Norwalk, CT). Both of these agents had previously established a history
of being bio-inert in other applications at MD Anderson Cancer Center (with this silicone
glue used in the assembly of eye plaques treating ocular melanomas with brachytherapy
and the suture being used surgically). These TLDs were secured inside this rectal catheter
tip as illustrated in Figure 3-25 using the method described below. Although the placement
of the TLDs within the catheter decreased its inner diameter, care was taken to ensure the
function of the device was not substantially altered.

Figure 3-25. Cross section diagram of TLD placement within the rectal catheter

The following steps were accomplished to assemble the two TLDs to the inner
lumen of the rectal catheter:
1. One end of the bag in which the E-Z-EM Super XL Enema Delivery System (Model
8925) was packaged was carefully cut using scissors (see contents of the bag in Figure
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1-2). Although the catheter assembly was not a sterile device, care was taken when
handling the device to minimize contamination and protect the components.
2. A pea-sized amount of silicone glue was placed onto the tip of an unfolded paperclip
and this glue was dabbed onto the inner lumen of the rectal catheter tip (see Figure 326) through the superior opening just proximal to (and on the same axis as) the balloon
inflation extrusion (as labeled in Figure 2-13). This application of glue was repeated
with several pea-sized applications of silicone glue applied to the same area such that
the interior of the catheter head was similar in appearance to Figure 3-27.
3. Two 10 cm lengths of 2-0 (0.3 mm diameter) polypropylene suture string (Tyco
Healthcare, Norwalk, CT) were weaved through the external ports of the rectal catheter
such that they bridged the bed of silicone glue (without becoming embedded into the
bed of glue) and the two ends were loosely tied with the first throw of a surgeon’s knot
(the right end of the suture was tied over the left end twice yielding a double overhand
knot) as shown in Figure 3-28.
4. One TLD was then inserted into the superior opening of the rectal catheter and carefully
navigated to the applied glue bed (under the suture bridge) using an unfolded paperclip
fed through the superior and exterior bores of the rectal catheter. When the TLD was in
position along the inner surface of the rectal catheter tip abutting to the superior lip of
the rectal catheter lumen (adjacent to the superior opening), the TLD was pressed into
the glue using the paper clip and the double overhand knots were drawn taught. The
Surgeon’s knots were then completed with the second throw such that the TLD was
secured into position. With the TLD secure, most of the excess suture was removed,
and the knots were rotated into the interior of the rectal catheter as shown in Figure 329.
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Figure 3-26. Application of a pea-sized amount of silicone glue to the interior of the rectal
catheter.

Bed of Silicone Glue

Figure 3-27. Proper amount of silicone glue applied to the inner lumen of the rectal catheter
tip.
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Figure 3-28. Two 10 cm lengths of suture string tied in the first throws of surgeon’s knots.

Figure 3-29. Proper placement of the first TLD to the inner lumen of the rectal catheter tip.

5. The excess glue within the rectal catheter was smoothed over using a paperclip to
ensure that no more than one of the external holes on the rectal catheter head was
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occluded (to ensure that the functionality required of the rectal catheter was
maintained).
6. While slightly pinching the tip of the rectal catheter such that the superior bore assumed
an oval shape, the second TLD was inserted into the rectal catheter head such that the
end of the TLD that contained the wax plug was the last portion of the TLD to enter the
rectal catheter (see Figure 3-30). Inserting the TLD in this manner ensured that the
TLD was placed with minimal effort and that the TLD would remain within the rectal
catheter during the VC procedure due to the tapered geometry of the TLD capsule (with
the plugged end of the TLD having the largest diameter). This TLD was not secured
with silicone glue or suture because the partial occlusion of the superior opening of the
catheter by the secured TLD prevented the escape of the unglued TLD.

Figure 3-30. Proper insertion of the second TLD into the rectal catheter head.

7. Excess glue was wiped from the exterior of the rectal catheter tip.
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8. The rectal catheter/TLD assembly was placed in a warm and dry environment, and the
silicone glue was permitted to dry for a minimum of 24 hours.
9. After at least 24 hours had passed, the assemblies were visually inspected to verify the
placement of the TLD within the rectal catheter head and to verify that the TLDs and
glue did not occlude more than one external hole on the rectal catheter head. The final
TLD/rectal catheter assembly is shown in Figure 3-31.
10. As a final check of the functionality of the rectal catheter assembly, air was forced
through the open end of the blue insufflation tube to verify that the gas insufflation port
within the rectal catheter was not accidentally occluded with silicone glue. If it was
discovered that this hole was occluded, a hole was punctured and reamed out in the
silicone glue at the gas insufflation port (shown in Figure 2-13) to reestablish gas
insufflation capability.

Figure 3-31. Proper final placement of two TLDs within the rectal catheter.
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3.3.2.3 QC Step 2: Testing for Secure TLD Attachment to the Rectal Catheter
The second stage of QC was designed to ensure that the TLDs would remain
attached to the rectal catheter at all times while in a patient. This was accomplished by
applying compression and flexion conditions to the exterior surface of the rectal catheter
with forces exceeding those encountered in the rectal environment; and by water flow
testing the apparatus with pressures exceeding those encountered in the contrast
administration process. The second stage of QC was not executed until the glue had been
permitted to dry for at least 24 hours, and execution of this QC stage was conducted with
the following steps:
1. Observing the TLDs through the superior opening of the catheter, the rectal catheter
head was physically compressed several times by hand force such that the two TLDs
came into contact with one another. During compression, the secured TLD was
observed for movement away from the catheter wall as the tension within the tip of the
rectal catheter was applied and relieved. If little or no TLD movement from the catheter
lumen wall was observed, additional compression forces were applied to the catheter
head such that the TLDs both came in contact with the opposite catheter wall
(completely collapsing the catheter tip). Again, the secured TLD was observed for
movement away from the wall to which it was glued.
2. If little or no TLD movement was observed, the catheter head was again compressed
such that the TLDs came in contact with the respective opposite walls, and the
assembly was then rolled/flexed three or four times by hand force such that the TLDs
were leveraged against each other and forced to peal the secured TLD away from the
rectal catheter wall. While doing this, the secured TLD was observed for movement
away from the catheter wall to which it was attached.
3. If little or no TLD movement was observed, tap water was poured into the contrast
agent bag and the cap on the bag was closed. The rectal catheter tip was directed into
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a sink and the contrast bag was held several feet higher than the rectal catheter tip.
The contrast bag containing the tap water was then squeezed such that water was
forced through the rectal catheter at pressures greater than those encountered by
hydrostatic means (i.e. at pressures greater than those experienced during VC).
4. If the TLDs remained within the rectal catheter, the catheter assembly was determined
to have passed the second QC step. If, however, a catheter assembly failed any of
these tests, the assemblies were immediately dried and the TLDs were reapplied using
the same process described above (Section 3.3.2.2). No TLD/catheter assembly was
be used clinically unless it passed each of these tests.

3.3.2.4 QC Step 3: Disinfection of Rectal Catheter Assembly
The third stage of QC was implemented to ensure patients did not receive an
infection as a result of participation in this study. In spite of the fact that VC is a clean
procedure (and not a sterile procedure), the TLD/rectal catheter assemblies underwent
disinfection after successfully completing the first two stages of QC (and before being
inserted into patients). Careful handling ensured disinfection was maintained until the
catheter came in contact with a patient. To conduct this QC procedure, the following steps
were accomplished:
1. 70% isopropyl alcohol solution (Target Corporation, Minneapolis, MN) was poured into
an appropriately sized container to 10 cm of depth.
2. The contrast agent bag, tubes and rectal catheter were coiled into a circle
approximately 25 cm in diameter, similarly to the configuration in which it was packaged
by the manufacturer.
3. The contrast agent tubing was grasped, exposing the rectal catheter (the portion that
was to be inserted into the rectum), and the rectal catheter was submerged 9 cm into
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the 70% isopropyl alcohol (up to the bulge on the shaft). The catheter assembly
remained in the alcohol solution for at least 10 seconds.
4. After the alcohol bath was completed, the catheter tip was removed from the alcohol
solution and excess alcohol was gently shaken from the rectal catheter back into the
container.
5. With the assembly still coiled, the disinfected assembly was returned to the original E-ZEM Double Contrast Enema Delivery System packaging in a similar manner as
originally packaged for storage until used clinically. Careful handling ensured
disinfection was maintained until the catheter came into contact with a patient. The
enema packaging was secured with packing tape to ensure the contents of the bag
remained secure while in storage.
6. The disinfected rectal catheter assemblies were stored in a dark location that was
secure from outside radiation sources.

3.3.2.5 Irradiating TLDs during VC and QC Step 4: Maintenance of Control of TLDs at All
Times
Once the TLD/rectal catheter assemblies, preparatory QA steps, and disinfection
were completed, 6 patients were recruited for the study in accordance with the conditions
established for IRB approval. This study was limited to those patients whom were already
approved for VC by their primary physician and their insurance. Patient recruitment,
informed consent, and evaluation were conducted by one of two board certified radiologists
experienced in VC interpretation (Drs. David Vining and Priya Bhosale). The process of
obtaining informed consent for this protocol was overseen by the Office of Translational and
Clinical Research within the Division of Diagnostic Imaging at MD Anderson Cancer Center.
The criteria for inclusion in this study included: those patients scheduled for VC as
part of routine standard-of-care (including both screening and diagnostic VC exams), an
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ability to provide informed consent, and an ability to read and speak English (because the
team was unable to conduct the informed consent process in any other language). Criteria
for exclusion from this study included: women of childbearing age (unless a negative urine
or serum pregnancy test was obtained within 48 hours prior to participating in the study), a
history of allergic reaction to iodinated‐contrast agents, and patients under the age of 18.
Eligible participants were asked to participate in this research study between one and 30
days before the VC CT scan was conducted. Participants were made aware that if for any
reason during the procedure the participant wished to cease their involvement with the
study, their desires would be adhered to without prejudice and that their VC examination
would be conducted in the usual manner.
Once a patient had agreed to participate in this study and provided informed
consent, a disinfected and sealed rectal catheter/TLD assembly was removed from storage
for the scheduled VC appointment and provided to the radiologist at the MDCT scanner.
Although the typical VC protocol at MD Anderson Cancer Center does not require a
physician to administer the rectal catheter, appropriately trained radiologists conducted all
enema tip administration and removals for this study. The fourth stage of QC was
incorporated to ensure that the radiologist maintained control of the TLDs at all times. This
was accomplished by adhering to the following procedures:
1. The bag was opened, but not disposed of, using standard infection control personal
protective equipment (PPE) (gloves).
2. When beginning the procedure, the catheter assembly was carefully removed from the
bag and the inner lumen of the rectal catheter visually inspected through the superior
opening to verify that two TLDs could be visualized within the catheter (verifying an
appearance similar to that shown in Figure 3-31). The VC procedure was not to
proceed unless both TLDs were present.
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3. Upon verification of the presence of two TLDs within the catheter tip, the contrast bag
was clamped at the tubing and filled with the iodinated contrast agent by the CT
technologist. Additionally, the gas insufflation pump was connected to the blue tube by
the technologist and the rectal catheter was inserted into the patient by the radiologist
for the VC procedure (see Figure 1-4).
4. Upon completion of the CT scan, the catheter was removed from the patient’s rectum
and the radiologist immediately verified that two TLDs were present within the catheter.
If both TLDs were discovered to not be present within the catheter, it would be up to the
discretion of the radiologist to determine whether active retrieval actions should be
taken (i.e. Fleet’s enema). If such an event were to occur, active retrieval actions would
not typically be necessary after VC as all contents of the rectum and bowel are
discharged from the patient into a toilet almost immediately upon the completion of the
exam.
5. In the very unlikely event that one or both TLDs became dislodged from the rectal
catheter during a VC procedure, only the TLD that remained (if any) was to be used for
data acquisition purposes. If the situation were to arise, any dislodged TLDs were not
to be pursued due to infection control reasons.
6. Upon the completion of the VC procedure and verification of the presence of both TLDs
within the catheter, the radiologist held the rectal catheter such that it could be cut with
scissors and separated from the rest of the enema delivery system. The enema
delivery system was disposed as medical biohazardous waste. The rectal catheter was
closed within a zipper-style bag and this bag was enclosed into an additional bag for
infection control purposes. A folded piece of paper was placed between the two bags
containing the patient’s medical record number, the date of the exam, and the patient’s
study number (1-10).
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The CT scans were performed in accordance with the standard MD Anderson
Cancer Center VC procedure outlined in Chapter 1.1.2, with each patient receiving CT
scans in both a supine and prone position using a standard technique. As discussed
above, the two scans are necessary during VC to evaluate segments of the colon that may
be collapsed during one of the scans, as well as to shift residual feces/water that may mask
or simulate colonic lesions. During each VC procedure, the two affixed TLDs acquired a
total of four measurements of the accumulated absorbed radiation dose delivered to that
patient’s rectum during the two PA scout scans, the two lateral scout scans, and the two CT
scans.

3.3.2.6 TLD Retrieval and QC Step 5: Disinfection of Rectal Catheter Assembly and TLD
Capsules
The fifth stage of QC was incorporated to ensure the investigators and RPC staff did
not receive an infection as a result of participation in this study. This step involved a
thorough disinfection of the TLD/rectal catheter assembly, the harvesting of irradiated TLDs
from the rectal catheters, and an additional thorough disinfection of these TLD capsules.
To do so, the following procedures were conducted:
1. A suitable work environment was established with a deep sink and running water. Antimicrobial soap, disinfection wipes (containing bleach), 70% isopropyl alcohol in a
container, and appropriate personal protective equipment (PPE) (non-latex gloves, eye
protection, and disposable coat/covering) were collected.
2. With PPE donned, the bag containing the used rectal catheter was opened and the
paper containing patient identity information was also removed from the bag.
3. The exterior of the rectal catheter was then scrubbed for 30 seconds (with PPE donned)
with anti-microbial soap, disinfection wipes and copious warm tap water.
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4. The sutures holding the superior TLD to the rectal catheter were then cut, and the TLDs
were squeezed from the rectal catheter with hand pressure into the container containing
the 70% isopropyl alcohol solution; where they remained for several minutes.
5. When the TLDs had been retrieved from a catheter, that catheter was inserted back into
the zipper-style plastic bags and discarded as standard waste.
6. Upon completion of the TLD disinfection within the isopropyl alcohol, the TLDs were
dried with paper towels, securely attached to a sheet of paper labeled only with the
patient’s study number (1-6) and the date of the VC scan, and stored as appropriate
(i.e. in a dark place away from outside radiation sources) for at least 14 days before
being delivered to the RPC for reading.
7. Upon completion of these TLD resection and disinfection steps, the workspace and sink
were thoroughly disinfected with disinfection wipes. When workspace disinfection was
completed, the PPE were disposed as standard waste (except the eye protection, which
was disinfected as appropriate).
8. When clean-up and disinfection were accomplished, the patient study number (1-6) was
listed along with the patient medical record number and the date of the exam in a
password-protected study data collection Excel spreadsheet (Microsoft Corporation,
Redmond, WA) located on a secure computer at MD Anderson Cancer Center that was
password protected and located in a locked room. The spreadsheet columns
containing the patient identifiers were additionally hidden when not in use (to prevent
unnecessary personnel from incidentally viewing this information). When the necessary
information was recorded, those papers containing the patient identifiers that were
placed in the bags immediately after the VC scans had occurred were shredded.
Medical record numbers were only used when necessary to preserve data integrity, and
all involved research staff that had access to these records completed training for
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maintaining confidentiality of health information. Complete confidentiality was
maintained during this study and during manuscript preparation.

3.3.2.7 Patient Rectal Dose Determination
Once at least 14 days had passed from a VC procedure and TLD readout had been
accomplished, the RPC provided the following information for the purpose of calculating
patient rectal dose: TLD aliquot charge reading (in µC), aliquot TLD mass (in mg),
sensitivity correction factor (in cGy/µC/mg) and fading correction factor (unitless). These
values, along with the regression model for the dose linearity correction factor at 120 kVp
(KL,120) established in Specific Aim 1, were used to calculate the four rectal dose
measurements (in mGy) obtained for each of the 6 VC patients using Equation 3-8. Since
each of these TLD measurements included the rectal dose administered by the four to five
scout scans and two CT scans administered in each VC, additional efforts were made to
estimate the contribution of the scout scans to the measured doses.
Estimation of rectal dose from scout scans was performed in a similar manner as
that published by O’Daniel, et.al. in (15). First, patient lateral and PA TLD-to-surface
distance measurements were obtained from patient DICOM images, and the average
distance of the TLDs from the table during the in-vivo measurements were recorded for
both the prone and supine scans. Next, a Farmer style ionization chamber was placed on a
block on the CT scanner table such that the active volume of the chamber was at the
measured average supine TLD distance above the CT table. Lateral and PA scout scan
lengths were then established such that the active volume of the Farmer style ionization
chamber was placed in the center of each scout image. In-air exposure measurements
were then acquired using the same techniques as those to which the patients were
exposed (120 kVp, 10 mA). This process was repeated for the average distance from the
CT table to the TLDs when patients were placed in a prone position and for the scout
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technique used for the prone scout scans (120 kVp and 80 mA). Using the inverse square
law and patient lateral and PA TLD-to-surface distance measurements obtained from
patient DICOM images, each patient’s entrance skin exposure was then estimated for both
the PA and lateral scout scans in both the supine and prone positions. By assuming an
effective keV of 60 from the scout image technique of 120 kVp, a mass attenuation
coefficient of µ/ρ=0.2025 cm2/g (100), and density of 1.04 g/cm3 (90) for soft tissue, the
attenuated exposure to the rectum for each scout scan was estimated using the LambertBeer equation (Equation 3-2). These attenuated exposure estimates were added and were
converted to dose estimates using the f-factor for muscle (fMuscle=0.94 rad/R), thus yielding a
total rectal dose estimate from the scout scans. These total scout scan dose estimates
were subtracted from the four TLD rectal dose measurements obtained in each patient to
calculate CT rectal dose measurements for each patient. The average of these four CT
dose measurements was determined to be the rectal dose to a specific patient from the CT
scans administered in VC, and these average dose values were used to accomplish
Specific Aim 3 in comparing the TLD dose measurements to anthropomorphic phantom
measurements, CTDIvol-based dose estimates (including the size specific dose estimates
(SSDE)) and Farmer chamber dose measurements obtained in a uniform CTDI body
phantom.

3.4 Specific Aim 3: Compare In-Vivo Rectal Dose Measurements to Anthropomorphic
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements
from a Uniform Phantom

3.4.1 Introduction
When the TLD measurement results were received from the RPC and absorbed
dose measurements were calculated for every in-vivo dose measurement patient (along
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with the average rectal dose for each phantom configuration and patient) in Specific Aim 2,
these average dose measurements were compared to anthropomorphic phantom
measurements, CTDIvol-based size specific dose estimates (SSDE) estimates and a Farmer
chamber dose measurement taken in a uniform CTDI body phantom. To do so, the
following values were tabulated by phantom configuration and patient in a passwordprotected Excel spreadsheet (Microsoft Corporation, Redmond, WA) to protect patient
identity in accordance with IRB and HIPAA requirements: phantom configuration (P0-P2)
or patient identifier (a number 1-6), patient medical record number and VC scan date (with
these columns hidden and password protected for additional patient identity protection),
patient thickness measurements obtained using Philips iSite Enterprise PACS software
(Philips Healthcare, Andover, MA) from a supine CT image that was determine to be the
median location of the TLDs (posterior-anterior (PA), lateral, and circumference
measurements, along with effective diameter), percentile of US adults aged 18-64 the
patient represents, the image number that was used to measure patient thickness, the
number of scout scans in the VC procedure, the number of CT scans in the VC procedure
(because a prone or supine scan occasionally must be repeated; such as in cases where a
scan shows that the bowel was not insufflated sufficiently), all rectal doses from TLD
measurements, average phantom or patient TLD rectal dose measurements, CTDIvol based
rectal dose estimates, Farmer chamber measurements performed in a uniform CTDI body
phantom, and SSDE dose estimates (described below). Mean square errors were
calculated to compare these dose estimates to the in-vivo dose measurements for each
patient. 95% confidence intervals (CI) were also established for the in-vivo TLD dose
measurements, as was the percent coefficient of variation (%CoV) for each patient and for
the population of patients that participated in this study. This between-patient %CoV value
was calculated based on the average rectal dose measurement of each patient as was
used as an indirect assessment of the size range of patients receiving VC at MD Anderson
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Cancer Center. It was hypothesized in chapter 1.4.1 that this between-patient %CoV would
be greater than 50%.

3.4.2 Size Specific Dose Estimate (SSDE)
Size specific dose estimate (SSDE) is a dose estimate introduced in AAPM Report
204 (101) that incorporates a correction factor to account for underestimation or
overestimation of CTDIvol dose estimates resulting from patient size (with large patient dose
being overestimated and small patient dose being underestimated by CTDIvol) (42, 101).
SSDE does not address other problems with CTDI measurements such as CTDI’s lack of
ability to measure extended scatter dose tails (43). The SSDE technique includes several
options for determining patient size. The approach utilized in this work is that of the
effective diameter, where AP and lateral measurement are acquired from one crosssectional CT image (at the average location of the TLDs within the rectal catheter),
multiplied together and the square root is taken of this product. Tables in AAPM Report
204 provide a specific correction factor based on the phantom used to determine the
Phantom
CTDIvol estimate and a specific patient’s size measurement ( f Patient
) (101). For example, if

a patient’s AP and laterial dimensions summed to 22.2 cm such that an effective diameter
of 10.7 cm is calculated (a small patient), and the CTDIvol estimate (in mGy) provided by the
scanner was based on the 32 cm CTDI body phantom, the physicist would reference Table
1A in AAPM Report 204 to obtain a correction factor of f 2232.2S = 2.5 (unitless) (101). This
correction factor would be used to calculate the SSDE (in mGy) using Equation 3-11:

Phantom
SSDE = CTDI vol ⋅ f Patient
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(3-11)

The importance of this technique to correct CTDIvol dose estimates is underscored in this
example, where the correction factor of f 2232.2S = 2.5 implies that the CTDIvol estimate
provided by the scanner underestimated the actual patient dose by 250% (due to the small
size of the patient).
Phantom
The f Patient
values published in AAPM Report 204 show an exponential relationship

between the normalized dose correction coefficient and patient dimension measurements.
Phantom
values were independently verified by four different laboratories
Additionally, the f Patient

(two involving Monte Carlo calculations and two involving physical measurements in
phantoms), with the results showing considerable agreement (101). As SSDE provides
users with an estimate of patient dose based on patient size and MDCT scanner output,
this technique theoretically provides a better estimate of the average patient dose than
standard CTDIvol dose estimates.

3.4.3 Outlier Analysis
In order to explain potential differences between patient rectal dose measurements
and anthropomorphic phantom dose measurements due to insurmountable differences that
may arise during in-vivo sampling (such as differences in TLD placement, amount of iodine
contrast, and body composition), several additional Hounsfield Unit (HU) measurements
were performed on the axial images for each patient. Relative bone density measurements
were obtained by averaging six HU measurements acquired in supine images of the ATOM
phantom and in each patient’s femoral heads as illustrated in Figure 3-32. These
measurements were acquired in the femoral heads of each patient regardless of the
location of the TLDs within the rectum in order to provide a consistent assessment of each
patient’s bone density, and the average HU measurements were plotted in a bar chart (in
Chapter 4) for comparison purposes.
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Figure 3-32. Illustration of the assessment of patient relative bone density via HU
measurements in six ROI measurements encompassing the femoral heads.

The combined effects of differences in iodine contrast present, bone density, and
TLD placement were assessed through histograms of the supine and prone CT images
(see Figure 3-33). The images analyzed for each patient and the ATOM phantom were
chosen on the basis of being the average location of the two TLDs in each scan series.
Since iodine and bone provided the highest HU numbers in each VC image, the histogram
of each of these images were thresholded to those values greater than 200 HU, and that
number of pixels was divided by the total number of pixels in an image (512x512=262,144
pixels). For comparison purposes between patients, each of these percentages were then
normalized to a display field of view (DFOV) of 50 cm (such that the pixel areas were equal
in each image) by multiplying the ratio of the pixel area in an image by the pixel area at 50
cm DFOV (0.0095 cm2). Such quantification of highly attenuating material provided insight
into the effects of such factors as TLD placement, iodine contrast, and bone density on the
TLD rectal dose measurements.
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A)

B)

Figure 3-33. A) Histogram of a supine VC image of a patient. B) Patient supine VC image after
being thresholded to include only those voxels with HU values greater than 200.

3.4.4 Statistical Analysis
Regression analysis was used to establish a rectal dose predictive model from
anthropomorphic phantom measurements. A multiple-order polynomial regression equation
and R2 goodness of fit coefficient were also established for this anthropomorphic phantom
regression analysis. These predictive rectal dose values were compared to the in-vivo
patient rectal dose measurements obtained in Specific Aim 2.
Understanding the size of patients undergoing VC at MD Anderson Cancer Center
was determined to be important based on the fact that the dose delivered to a patient’s
rectum using this fixed CT technique will be a function of the size of that patient. As an
indirect assessment of the size distribution of VC patients participating in this study, a
between-patient percent coefficient of variation (%CoV) value was determined by dividing
the standard deviation of the average rectal dose measurements from the six patients by
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the average measured rectal dose for the study population. This %CoV value was
assessed to determine whether it exceeded 50%, as stated in the hypothesis.
Mean square error (MSE) calculations were performed to compare the in-vivo rectal
dose measurements to anthropomorphic phantom measurements, SSDE dose estimates,
and uniform CTDI phantom-based dose estimates (including Farmer chamber dose
measurements, measured CTDIvol for the beam output received by patients undergoing VC,
and CTDIvol,center (providing a CTDI dose estimate that did not consider the peripheral pencil
chamber measurements)). Calculations were also performed to determine if the differences
between the mean TLD rectal dose measurements, the anthropomorphic phantom, the
SSDE estimates, the CTDIvol-based estimates, and the Farmer chamber measurements in
a CTDI body phantom were outside the 95% confidence interval (as stated in the
hypothesis). The results of these analyses are provided in Chapter 4.
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CHAPTER 4.0: RESULTS

4.1 Introduction
The results from the phantom and patient virtual colonoscopy (VC) rectal dose
measurements are reported in the order presented in Chapter 3 and arranged according to
the specific aims outlined in Chapter 1. First, in accordance with Specific Aim 1,
thermoluminescent dosimeter (TLD) linearity correction factors were established for a range
of doses at 120 kVp for a multi-detector computed tomography (MDCT) scanner using VC
scan parameters in a 32 cm CT dose index (CTDI) body phantom. Next, in accordance
with Specific Aim 2, rectal dose measurements using TLDs were obtained in VC
simulations within an anthropomorphic phantom and in-vivo within patients undergoing VC.
Finally, in accordance with Specific Aim 3, in-vivo rectal dose measurements were
compared to anthropomorphic phantom measurements, CTDIvol-based dose estimates, and
point dose measurements obtained in a CTDI body phantom. These specific aims were
accomplished in order to test our hypotheses: In-vivo rectal dose measurements obtained
during virtual colonoscopy will have a rectal dose coefficient of variation that will be greater
than 50%, and the differences between the anthropomorphic phantom measurements,
CTDIvol-based dose estimates, and Farmer chamber measurements in a CTDI body
phantom will exceed the 95% confidence interval of in-vivo rectal dose measurements.

4.2 Specific Aim 1: Establish TLD Linearity Correction Factors for VC Scan
Parameters on a MDCT
As stated earlier, although the Radiologic Physics Center (RPC) (Houston, TX)
typically provides energy and dose linearity correction coefficients to customers as a
standard service, their established correction factors pertain to those doses and energies
encountered in photon or electron cancer therapy by linear accelerator and are specifically
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defined for higher energies (a minimum of 1 MV) and doses (a minimum of 200 mGy) than
those obtained by MDCT dose to a patient’s rectum during a VC exam. Therefore Specific
Aim 1 characterized baseline x-ray beam performance and provided correction factors
relevant for MDCT at the energy and dose range encountered in VC.

4.2.1 MDCT Beam Characterization
In order to identify any discrepancies in TLD readings and actual dose
measurements between MDCT scanners used for VC or in the event of a change in the
MDCT x-ray tube between TLD irradiation and anthropomorphic phantom or in-vivo patient
VC measurements, several x-ray beam quality factors were measured. These
measurements were conducted in the same CT sessions as when the TLDs were irradiated
to establish the dose linearity correction factors for VC conditions, and upon completion of
in-vivo patient dose measurements. These measured beam factors included: the halfvalue layer (HVL), quarter-value layer (QVL), CTDI in-air measured with a 100 mm pencil
chamber ((CTDI100)air), weighted CTDI (CTDIw), and volume CTDI (CTDIvol) for the MD
Anderson Cancer Center VC technique.

4.2.1.1 HVL and QVL Measurement
The HVL and QVL measurements were made using the method described by
Mathieu, et al (95) incorporating the Lambert W function described in Chapter 3.2.1.1 for
the polyenergetic spectrums encountered in CT. These HVL and QVL measurements were
obtained on the two scanning occasions where the TLD dose linearity correction factors
were established for a 120 kVp MDCT photon beam. This technique required the
acquisition of in-air exposure measurements using a 100 mm pencil ionization chamber of
unattenuated and attenuated stationary (i.e. non-rotating) beams specified to approximate
conditions used in VC at MD Anderson Cancer Center (120 kVp, 100 mA, 1 sec exposure
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time, large body filter, small focal spot, 40 mm nominal beam). The total beam quanta
output per rotation of 100 mAs was used to simulate the combined beam output from both
the prone and supine scans used in VC. The results of the three exposure measurements
obtained with each amount of beam filtration on each testing date (in mR); the average,
standard deviation, and percent coefficient of variation (%CoV) of those exposure
measurements; the values for λ and µ0 calculated from Equations 3-6 and 3-7, respectively;
and the HVL and QVL (both in mm Al) values calculated from Equations 3-4 and 3-5,
respectively, are provided in Table 4-1.
These results demonstrated excellent measurement precision, with all exposure
measurements at a given filtration having a %CoV less than 0.1% and with the HVL and
QVL values demonstrating consistent x-ray tube quality on different days five months apart
and across 3 MDCT scanners. The HVL values also corresponded well with the HVL
measured during acceptance testing of the scanner (7.96 mm Al). This 2% difference may
be the result of a small drift in tube output, or may be caused by inherent uncertainties in
the measurement of the filtration thickness or of the ionization chamber measurements. No
standards currently exist stating an amount of allowable change in HVL measurements a
tube may experience before requiring replacement. The effect of these differences in x-ray
tube output between the respective dates and scanners likely had a minimal impact on the
TLD doses calculated based on the linearity correction factors determined at 120 kVp on
the “CT9” MDCT at MD Anderson Cancer Center, regardless of the CT scanner used to
accomplish a VC.
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Table 4-1. Results of HVL and QVL measurements obtained on the MDCT scanners at MD
Anderson Cancer Center used for VC procedures under VC simulation conditions; where
Date is the date the measurements were obtained (corresponding to the dates used to
determine the TLD correction factors), CT is the MD Anderson Cancer Center nomenclature
for the MDCT scanner on which the exposure measurements were performed, Filtration is the
thickness of aluminum 1100 alloy used to attenuate the primary beam, Exp represents the
respective exposure measurements obtained at each thickness, Avg Exp is the average of the
exposure measurements, St Dev is the standard deviation of the exposure measurements,
%CoV is the percent coefficient of variation of the exposure measurements, λ and µ0 are
coefficients utilized by Lambert W interpolation, HVL is the half-value-layer, and QVL is the
quarter-value-layer.
Exp
Exp
Exp
Avg
St Dev %CoV
HVL
λ
µ0
#1
#2
#3
Exp
(mR)
(%)
(mm Al)
(mR)
(mR)
(mR)
(mR)
0
1263
1263
1264
1263
0.577
0.05
1/17/11
CT9
6.36
706.6
705.9
706.4
706.3
0.361
0.05
0.0412 0.0683
7.79
19.84
272.7
273.1
272.9
272.9
0.200
0.07
0
1269
1271
1269
1270
1.155
0.09
4/2/11
CT9
6.36
709.1
710.0
709.8
709.6
0.473
0.07
0.0411 0.0685
7.78
19.84
273.4
273.3
273.7
273.6
0.173
0.06
0
1306
1305
1305
1305
0.577
0.04
6/18/11
CT9*
6.36
727.7
727.8
727.6
727.7
0.100
0.01
0.0420 0.0685
7.75
19.84
280.6
280.4
280.8
280.6
0.200
0.07
0
1303
1302
1303
1303
0.577
0.04
6/18/11
CT12
6.36
721.3
721.3
721.4
721.3
0.058
0.01
0.0429 0.0692
7.65
19.84
275.8
275.6
276.0
275.8
0.200
0.07
0
1277
1277
1276
1277
0.577
0.05
6/18/11
CT5
6.36
711.5
711.4
710.9
711.3
0.321
0.05
0.0419 0.0686
7.74
19.84
273.8
273.7
273.8
273.8
0.058
0.02
*The x-ray tube on this scanner was replaced between the time the last in-vivo VC was performed and before the final HVL
Date

CT

Filtration
(mm Al)

and QVL measurements could be acquired.

4.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination
(CTDI100)air measurements were acquired using the same pencil ionization chamber
configuration as that used to determine the HVL and QVL. (CTDI100)air required slightly
different scan settings, however, as the scans were performed in axial mode (as opposed to
the tube remaining stationary while the beam was on). In order to replicate beam
conditions during VC at MD Anderson Cancer Center, the CT scan settings used to
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QVL
(mm Al)
17.63

17.60

17.56

17.35

17.52

determine (CTDI100)air via Equation 1-11 were: axial scan, 0.5 sec per rotation of the x-ray
tube, a nominal beam width of 40 mm, 120 kVp, 200 mA, standard reconstruction algorithm,
large (body) bowtie filter, large body scan field of view (SFOV) and 50 cm display field of
view (DFOV). In a manner similar to the scan technique utilized in the beam HVL and QVL
measurements, 100 mAs was used to acquire these CTDI measurements to simulate the
combined dose received by patients undergoing VC from the prone and supine CT scans.
The results of the exposure measurements (in mR), the average and standard deviation of
those exposures (in mR), the percent coefficient of variation (in %), and the calculated
(CTDI100)air values (in mGy) for the two scanning sessions that determined the TLD
correction factors specific to MDCT are provided in Table 4-2.

Table 4-2. Results of in-air exposure measurements and corresponding (CTDI100)air
calculations obtained on MD Anderson Cancer Center “CT9” MDCT under conditions
simulating VC at MD Anderson Cancer Center; where Date is the date the measurements were
obtained (corresponding to the dates used to determine the TLD correction factors and
completion of in-vivo measurements), Exp represents the respective exposure measurement
iteration obtained in each day, Avg Exp is the average of the exposure measurements, St Dev
is the standard deviation of the exposure measurements, %CoV is the percent coefficient of
variation, and (CTDI100)air is the corresponding in-air CTDI100 value.
Date
1/17/11
4/2/11
6/18/11*

Exp #1
(mR)
1032
1028
1066

Exp #2
(mR)
1034
1028
1069

Exp #3
(mR)
1034
1028
1069

Avg Exp
(mR)
1033
1028
1068

St Dev
(mR)
1.155
0
1.732

%CoV
(%)
0.1
0
0.2

(CTDI100)air
(mGy)
22.25
22.36
23.23

*The x-ray tube on this scanner was replaced between the time the last in-vivo VC was performed and before the final HVL
and QVL measurements could be acquired.

The results of these (CTDI100)air measurements also showed excellent precision with
the %CoV being 0.2% or less, and good agreement between respective (CTDI100)air
measurements on the different days and different x-ray tubes (which was replaced on the
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“CT9” scanner in the three days between the last in-vivo patient measurement being
acquired and the exposure tube measurements). The 0.5% difference between the
(CTDI100)air measurements acquired on the same x-ray tube may be the result of inherent
uncertainties in the measurement process and likely had a minimal impact on the TLD dose
linearity correction factors determined at 120 kVp for the “CT9” MDCT at MD Anderson
Cancer Center. The 4% difference between the (CTDI100)air measurements acquired on the
different x-ray tubes was likely the combined result of changes in respective tube
performance and inherent uncertainties in the measurement process, but these results still
demonstrated good agreement between the outputs of several x-ray tubes and provided
confidence in the uniformity of the in-vivo doses measured on multiple MDCT scanners
during VC.

CTDI(100,air) versus mAs
CTDI(100,air) (mGy)

50
y = 0.2241x - 0.0171
R² = 0.9999

40
30
20
10
0
0

50

100

150

200

mAs

Figure 4-1. Linear relationship between MD Anderson Cancer Center “CT9” beam
administered dose (measured in the form of (CTDI100)air) and mAs.
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In order to establish the linearity of the MDCT scanner dose output with mAs,
(CTDI100)air measurements were acquired using this same scan technique in 10 mAs
increments from 20 mAs (40 mA) to 170 mAs (340 mA),. These linearity measurements
were helpful in extrapolating doses at the center of the CTDI body phantom that were
sufficiently low as to be undetected with a Farmer ionization chamber (without this data,
TLD dose linearity correction coefficients at 120 kVp could not be obtained for administered
point doses less than 2.1 mGy). The linear relationship between these (CTDI100)air
measurements and increasing mAs is demonstrated in Figure 4-1. The R2 value of 0.999
demonstrates a very strong goodness of fit of the linear regression between the scanner
mAs and the (CTDI100)air calculations.
In order to measure the weighted CTDI (CTDIw) and volume CTDI (CTDIvol), the
pencil ionization chamber was placed within the CTDI body phantom and exposure
measurements were acquired within the center bore and in the peripheral bores located in
the 12, 3, 6, and 9 o’clock positions using the same scan technique as that used to
determine (CTDI100)air at 100 mAs. These exposure measurements were used to calculate
CTDI100 values at each of these locations ((CTDI100)c, (CTDI100)12, (CTDI100)3, (CTDI100)6,
and (CTDI100)9, respectively). The peripheral CTDI values were averaged to calculate the
CTDI100 value at the periphery of the phantom ((CTDI100)periphery), and this value was used
with (CTDI100)c to calculate CTDIw via Equation 1-12. CTDIvol was calculated from CTDIw
using Equation 1-14. Each of these CTDI values are provided in Table 4-3 for the two
sessions used to determine the TLD dose linearity correction coefficients at 120 kVp and in
a session that was conducted upon the conclusion of in-vivo dose measurements (where
the “CT9” MDCT scanner contained a newly replaced x-ray tube).
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Table 4-3. Results of exposure measurements within a CTDI body phantom and
corresponding CTDI calculations obtained on the MD Anderson Cancer Center “CT9” MDCT
scanner under conditions simulating VC at MD Anderson Cancer Center; where Date is the
date the measurements were collected (corresponding to the dates used to determine the
TLD correction factors), Pos is the position of the pencil chamber within the CTDI phantom,
Exp represents the respective exposure measurements obtained at each position, Avg Exp is
the average of the exposure measurements, St Dev is the standard deviation of the exposure
measurements, %CoV is the percent coefficient of variation, (CTDI100)pos is the corresponding
CTDI100 value at that position, CTDIw is the weighted CTDI, CTDIvol is the measured volume
CTDI, and Scanner CTDIvol is the volume CTDI value provided by the CT scanner console.
Date

Pos

Exp
#1
(mR)
217.6
447.9
451.0
406.5
452.3

Exp
#2
(mR)
216.8
465.0
457.4
407.4
451.6

Exp
#3
(mR)
216.8
461.1
450.5
408.5
451.8

Avg
Exp
(mR)
217.1
458
453.0
407.5
451.9

Center
12:00
3:00
1/17/11
6:00
9:00
Periph
Center 215.5 216.0 215.9
215.8
12:00
459.3 461.5 461.6
460.8
3:00
480.5 479.6 475.9
478.7
4/2/11
6:00
431.3 427.1 424.6
427.7
9:00
447.0 447.3 447.0
447.1
Periph
Center 223.2 222.3 222.8
222.8
12:00
473.5 482.0 478.5
478.0
3:00
464.8 463.4 461.1
463.1
6/18/11†
6:00
415.7 415.5 421.3
417.5
9:00
468.7 467.9 469.0
468.5
Periph
* Approximate position of the rectum within a patient
†

St Dev
Exp
(mR)
0.462
8.96
3.85
1.00
0.361

%CoV
Exp
(%)
0.21
1.96
0.85
0.25
0.08

0.265
1.30
2.44
3.39
0.173

0.12
0.28
0.51
0.79
0.04

0.451
4.27
1.87
3.29
0.569

0.20
0.89
0.40
0.79
0.12

(CTDI100)pos
(mGy)
4.72*
9.96
9.85
8.86
9.83
9.63
4.69*
10.02
10.41
9.30
9.72
9.86
4.85*
10.40
10.07
9.08
10.19
9.94

CTDIw
(mGy)

CTDIvol
(mGy)

Scanner
CTDIvol
(mGy)

7.99

8.12

8.26

8.14

8.27

8.26

8.24

8.37

8.26

Measurements were performed on the same MDCT scanner with a replaced x-ray tube

The results of these CTDI100 measurements also demonstrated good precision, with
the %CoV being 2% or less, and good agreement between the respective CTDIw and
CTDIvol measurements. The 2% difference between the CTDIw and CTDIvol measurements
obtained with the same x-ray tube may be the result of inherent uncertainties in the
measurement procedures. The 2% difference between the average CTDIw and CTDIvol
measurements obtained with different x-ray tubes may be the result of slight differences in
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performance between the x-ray tubes and inherent uncertainties in the measurement
equipment. These CTDIvol values also corresponded well with the CTDIvol value provided
by the MDCT scanner for this scan technique (CTDIvol=8.26 mGy), with an average percent
difference of 0.08%. The effect of these differences in x-ray tube output between the
respective dates and x-ray tubes likely had a minimal impact on the TLD dose linearity
correction factors determined at 120 kVp for the “CT9” MDCT at MD Anderson Cancer
Center, and provided confidence regarding the dose measurements obtained from different
MDCT scanners of the same model.

4.2.2 Determination of TLD Dose Linearity Correction Coefficients for Virtual Colonoscopy
With the x-ray tube beam output well characterized at 120 kVp for the TLD
irradiation sessions that would determine dose linearity response correction factors of the
TLDs at 120 kVp (KL,120), the pencil ionization chamber was replaced with a Farmer style
ionization chamber in the center of the 32 cm CTDI body phantom. Using a scout image,
the scan length was specified to be conducted from 75 mm superior to 75.4 mm inferior to
the center of the CTDI body phantom. The CT scanner was set to standard MD Anderson
VC protocols (also listed in Table 1-1 above): full helical scan mode with 0.5 sec rotation
time, 1.25 mm image thickness, 39.37 mm/rotation table speed, 0.984 pitch, 1/64 channel
setting, 0.8 mm interval, 120 kVp, 100 mA, 0 sec delay, and standard reconstruction
algorithm. The ionization chamber exposure was measured and recorded for two scans
under the specified CT technique for a total photon output of 100 mAs per x-ray tube
rotation (representing the cumulated exposure acquired from both the prone and supine 50
mAs scans in VC).
The exposure measurements obtained by the Farmer ionization chamber (in mR)
were converted to dose in the acrylic CTDI body phantom (in mGy) using an f-factor of
fAcrylic= 0.78 rad/R. This process was repeated three times and the average of these three
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acrylic dose measurements was used to calculate the dose at the center of the CTDI body
phantom at 100 mAs. This entire process was repeated for scanner photon outputs per
rotation ranging from 20 mAs to 170 mAs in 10 mAs increments to administer doses to the
center of the CTDI body phantom ranging from 0.6 mGy to 8.9 mGy (using the f-factor for
acrylic), approximately reflecting the expected range of rectal doses administered in VC at
MD Anderson Cancer Center as estimated in Chapter 1.3.5 (0.7-10.8 mGy when an f-factor
appropriate for rectal dose is used, fMuscle= 0.94 rad/R). Doses were extrapolated based on
the linear relationship between Farmer ionization chamber measured doses and mAs and
assigned to those tube output values where doses were too low to be directly measured by
the Farmer chamber (i.e. at 20 and 30 mAs). The principle of linearity between
administered dose and mAs was demonstrated in Figure 4-1.

Farmer Dose versus Apparent TLD Dose
Farmer Dose (mGy)

12
y = 0.0009x4 - 0.0316x3 + 0.3704x2 - 0.7412x + 0.1979
R² = 0.9985

10
8
6
4
2
0
0

2

4

6

8

10

12

14

Apparent TLD Dose (mGy)

Figure 4-2. Fourth-order polynomial regression curve predicting Farmer ionization chamber
response for the RPC’s B09 TLD-100 batch from apparent TLD dose measurements (those
uncorrected for dose linearity or energy) on MD Anderson Cancer Center “CT9” MDCT
scanner.
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After determining the average Farmer chamber dose at each respective mAs
technique, double chambered TLDs were placed within the center of the CTDI body
phantom (in a custom-designed insert rod), and the TLDs were irradiated under the same
conditions as the Farmer ionization chamber. After TLD readout, the RPC provided the
following information: measured TLD aliquot charge reading (Q) (in µC), TLD aliquot mass
(mg) (in mg), sensitivity (KS) (which was converted to mGy/µC/mg for the order of
magnitude of rectal doses received by patients undergoing VC), and fading correction factor
(KF) (unitless). An f-factor for acrylic (fAcrylic = 0.78 rad/R) was divided by the f-factor for
muscle/soft tissue (fMuscle = 0.94 rad/R), and the uncorrected TLD dose to the CTDI body
phantom was calculated by Equation 3-8 for each TLD chamber. The results of the Farmer
ionization chamber measurements are plotted with a fourth-order polynomial regression
against the resultant apparent (i.e. uncorrected) TLD dose measurements in Figure 4-2.
KL,120 values were calculated for every TLD chamber in this dose range by dividing
the Farmer measured dose by the apparent TLD dose as demonstrated in Equation 3-9.
The average KL,120 value and the %CoV were determined for every mAs setting. These
TLD charge and mass measurements, the KS and KF correction coefficients, the calculated
TLD doses (not corrected for dose linearity or photon energy), the Farmer ionization
chamber measured doses, the KL,120 values and the average KL,120 values at each mAs
setting, and the %CoV for the KL,120 values at each mAs setting are provided in Table 4-4.
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Table 4-4. Results of Farmer ionization chamber determined dose measurements, TLD dose
measurements, and TLD dose linearity correction factors at 120 kVp obtained in a 32 cm
diameter CTDI body phantom under identical conditions simulating VC on MD Anderson
Cancer Center “CT9” MDCT; where mAs represents the scanner setting used, Charge
represents the measured reading, Mass is the mass of TLD aliquot read, KS is the sensitivity
correction factor, KF is the fading correction factor, TLD Dose represents the apparent dose
predicted by the TLD, Farmer Dose represents the dose measured by a Farmer chamber or
extrapolated from data demonstrating dose linearity with mAs, KL,120 represents the TLD dose
linearity correction factor at 120 kVp, Avg KL,120 is the average of the KL,120 values at a mAs
value, and %CoV is the percent coefficient of variation of the KL,120 values.
mAs

20

30

40

50

60

Charge
(µC)

Mass
(mg)

0.07693
0.07878
0.07465
0.07301
0.07430
0.07564
0.07758
0.07530
0.08889
0.09289
0.09111
0.09484
0.09250
0.09147
0.09337
0.09258
0.1063
0.1073
0.1068
0.1110
0.1045
0.1066
0.1050
0.1063
0.1308
0.1217
0.1198
0.1214
0.1192
0.1225
0.1222
0.1201
0.1373
0.1361
0.1347

21.69
21.92
21.22
21.27
22.03
21.30
21.98
21.35
21.99
22.09
22.37
21.80
21.99
21.57
22.14
21.66
21.70
21.39
21.82
21.81
21.72
22.00
21.83
21.57
21.74
22.10
21.40
21.69
21.76
21.64
22.46
21.77
21.81
21.72
22.11

KS
(cGy/
µC/mg)
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
108.7
108.7
108.7
108.7
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
108.7
108.7
108.7
108.7
110.0
110.0
110.0
110.0
108.7
108.7
108.7

KF
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.048
1.048
1.048
1.048
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.048
1.048
1.048
1.048
1.042
1.042
1.042
1.042
1.048
1.048
1.048
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TLD
Dose
(mGy)
3.373
3.418
3.346
3.265
3.208
3.378
3.357
3.354
3.821
3.975
3.850
4.112
4.001
4.033
4.011
4.065
4.659
4.771
4.655
4.841
4.576
4.609
4.575
4.687
5.687
5.205
5.292
5.291
5.210
5.384
5.175
5.247
5.951
5.923
5.759

Farmer
Dose
(mGy)
0.565
0.565
0.565
0.565
0.565
0.565
0.565
0.565
1.176
1.176
1.176
1.176
1.143
1.143
1.143
1.143
1.722
1.722
1.722
1.722
1.722
1.722
1.722
1.722
2.282
2.282
2.282
2.282
2.300
2.300
2.300
2.300
2.848
2.848
2.848

KL,120
0.167
0.165
0.169
0.173
0.176
0.167
0.168
0.168
0.308
0.296
0.305
0.286
0.286
0.283
0.285
0.281
0.370
0.361
0.370
0.356
0.376
0.374
0.376
0.367
0.401
0.438
0.431
0.431
0.441
0.427
0.444
0.438
0.479
0.481
0.494

Avg
KL,120

%CoV
KL,120
(%)

0.169

2.07

0.291

3.56

0.369

1.98

0.432

3.15

0.482

1.74

70

80

90

100

110

120

130

140

150

160

170

Bkg

0.1381
0.1507
0.1510
0.1499
0.1459
0.1683
0.1631
0.1661
0.1681
0.1773
0.1810
0.1888
0.1832
0.1941
0.1922
0.1918
0.1958
0.2059
0.2115
0.2090
0.2102
0.2294
0.2207
0.2278
0.2195
0.2415
0.2429
0.2307
0.2428
0.2523
0.2534
0.2508
0.2614
0.2659
0.2755
0.2671
0.2736
0.2854
0.2730
0.2893
0.2874
0.3037
0.2997
0.3049
0.2948
0.04755
0.05089
0.04804
0.05071
0.04692
0.05224
0.04690
0.04664
0.04538
0.04963

21.80
21.98
22.61
22.06
20.68
22.02
21.28
21.25
21.84
21.72
21.98
22.22
22.25
22.17
21.67
21.80
21.62
21.38
21.96
21.88
22.10
22.20
21.53
21.82
21.29
22.04
21.86
21.30
21.90
21.82
22.26
21.66
21.93
21.31
21.91
21.65
21.94
21.94
20.89
22.36
22.13
21.89
21.84
22.30
22.27
22.30
21.78
22.16
22.32
21.98
21.79
22.33
21.99
22.11
22.23

108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
108.7
104.7
104.7
104.7
104.7
104.7
104.7
110.0
110.0
110.0
110.0

1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.048
1.059
1.059
1.059
1.059
1.059
1.059
1.042
1.042
1.042
1.042
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5.988
6.481
6.313
6.423
6.669
7.225
7.245
7.389
7.276
7.716
7.784
8.032
7.783
8.280
8.384
8.317
8.561
9.103
9.104
9.029
8.991
9.768
9.690
9.869
9.746
10.358
10.504
10.238
10.480
10.930
10.761
10.945
11.267
11.795
11.886
11.662
11.788
12.296
12.353
12.230
12.276
13.115
12.972
12.924
12.513
1.962
2.150
1.995
2.090
1.964
2.206
1.998
2.017
1.952
2.123

2.848
3.404
3.404
3.404
3.404
3.954
3.954
3.954
3.954
4.517
4.517
4.517
4.517
5.076
5.076
5.076
5.076
5.640
5.640
5.640
5.640
6.184
6.184
6.184
6.184
6.736
6.736
6.736
6.736
7.281
7.281
7.281
7.281
7.754
7.754
7.754
7.754
8.314
8.314
8.314
8.314
8.934
8.934
8.934
8.934
0
0
0
0
0
0
0
0
0
0

0.476
0.525
0.539
0.530
0.510
0.547
0.546
0.535
0.544
0.585
0.580
0.562
0.580
0.613
0.605
0.610
0.593
0.620
0.619
0.625
0.627
0.633
0.638
0.627
0.634
0.650
0.641
0.658
0.643
0.666
0.677
0.665
0.646
0.657
0.652
0.665
0.658
0.676
0.673
0.680
0.677
0.681
0.689
0.691
0.714
0
0
0
0
0
0
0
0
0
0

0.526

2.28

0.543

1.00

0.577

1.75

0.605

1.47

0.623

0.62

0.633

0.76

0.648

1.18

0.664

1.91

0.658

0.78

0.677

0.41

0.694

2.03

0

4.39

The KL,120 values were used to establish a third-order polynomial regression curve
based on apparent TLD dose measurements (i.e. TLD dose measurements not corrected
by KL,120 values). The results of this regression analysis are shown in Figure 4-3. Although
Chapter 1 discussed several of the inherent difficulties involved with using TL-100 material
to measure doses at diagnostic energies and doses, the TLDs demonstrated good
reproducibility with all %CoV values for an administered mAs setting being 3.56% or less
(with several %CoV values being less than 1%). The TLDs also demonstrate a general
increase in %CoV values at lower administered doses. The R2 value of 0.992
demonstrates a very strong goodness of fit of the third-order polynomial regression
between the uncorrected TLD predicted doses and the KL,120 calculations. This third-order
polynomial regression equation was used to calculate anthropomorphic phantom and invivo patient rectal doses from apparent TLD dose measurements in VC at MD Anderson
Cancer Center in Specific Aim 2.

K(L,120)

K(L,120) versus TLD Predicted Dose
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

y = 0.0003x3 - 0.0147x2 + 0.2181x - 0.4616
R² = 0.9923

0

5

10

15

TLD Predicted Dose (mGy)

Figure 4-3. Third-order polynomial regression curve predicting KL,120 values for the RPC’s
B09 TLD-100 batch from apparent TLD dose measurements (those uncorrected for dose
linearity or energy) on MD Anderson Cancer Center “CT9” MDCT scanner.
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From Table 4-3, by approximating that the rectum is located in the center of the
phantom, the estimated dose to a patient’s rectum from CTDI measurements is provided by
the average CTDIvol,center measurements (the average (CTDI100)center measurements
corrected for pitch), which yields a dose estimate of 4.78 mGy. Similarly, the dose to a
patient’s rectum estimated by the Farmer style ionization chamber measurements in the
center of a CTDI body phantom is provided by the measurements displayed in Table 4-4 at
100 mAs, which average to be 6.12 mGy after applying the f-factor for dose to muscle
(f=0.94 rad/R) to the exposure measurements. These uniform phantom-based dose
estimates (summarized in Table 4-5) were compared in Specific Aim 3 to the dose
estimates provided by the TLD measurements within the anthropomorphic phantom and
within patients undergoing VC in Specific Aim 2 to assess whether the differences between
the mean TLD rectal dose measurements, the CTDIvol-based SSDE estimates, and the
ionization chamber measurements in a CTDI body phantom exceeded 10% of a 95%
confidence interval (as stated in the hypothesis).

Table 4-5. Summary of rectal dose estimates obtained in a uniform CTDI body phantom,
where CTDIvol is the volume CTDI value determined from pencil chamber measurements
simulating the technique used in virtual colonoscopy, CTDIvol,center is the volume CTDI
estimate only considering the center bore measurement in the CTDIw calculation, and Farmer
is the dose measured by the Farmer chamber in the center bore.
CTDIvol
(mGy)
8.3

CTDIvol,center
(mGy)
4.8
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Farmer
(mGy)
6.1

4.3 Specific Aim 2: Obtain In-Vivo Rectal Dose Measurements in Patients
Undergoing VC with TLDs
With Specific Aim 1 accomplished, both the MDCT beam quality and the TLD
response had been established for the dose range and energy spectrum received by a
patient’s rectum when undergoing virtual colonoscopy (VC). With this data, rectal dose
measurements were obtained in an anthropomorphic phantom during simulated VC and invivo rectal dose measurements were obtained in actual patients undergoing VC at MD
Anderson Cancer Center. All of these rectal dose measurements were acquired with
thermoluminescent dosimeters (TLDs) (provided by the Radiologic Physics Center (RPC),
Houston, TX).

4.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic Phantom
Two double chamber TLDs were inserted within a rectal catheter that was placed in
a simulated insufflated rectum within an anthropomorphic phantom. The 15th percentile
phantom configuration was then placed on the MD Anderson “CT9” MDCT scanner in a
supine position irradiated twice with the standard MD Anderson Cancer Center VC protocol
to simulate patient scans in both a prone and a supine position: full helical scan mode with
0.5 sec rotation time, 1.25 mm image thickness, 39.37 mm/rotation table speed, 0.984
pitch, 0.8 mm image interval, 120 kVp, 100 mA, 0 sec delay, and standard reconstruction
algorithm. The two irradiated TLDs were then replaced with a set of two un-irradiated TLDs
within the phantom; and this process was repeated twice for a total of three sets of virtual
colonoscopy rectal dose measurements.
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Table 4-6. Results of TLD dose measurements during simulated VC in an anthropomorphic
phantom configured to represent patients of three sizes of US adults aged 18-64 (15
th

th

th

percentile, 87 percentile, and 99 percentile); %ile represents the population percentile at
the TLD location represented by the phantom configuration, Dim is the effective diameter of
the phantom at the location of the TLDs, Charge represents the measured reading, Mass is
the mass of TLD aliquot read, KS is the sensitivity correction factor, KF is the fading
correction factor, Uncorr Dose represents the dose predicted by the TLD before corrections
for dose linearity and energy were applied, KL,120 represents the TLD dose linearity correction
factor at 120 kVp, TLD Dose represents the dose predicted by the TLD after corrections for
dose linearity and energy were applied, Avg Dose is the average of the dose measurements
for a phantom configuration, and %CoV is the percent coefficient of variation of the TLD dose
measurements.

%ile

Dim
(cm)

15

26.61

87

34.90

99

43.75

Charge
(µC)

Mass
(mg)

KS
(cGy/
µC/mg)

0.2532
0.2515
0.2504
0.2432
0.2475
0.2509
0.2495
0.2278
0.2600
0.2397
0.2471
0.2381
0.1786
0.1783
0.1776
0.1784
0.1773
0.1746
0.1698
0.1688
0.1778
0.1770
0.1760
0.1695
0.1269
0.1278
0.1288
0.1329
0.1258
0.1288

21.82
21.83
21.74
21.64
21.82
21.66
22.08
20.50
22.49
21.55
21.58
20.96
22.11
21.49
22.14
21.35
22.20
21.81
21.72
21.05
21.71
22.08
21.83
21.44
22.16
21.43
22.10
21.99
21.67
21.62

110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0
110.0

KF

Uncorr
Dose
(mGy)

KL,120

TLD
Dose
(mGy)

1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042
1.042

13.301
13.205
13.202
12.882
13.001
13.277
12.952
12.737
13.251
12.749
13.124
13.021
9.259
9.510
9.194
9.578
9.154
9.176
8.691
9.191
9.387
9.188
9.241
9.062
6.564
6.835
6.680
6.927
6.654
6.828

0.677
0.676
0.676
0.672
0.673
0.677
0.673
0.670
0.677
0.670
0.675
0.674
0.622
0.627
0.620
0.629
0.619
0.620
0.615
0.620
0.625
0.620
0.621
0.617
0.515
0.531
0.522
0.536
0.521
0.531

9.011
8.928
8.925
8.653
8.754
8.990
8.712
8.533
8.968
8.543
8.859
8.770
5.758
5.966
5.704
6.021
5.671
5.689
5.508
5.702
5.864
5.699
5.743
5.593
3.383
3.631
3.489
3.714
3.465
3.624
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Avg
TLD
Dose
(mGy)

%CoV
TLD
Dose
(%)

8.804

1.92

5.743

2.53

3.475

4.33

0.1260
0.1247
0.1206
0.1248
0.1275
0.1301

22.00
21.70
21.91
21.47
22.20
21.99

110.0
110.0
110.0
110.0
110.0
110.0

1.042
1.042
1.042
1.042
1.042
1.042

6.565
6.587
6.309
6.663
6.583
6.781

0.515
0.517
0.499
0.521
0.517
0.528

3.383
3.404
3.150
3.473
3.400
3.581

In order to use the phantom to represent sub-populations of patients of larger
habitus than the 15th percentile of US adults aged 18-64, bags of simulated phantom
adipose material were placed around the phantom pelvis and bags of pig adipose material
(lard) were placed around the thorax, abdomen and legs to represent patients of the 87th
and 99th percentile of US adults aged 18-64. The results of the TLD rectal dose
measurements for each phantom configuration are provided in Table 4-6. The percent
coefficients of variation (%CoV) of the 12 measurements obtained at each habitus
demonstrate good precision (i.e. less than 5%) in the TLD measurements, and demonstrate
the same trend observed in Specific Aim 1 that lower doses yield higher %CoV values.
Figure 4-4 plots the mean TLD organ dose, Farmer ionization chamber, SSDE,
CTDIvol, and CTDIvol,center measurements against patient size measurements (effective
diameter). An exponential regression curve for the TLD measurements is also provided
along with 95% confidence intervals of the regression and of the mean TLD measurements
at each phantom habitus. The R2 value of 0.993 demonstrates a very strong goodness of
fit of the regression equation to the data. This regression additionally demonstrates the
exponential relationship between dose and patient size predicted in other studies (101,
102).
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Rectal Dose (mGy)

Phantom TLD Dose and Dose Predictors versus Effective
Diameter
(with 95% Confidence Intervals)
12
SSDE

10
8

Anthro Phantom

6

CTDI(vol)

4

Farmer

2
25

30

35

40

45

CTDI(vol,c)

Effective Diameter (cm)

Figure 4-4. Anthropomorphic phantom mean TLD rectal dose measurements as a function of
phantom effective diameter with an exponential regression curve (including 95% confidence
intervals of both entities), as well as rectal dose estimates obtained from a uniform CTDI body
phantom (all in mGy). CTDIvol is the measured volume CTDI dose estimate, CTDIvol,center is the
CTDI100 measurement acquired at the center of the CTDI body phantom and corrected for
pitch, and SSDE is the size specific dose estimate.

4.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy
Once MD Anderson Cancer Center Institutional Review Board (IRB) approval was
granted for in-vivo rectal radiation absorbed dose measurements during VC, 6 patients
previously approved by their respective insurances to receive the procedure that met all of
the criteria outlined in Chapter 1.1.1 were approached for enrollment in the study. Patient
rectal dose measurements were obtained from May – June 2011 at MD Anderson Cancer
Center. Based on retrospective measurements from patient CT images, the average
distance from the TLDs (within the rectum) to the table was calculated to be 10.5 cm for
supine scans and 14.6 cm for prone scans. These distances were used to estimate the
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rectal dose administered to each patient from the scout scans as described in Chapter
3.3.2.7. The results of these scout rectal dose estimates are provided in Table 4-7, with the
scout scans accounting for 1.4%-2.2% of the total VC rectal doses measured in each
patient.

Table 4-7. Results of dose estimates received from scout images during VC within 6 patients;
where Pt # represents the study specific patient identification number, Supine mA is the tube
current technique utilized to acquire the PA and lateral scout scans with the patient
positioned in the supine position, Supine PA Dist is the distance from the TLDs to the
patient’s surface in the PA direction, Supine PA Dose is the estimated dose administered to
the TLDs within the rectum from the supine PA scout, Supine Lat Dist is the distance from the
TLDs to the patient’s surface in the lateral direction, Supine Lat Dose is the estimated dose
administered to the TLDs within the rectum from the supine lateral scout, Prone mA is the
tube current technique utilized to acquire the AP and lateral scans with the patient positioned
in the prone position, Prone AP Dist is the distance from the TLDs to the patient’s surface in
the AP direction, Prone AP Dose is the estimated dose administered to the TLDs within the
rectum from the prone AP scout, Prone Lat Dist is the distance from the TLDs to the patient’s
surface in the lateral direction, Prone Lat Dose is the estimated dose administered to the
TLDs within the rectum from the prone lateral scout.
Pt
#

Supine
mA

Supine
PA Dist
(cm)

1
2
3
4
5
6

10
10
10
10
10
10

10.8
7.4
9.8
9.2
7.7
8.6

Supine
PA
Dose
(mGy)
0.016
0.032
0.020
0.022
0.030*
0.025

Supine
Lat Dist
(cm)
19.5
18.3
19.0
17.2
19.0
19.3

Supine
Lat
Dose
(mGy)
0.003
0.005
0.004
0.006
0.004
0.004

Prone
mA
80
80
80
80
80
80

Prone
AP
Dist
(cm)
11.0
10.0
13.6
11.5
13.0
11.2

Prone
AP
Dose
(mGy)
0.130
0.162
0.077
0.117
0.086
0.124

Prone
Lat
Dist
(cm)
17.8
14.7
18.0
17.5
17.6
20.2

Prone
Lat
Dose
(mGy)
0.041
0.078
0.039
0.043
0.043
0.025

Total
Scout
Dose
(mGy)
0.190
0.277
0.140
0.189
0.193
0.178

*Patient received two supine AP scans

The results of the TLD rectal dose measurements for each patient are provided in
Table 4-8. The percent coefficients of variation (%CoV) of the 4 TLD measurements
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obtained within each patient demonstrate reasonable precision in the TLD measurements,
but do not necessarily demonstrate the same trend observed in Specific Aim 1 that lower
doses yield higher %CoV values. Figure 4-5 plots the in-vivo TLD rectal dose
measurements as well as the anthropomorphic phantom measurements, SSDE dose
estimates, and CTDI phantom based dose estimates against patient size measurements
(effective diameter). A regression curve is provided for the anthropomorphic phantom
measurements (as a faint, dotted line), which is the same regression curve provided in
Figure 4-4. The in-vivo measurements appeared to include two outlier measurement points
(Patients 4 and 5) that were not believed to represent standard VC conditions in Specific
Aim 3, which will be explained in more detail below. Also provided in Figure 4-5 are the
95% confidence intervals of the in-vivo rectal dose measurements (which assumed a tdistribution of the TLD measurements at a patient habitus).
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Table 4-8. Results of in-vivo TLD rectal dose measurements during VC within 6 patients;
where # represents the study specific patient identification number, Dim is the effective
diameter of the patient at the location of the TLDs, %ile is the percentile of US Adults
represented by the patient circumference at the location of the TLDs, Charge represents the
measured reading, Mass is the mass of TLD aliquot read, KS is the sensitivity correction
factor, KF is the fading correction factor, Uncorr Dose represents the dose predicted by the
TLD before corrections for dose linearity and energy were applied, KL,120 represents the TLD
dose linearity correction factor at 120 kVp, TLD Dose represents the dose predicted by the
TLD after corrections for dose linearity and energy were applied, Scout Dose is the estimate
of patient rectal dose received, Avg Dose is the average of the CT dose measurements for a
patient (not including the scout scans), and %CoV is the percent coefficient of variation of the
TLD dose measurements.

#

Dim
(cm)

%ile
(%)

1

30.3

27

2

26.2

7

3

30.5

31

4

26.9

11

5

28.4

31

6

28.0

35

Charge
(µC)

Mass
(mg)

KS
(cGy/
µC/mg)

0.2763
0.2659
0.2963
0.2968
0.3570
0.3302
0.3475
0.3091
0.2760
0.2543
0.2833
0.2611
0.2685
0.2481
0.2587
0.2709
0.3644
0.3164
0.3716
0.3250
0.3362
0.3138
0.3046
0.3156

21.95
21.80
21.67
20.54
21.52
21.05
22.16
20.56
21.47
20.19
21.85
20.10
21.92
21.89
21.23
21.63
22.08
20.63
21.73
20.26
21.96
21.05
21.53
22.11

108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5
108.5

KF

Uncorr
Dose
(mGy)

KL,120

1.052
1.052
1.052
1.052
1.052
1.052
1.052
1.052
1.050
1.050
1.050
1.050
1.049
1.049
1.049
1.049
1.049
1.049
1.049
1.049
1.039
1.039
1.039
1.039

14.37
13.92
15.61
16.49
18.94
17.90
17.90
17.16
14.65
14.35
14.77
14.80
13.94
12.90
13.87
14.25
18.78
17.46
19.46
18.26
17.26
16.81
15.95
16.09

0.674
0.668
0.689
0.699
0.720
0.712
0.712
0.705
0.678
0.674
0.679
0.680
0.668
0.653
0.667
0.673
0.719
0.708
0.724
0.715
0.706
0.702
0.693
0.695
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Scout
Dose
(mGy)

0.190

0.277

0.140

0.189

0.193

0.178

TLD
Dose
(mGy)
9.497
9.113
10.57
11.33
13.36
12.47
12.46
11.82
9.788
9.532
9.896
9.920
9.131
8.231
9.068
9.401
13.31
12.16
13.90
12.85
12.01
11.62
10.88
11.00

Avg
TLD
Dose
(mGy)

%CoV
TLD
Dose
(%)

10.13

10.0

12.53

5.0

9.78

1.8

8.96

5.6

13.05

5.6

11.37

4.7

Measured and Estimated Rectal Dose versus Effective
Diameter

Rectal Dose (mGy)

15
Pt 5

13

Rectal Dose Meas

11

SSDE

Pt 1

Pt 4

9

Anthro Phantom

7

CTDI(vol)

5

Farmer

3

CTDI(vol,c)
26

27

28

29

30
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Effective Diameter (cm)

Figure 4-5. In-vivo mean TLD rectal dose measurements (with the 95% confidence intervals)
as a function of patient effective diameter, as well as rectal dose estimates obtained from an
anthropomorphic phantom and a uniform CTDI body phantom (all doses are provided in
mGy). SSDE is the size specific dose estimate, Anthro Phantom is the anthropomorphic
phantom TLD rectal dose measurement, CTDIvol is the measured volume CTDI dose estimate
based on the x-ray tube output in VC, Farmer is the Farmer chamber measurements within
the center bore of the uniform CTDI body phantom, CTDIvol,c is the CTDI100 measurement
acquired at the center of the CTDI body phantom and corrected for pitch. The data for
Patients 1, 4, and 5 are specified for outlier analysis purposes as they represent those data
measurements that were close to, below, and above, respectively, those dose prediction
made by the SSDE technique. The faint dotted line is the regression of the anthropomorphic
phantom dose measurements (also provided in Figure 4-4).

4.4 Specific Aim 3: Compare In-Vivo Rectal Dose Measurements to Anthropomorphic
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements
from a Uniform Phantom
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4.4.1 Introduction
Once all TLD measurement results were received from the RPC and absorbed dose
measurements were calculated for every phantom configuration and patient (along with the
average rectal dose for each phantom configuration and patient) in Specific Aim 2, the
average in-vivo rectal dose measurements were compared to anthropomorphic phantom
measurements, CTDIvol-based dose estimates (including the size specific dose estimates
(SSDE)) and Farmer ionization chamber dose measurements obtained in a uniform CTDI
body phantom. Figures 4-4 and 4-5 display the measurements within the anthropomorphic
phantom at each phantom configuration and within each patient and compare these
measurements with the CTDI-based and Farmer chamber measurements. Each of these
values are additionally tabulated in Table 4-9 by phantom configuration and patient:
phantom configuration percentile (a number P0, P1, P2) or patient identifier (a number 1-6),
phantom or patient effective diameter measurements from a CT image that contained both
TLDs, the percentile of US adults aged 18-64 represented by each phantom or patient
circumference, the average phantom or patient TLD rectal dose measurements, the upper
and lower 95% confidence intervals of the average measurements (based on a t-distribution
assumption), Farmer chamber measurements in a CTDI body phantom, CTDIvol,center dose
estimates, CTDIvol dose estimates, SSDE dose estimates, and the percent differences of
each of these dose estimates from the confidence interval of the measured rectal dose
estimates. As can be seen in Figures 4-4 and 4-5 and Table 4-9, SSDE is the only
homogeneous phantom-based predictive model that varies with patient size; with the SSDE
predictions appearing to run approximately parallel with the exponential regression line for
the anthropomorphic phantom and concurrently with most of the in-vivo VC rectal dose
measurements.
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Table 4-9. Results of anthropomorphic phantom and in-vivo TLD dose measurements during
VC within 3 phantom sizes and 6 patients; where # represents the study specific phantom or
patient identification number, %ile represents the percentage of US adults aged 18-64
represented by the circumference of a specific phantom or patient, Dim is the effective
diameter of the patient at the location of the TLDs, TLD Dose is the average of the dose
measurements for a phantom configuration or patient, Low 95% CI is the lower 95%
confidence interval of the mean dose measurement, Up 95% CI is the upper 95% confidence
interval of the mean dose measurement, Farmer is the dose estimate obtained by Farmer
chamber measurement in a CTDI body phantom, Farmer % Diff is the percent difference of the
Farmer chamber measurement from the confidence interval of the mean TLD dose value,
CTDIvol,c is the (CTDI100)center measurement corrected for pitch, CTDIvol,c % Diff is the percent
difference of the CTDIvol,center measurement from the confidence interval of the mean TLD dose
value, CTDIvol is the volume CTDI measurement (accounting for the tube output experienced
by a patient in both the supine and prone scans), CTDIvol % Diff is the percent difference of
the CTDIvol measurement from the confidence interval of the mean TLD dose value, SSDE is
the size specific dose estimate, and SSDE % Diff is the percent difference of the SSDE
estimate from the confidence interval of the mean TLD dose value. If a % Diff value is not
provided (-), that value indicates that the dose estimate is within the 95% CI for the average
TLD measurement.

#

%ile

Dim
(cm)

P0
P1
P2
1
2
3
4
5
6

15
87
99
27
7
31
11
31
35

26.6
34.9
43.8
30.3
26.2
30.5
26.9
28.4
28.0

Low
95%
CI
(mGy)
8.418
5.358
3.089
9.699
12.10
9.355
8.529
12.63
10.94

TLD
Dose
(mGy)
8.804
5.743
3.475
10.13
12.53
9.784
8.958
13.05
11.37

Up
95%
CI
(mGy)
9.189
6.129
3.860
10.56
12.96
10.21
9.387
13.48
11.80

Farmer
(mGy)

CTDIvol,c
(mGy)

CTDIvol
(mGy)

SSDE
(mGy)

Farmer
% Diff
(%)

CTDIvol,c
% Diff
(%)

CTDIvol
% Diff
(%)

SSDE
% Diff
(%)

6.12
6.12
6.12
6.12
6.12
6.12
6.12
6.12
6.12

4.83
4.83
4.83
4.83
4.83
4.83
4.83
4.83
4.83

8.25
8.25
8.25
8.25
8.25
8.25
8.25
8.25
8.25

12
9
6
10
12
10
12
11
11

-27.3
58.5
-35.2
-48.3
-32.8
-26.1
-50.5
-42.8

-42.6
-9.8
25.1
-48.9
-59.2
-46.9
-41.6
-61.0
-54.8

-2.0
34.6
113.7
-12.7
-30.3
-9.4
-0.3
-33.3
-22.8

25.4
39.1
60.4
-0.4
19.8
-13.3
-

4.4.2 Percent Coefficient of Variation (%CoV)
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The percent coefficient of variation (%CoV) was calculated to be 14.2% for the invivo TLD rectal dose measurements. This between-patient %CoV value was based on the
mean TLD dose measurements of the six in-vivo patients, and was calculated to assess
whether the between-patient rectal dose %CoV was greater than 50% (as stated in the
hypothesis). The calculated %CoV value was much lower than expected, which is a
reflection of the distribution of the sizes of patients that participated in this study. As can be
seen in Figure 4-6, the distribution of patients that participated in this study was skewed
toward the smaller percentiles of US adults aged 18-64; and more Gaussian distribution of
patient sizes would likely have increased the between-patient %CoV. Therefore, the
between-patient %CoV value of rectal dose measurements would likely increase with a
larger sample population that would include patients of a larger habitus.

Number of VC Patients

Distribution of Patient Percentiles
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Percentile of US Adults Aged 18-64 (%)

Figure 4-6. Distribution of VC patient percentiles participating in this study.

4.4.3 Outlier Analysis
The results of the relative bone density quantification via Hounsfield Unit (HU)
numbers is provided in Figure 4-7. As can be seen from this figure, the anthropomorphic
phantom demonstrates considerably higher bone density than any of the patients, with
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Patients 4 and 5 demonstrating the highest relative bone density of the in-vivo
measurement patients. This was not surprising considering the age and gender of Patient
4 (23 year old male), compared to that of the other patients who underwent VC in this study
(ages ranging from 61 years to 78 years with an average age of 71.4 years among the four
females and one male remaining); but was somewhat surprising for Patient 5 (78 year old
female). It is likely that these differences in bone density impacted the in-vivo dose
measurements provided in Figure 4-5, and Figure 4-7 perhaps only partially explains the
outlier measurement point that appeared considerably lower than the rest of the in-vivo
dose measurements (Patient 4). Further explanation regarding this outlier point is provided
in Chapter 5.
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Figure 4-7. Patient and anthropomorphic phantom relative bone density quantified as the
average HU values of six femoral head region of interest HU measurements within supine VC
images. The gender of each patient is also provided.
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Figure 4-8. Average percent of pixels containing highly attenuating material as determined
from histograms of the median location of the TLDs within the rectum in supine and prone VC
scans. These measurements provided understanding regarding the effects of factors such as
amount of iodine contrast agent present, bone density, and placement of TLDs with respect
to surrounding anatomy have on in-vivo dose measurements.

Figure 4-9. Visual comparison of CT images of Patients 4 and 5 at the mean TLD location;
which represent the high and low extremes, respectively, of the amount of highly attenuating
material at the mean TLD location present among the patients enrolled in this study.
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The results of the determination of the percentage of highly attenuating material via
histogram of supine and prone images containing the median TLD placement within the
anthropomorphic phantom and each patient are provided in Figure 4-8. As can be seen
from this figure, the anthropomorphic phantom and Patient 4 demonstrate considerably
higher percentages of highly attenuating material than the rest of the patients. It can also
be observed from this figure that Patient 5 (represented by the data point that considerably
exceeded the rest of the in-vivo patient measurements) provided the lowest percentage of
highly attenuating material of any of the patients at the level of the TLDs (somewhat inferior
relative to the other patients). A visual comparison of the CT images at the average TLD
location for Patients 4 and 5, which represent the high and low extremes of amount of
highly attenuating material at the mean location of the TLDs, is provided in Figure 4-9.
Although it is observed in Figure 4-7 that this Patient 5 did not have the lowest relative bone
density, analysis of the VC scan images revealed that the TLDs were placed inferior within
the rectum compared to the other patients such that the x-rays within the primary beam
were only attenuated by the femurs and ischia (where the other patients’ TLDs received
more attenuation by the pelvis, as suggested by the higher percentages of highly
attenuating material displayed in Figures 4-8 and 4-9). It additionally appears in Figure 4-9
that the ratio of soft tissue to fat within Patient 4 was greater at the TLD level than within
Patient 5 (with soft tissue providing more beam attenuation than fat). As the
anthropomorphic phantom and Patient 4 were of similar size (26.6 cm and 26.9 cm effective
diameter, respectively) and percentage of highly attenuating material (3.06% and 3.17%,
respectively), it was not surprising that the TLD dose measurements for the
anthropomorphic phantom and Patient 4 were similar; and lower rectal doses were
measured within these two entities than in the rest of the VC patients. Further, as the xrays incident on the TLDs within Patient 5 underwent less attenuation from such highly
attenuating materials as iodine contrast and pelvic bone, higher doses were measured in
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this patient than in the rest of the VC patients. Further explanation regarding these outlier
points is provided in Chapter 5.

4.4.4 Statistical Analysis
Mean Square Error (MSE) analysis was conducted to assess the quality of the rectal
dose estimates provided by anthropomorphic phantom measurements, SSDE dose
estimates, and uniform CTDI phantom based dose estimates (including Farmer chamber
dose measurements, CTDIvol, and CTDIvol,center) to the in-vivo rectal dose measurements.
The results of this analysis are provided in Table 4-10, with the best prediction model for
each patient being highlighted. It can be seen from this table that the SSDE provided the
best fit to the in-vivo dose measurements for all patients except one (the patient that was
considerably younger than the rest of the population), where the anthropomorphic phantom
regression provided the best dose estimate for that patient. As the Farmer chamber
estimate, the CTDIvol, and the CTDIvol,center dose estimates provided models that did not
change with changing patient size, these models do not provide an adequate fit to rectal
dose data for an entire population.
Calculations were also performed to determine whether the differences between the
anthropomorphic phantom rectal dose measurements, the SSDE dose estimates, the
CTDIvol-based estimates, and the Farmer chamber measurements in a CTDI body phantom
was outside the 95% confidence interval of the in-vivo rectal dose measurements during VC
(as stated in the hypothesis). This analysis (summarized in Table 4-9) determined that the
rectal dose delivered to Patients 1, 3, and 6 during VC was predicted within the 95% CI by
the SSDE model (with a 1.4%, 1.2%, and -4.3% difference from the mean TLD dose
measurements, respectively) and not within the 95% confidence interval by any other
method. Patient 2 exceeded the 95% CI by -0.4%. The rectal dose delivered to Patient 4
during VC was predicted within the 95% CI by the anthropomorphic phantom regression
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model (2.0% from the mean TLD dose measurement), and the measured CTDIvol dose
estimate at the VC beam output was -0.3% outside the 95%CI. The rectal dose delivered
to Patient 5 was not predicted within the 95% CI by any dose estimation model, but was
most closely estimated by the SSDE model (15.1% from the CI). Discussions regarding
these results are provided in Chapter 5.

Table 4-10. Results of the mean square error (MSE) assessment of the quality of the
predictions of patient rectal dose during VC provided by the anthropomorphic phantom
measurement regression, the SSDE, and the uniform CTDI phantom-based dose estimate
models compared with the in-vivo TLD dose measurements; where SSDE is the MSE of the
size specific dose estimate model to the in-vivo dose measurements, Anth is the MSE of the
anthropomorphic phantom measurement regression to the in-vivo dose measurements,
Farmer is the MSE of the Farmer chamber measurement model to the in-vivo dose
measurements, CTDIvol,c is the MSE of the (CTDI100)center measurement model (corrected for
pitch) to the in-vivo dose measurements, CTDIvol is the MSE of the measured volume CTDI
(based on beam output during VC) dose estimate model to the in-vivo dose measurements.
The highlighted fields indicate the superior patient rectal dose prediction technique.

Patient
1
2
3
4
5
6

Farmer
2.00
3.20
1.83
1.42
3.47
2.63

Mean Square Error (MSE) (in mGy)
CTDIvol,c
CTDIvol
SSDE
2.65
0.94
0.07
3.85
2.14
0.36
2.48
0.77
0.06
2.06
0.35
1.30
4.11
2.40
1.16
3.27
1.56
0.24
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Anth
1.41
1.73
1.30
0.09
2.52
1.57

CHAPTER 5.0: DISCUSSION

5.1 Introduction
Discussion of the results from the phantom and patient virtual colonoscopy (VC)
rectal dose estimates, and the steps that led to the accomplishment of these
measurements, are within this chapter and are reported in the order presented in Chapters
3 and 4. First, in accordance with Specific Aim 1, thermoluminescent dosimeter (TLD)
linearity correction factors were established for a range of doses at 120 kVp for a multidetector computed tomography (MDCT) scanner using VC scan parameters in a 32 cm CT
dose index (CTDI) body phantom. Next, in accordance with Specific Aim 2, in-vivo rectal
dose measurements using TLDs were obtained in VC simulations within an
anthropomorphic phantom and in patients undergoing VC. Finally, in accordance with
Specific Aim 3, rectal dose measurements were compared to CTDIvol-based dose estimates
and point dose measurements obtained in a CTDI body phantom. This specific aim was
accomplished in order to test our hypotheses: in-vivo rectal dose measurements obtained
during virtual colonoscopy will have a rectal dose coefficient of variation that will be greater
than 50%; and the differences between the anthropomorphic phantom measurements, the
CTDIvol-based dose estimates, and Farmer chamber measurements in a CTDI body
phantom will be outside the 95% confidence interval of in-vivo rectal dose measurements
during VC.

5.2 Specific Aim 1: Establish TLD Linearity Correction Factors for VC Scan
Parameters on a MDCT
Specific Aim 1 was accomplished in two phases: CT beam characterization and
TLD dose correction factor determination at 120 kVp (KL,120) for the photon spectrum
produced by GE LightSpeed VCT scanners at MD Anderson Cancer Center. The beam
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characterization phase was accomplished in order to assess the reproducibility of this
technique of determining the TLD KL,120 values as time progressed (i.e. as the performance
of the x-ray tube changed with time), to assess consistency of beam output on several
MDCT scanners that may be used for VC, to help explain potential variations in TLD
response, to assess potential effects of KL,120 values in the event of a change in the x-ray
tube as a part of scanner maintenance, and to better characterize the equivalent source
model output for future Monte Carlo rectal dose calculations (60). The KL,120 value
determination phase was necessary because neither the dose linearity correction factor nor
the energy correction factor were established by the Radiologic Physics Center (RPC)
(Houston, TX) for the dose and energy ranges encountered during VC; and these data
values could not reasonably be extrapolated from the correction factors established by the
RPC due to the well-documented potential for non-linear response of TLD-100 material in
this dose and energy range (25, 26, 28, 31).

5.2.1 MDCT Beam Characterization
As stated in Chapters 3 and 4, the beam quality measurements obtained within the
first phase of Specific Aim 1 included: the half-value layer (HVL), quarter-value layer
(QVL), CTDI in-air measured with a 100 mm pencil chamber ((CTDI100)air), weighted CTDI
(CTDIw), and volume CTDI (CTDIvol) for the MD Anderson Cancer Center VC technique on
the institution’s “CT9” GE LightSpeed VCT scanner. HVL and QVL measurements were
also obtained upon the completion of the in-vivo measurements on “CT5”, “CT9”, and
“CT12” scanners. As the x-ray tube was not replaced on any of the scanners until the
completion of all in-vivo dose measurments, the value of these beam quality measurements
were perhaps somewhat reduced. Reevaluation of HVL and QVL values with the replaced
x-ray tube was conducted to investigate the differences between the hardness produced by
a new x-ray tube and one at the end of its lifespan. The value of the beam output
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measurements was increased in this study in the fact that the variability observed in the
TLD measurements (and accordingly the KL,120 values) was correctly assigned to the TLD
process and not to the MDCT scanner output as the MDCT precision was characterized
with these beam quality measurements. Additional value will result from these
measurements if they are applied to the characterization of an equivalent source model in
future Monte Carlo simulation. Ultimately, it was better to have an abundance of
measurements that were not used than to desire such measurements retrospectively.

5.2.1.1 HVL and QVL Measurement
As mentioned in Chapter 4, the HVL and QVL measurements demonstrated good
precision with all exposure measurements at a specific filtration on a specific day, with a
percent coefficient of variation (%CoV) less than 0.1% being achieved. The HVL
measurements between the three dates (approximately five months apart) and in the three
MDCT scanners (with a total of four x-ray tubes) demonstrated a %CoV of 0.73% from one
another, which was within the range of HVL measurement precision values for GE VCT
scanners published by Mathieu et al (103) (0.20%-2.19% %CoV, with a mean of 0.42% for
quarterly between-run precision measurements). Further, the QVL measurements between
the two dates demonstrated a %CoV of 0.62% from one another, which was slightly greater
than the range of QVL measurement precision values for GE VCT scanners published by
Mathieu (103) (0.11%-0.50% %CoV, with a mean of 0.43% for quarterly between-run
precision measurements).
During acceptance testing of the “CT9” MDCT scanner at MD Anderson Cancer
Center in August 2008, the measured HVL with the large body bow-tie filter was 7.96 mm
Al. The 2% difference observed between our HVL measurements and this measurement
may be the result of differences in the methods used to obtain the HVL measuremetns, may
be caused by inherent uncertainties in the measurement of the filtration thickness (using
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several measurements with electronic calipers compared to the nominal thickness), or even
of the ionization chamber measurements themselves (with a published uncertainty of ±4%
after temperature and pressure condition corrections have been applied when using Co-60
as the calibration source). No standards currently exist stating an amount of allowable
change in HVL measurements a tube may experience before requiring replacement. These
results suggest that the effect of these observed differences in x-ray tube output between
the respective dates and MDCT scanners likely had a minimal impact on the calculated
TLD KL,120 values or on the rectal dose measurements acquired during VC; and any
variation observed in measured TLD dose between the MDCT scanner utilized in the VC
scan, or between the phantom configuration and patients of equivalent size, are likely the
result of uncertainties inherent within the TLDs’ ability to measure dose at diagnostic-level
doses and energies.

5.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination
The exposure measurements used to calculate respective (CTDI100)air values on the
two dates the KL,120 values were determined (approximately 3 months apart) demonstrated
a %CoV ranging from 0.00-0.20% from one another with a mean %CoV of 0.06%. This
range of precision values for GE VCT scanners was slightly greater than that published by
Mathieu et al (103) (0.04%-0.11% %CoV, with a mean of 0.05% for within-run precision
measurements obtained within seconds of one another). As stated in Chapter 4, the results
of the (CTDI100)air measurements also demonstrated very good agreement between
respective (CTDI100)air measurements, with a %CoV of 0.08% between the (CTDI100)air
measurements taken approximately 3 months apart. This precision was less than the
quarterly between-run range of precision values for GE VCT scanners published by
Mathieu (103) (a range of 0.47%-1.04% %CoV, with a mean of 0.58%).
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The need to acquire (CTDI100)air measurements in order to verify the linearity of the
MDCT scanner dose output with mAs became obvious retrospectively after the first
scanning session designed to establish KL,120 values. Ideally, this linearity would have been
established during both irradiation sessions for the entire dose range in which the KL,120
values were determined, but this was not accomplished. We are confident, however, that
the x-ray tube output was linear during both irradiation sessions because of the welldocumented linear relationship between dose and mAs (37) and the good precision
between the irradiation sessions. Although these (CTDI100)air measurements established
that the beam dose output was linear with mAs, the regression equation correlating the two
entities for (CTDI100)air was not used to extrapolate the doses used to determine the KL,120
values at 20 and 30 mAs. Rather, the linearity of the Farmer chamber measurements in the
CTDI body phantom with mAs were used to extrapolate these lowest doses using the linear
regression shown in Equation 5-1; where FarmerDose is the extrapolated point dose
estimated in the center of the CTDI body phantom (in mGy), and mAs is the scan technique
used.

FarmerDose = 0.0578 ⋅ mAs − 0.5912

(5-1)

As stated in Chapter 4, the results of the CTDI100 measurements within the CTDI
body phantom also demonstrated good precision, with the %CoV ranging from 0.04-1.96%.
Further, the %CoV of the CTDIw values measured approximately three months from one
another was 1.31%, which was within the range published by Mathieu (103) (a range of
0.61%-1.84% %CoV, with a mean of 0.84%). Good agreement was also observed between
the respective CTDIw and CTDIvol measurements. The measured CTDIvol values
corresponded well with the CTDIvol value provided by the MDCT scanner console for this
scan technique (CTDIvol=8.26 mGy), with a total %CoV of 1.03%.
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The observed 0.5% difference between the respective (CTDI100)air measurements
and the 2% difference between the respective (CTDI100)w and (CTDI100)vol measurements
may have been the result of inherent uncertainties in the measurement device (with a
published uncertainty of ±4% after temperature and pressure condition corrections have
been applied when using Co-60 as the calibration source). These results further reinforce
the belief that the effect of these observed differences in x-ray tube output between the
respective dates likely had a minimal impact on the uncertainties observed in the calculated
TLD KL,120 values or on the TLD-measured rectal doses administered during VC, and any
such uncertainties observed in the measured TLD doses obtained within a single phantom
configuration or within patients are likely the result of uncertainties inherent within the use of
TLD-100 powder as a measurement technique at diagnostic doses and energies.

5.2.2 Determination of TLD Dose Linearity Correction Coefficients for Virtual Colonoscopy
The results of the characterization of the RPC’s B09 TLD-100 batch to diagnostic
doses at the 120 kVp spectrum administered by MD Anderson Cancer Center’s “CT9”
scanner are provided in Figure 4-2 and Figure 4-3. With the determination of Figure 4-2,
which directly converts the apparent TLD dose (uncorrected for energy or dose linearity) it
was not technically necessary to determine the KL,120 values for the dose range
encountered in VC, since KL,120 was calculated by dividing the Farmer chamber dose by the
uncorrected TLD dose. However, in keeping with the traditional method of calculating TLD
dose of multiplying the charge per mass reading by correction factors for sensitivity, fading,
dose linearity and energy, KL,120 values were determined for the dose range encountered in
VC (shown in Figure 4-3).
It appears from the direct conversion of apparent (i.e. uncorrected) TLD dose to
Farmer chamber dose displayed in Figure 4-2 that the TLD dose response at the 120 kVp
spectrum is still within the linear region of the TLD-100 material’s dose response for all
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doses administered to the TLDs above background. In fact, if the background TLD
measurements were to be omitted from the dataset, a linear regression equation is
achieved that is characterized by a goodness of fit factor of R2=0.998. This observed
linearity is consistent with published lower dose limits of linearity for TLD-100 material, with
the low-dose supralinearity region being published to approximately begin at doses less
than or equal to 1 mGy (26).
The supralinearity observed in the regression line between the lowest dose
measured by TLD and the background measurements necessitated that a non-linear
regression line be created to completely characterize the relationship between the apparent
TLD dose and the Farmer chamber measured dose. Therefore a fourth-order polynomial
was used to characterize this relationship because it was found to be the minimally ordered
regression that provided a goodness of fit factor (R2=0.999) that was greater than that of
the linear regression when the background apparent TLD doses were not considered.
Without characterizing the background apparent TLD dose, a linear regression would
certainly have been appropriate (R2=0.998).
The observed linearity of the TLD dose response is not immediately apparent,
however, by viewing the KL,120 values provided in Figure 4-3. This figure demonstrates a
third-order polynomial regression being necessary to describe the relationship between the
apparent TLD dose and KL,120 value that corrects the apparent TLD dose to the Farmer
chamber dose (with a goodness of fit factor of R2=0.992). This observed nonlinearity of the
KL,120 values is a mathematical consequence of the added complexity inherent within the
KL,120 value determination. KL,120 is calculated by dividing the Farmer chamber dose
measurement by the apparent TLD dose measurement. Establishing a regression equation
where the dependent variable (KL,120) is inherently a function of the independent variable
(apparent TLD dose) is analogous to raising the order of the regression polynomial. In
other words, if an embedded independent variable were to be removed from the dependent
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variable of a linear regression by multiplication, the result would be a second-order
polynomial regression. This mathematical reality was the reason the KL,120 values did not
display a linear trend with increasing apparent TLD dose.
Typically, under conditions where the RPC must determine the TLD dose linearity
correction factor (KL) for orthovoltage energies, they do so by first estimating the energy
correction factor (KE) based on data previously collected by the RPC that predicts
appropriate KE values based on photon beam hardness (half-value layer) and then by
irradiating the TLDs to the dose range desired with Co-60 photons to determine KL. This
published data correlating orthovoltage KE values to beam hardness describes the
relationship as a non-linear function. Based on this data, an appropriate energy correction
factor for the HVL measured in Specific Aim 1 would be approximately KE=0.7. However,
this estimate is not specific to the RPC’s B09 batch of TLD-100 material and therefore
subject to error. Since both the dose and energy dependence had not been previously
characterized for the RPC’s batch of B09 TLD-100 powder at the 120 kVp spectrum
produced by MD Anderson Cancer Center’s “CT9” scanner, it was impossible to separate
the dose linearity correction from the energy correction to determine the proximity of the
calculated energy correction to this predicted energy correction for this batch of TLD-100
powder.
Regarding the characterization of the TLD dose response at diagnostic-level energy
doses, the goodness of fit factors of R2=0.992 and 0.999 obtained for the KL,120 correction
factors and the direct conversion from apparent TLD dose to Farmer dose, respectively,
provided confidence in the ability of the TLDs to determine the rectal doses delivered by
VC. Additionally, although the TLDs perhaps introduced the primary source of error into our
rectal dose measurements, the percent coefficient of variation values were determined to
be 3.56% or less for all doses greater than background. This degree of precision provided
additional confidence in the rectal dose measurements obtained in Specific Aim 2.
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5.3 Specific Aim 2: Obtain Rectal Dose Measurements in an Anthropomorphic
Phantom and In-Vivo in Patients Undergoing VC with TLDs
Specific Aim 2 was accomplished in two phases: measurement of rectal doses in an
anthropomorphic phantom during simulated VC and in-vivo rectal dose measurements in
patients undergoing actual VC procedures. The simulations within the anthropomorphic
phantom were performed in order to provide dry runs for the in-vivo measurements (to
ensure the process was well understood before any patients were subjected to the
measurement process), to obtain additional rectal dose estimates, and to make preliminary
determination regarding the legitimacy of using an anthropomorphic phantom to estimate
patient organ dose (which is commonly done and is considered the benchmark for other
indirect dose measurement techniques such as Monte Carlo simulation). Once doses had
been measured within the anthropomorphic phantom during simulated VC and IRB
approval had been obtained from MD Anderson Cancer Center, in-vivo rectal dose
measurements were performed for 6 patients undergoing VC.

5.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic Phantom
As mentioned in Chapter 1, anthropomorphic phantoms contain many inherent
approximations; such as assuming all soft tissue organs interact with radiation in an equal
manner, using “standardized” anatomical geometry that may or may not reflect a true
patient’s anatomy, using proprietary materials that provide simulated bony tissue radiation
interactions across a wide range of ages and for multiple types of bones, etc. Therefore the
use of anthropomorphic phantoms to estimate patient doses is limited in many ways that
are not yet fully understood. Therefore, in a similar manner in which Monte Carlo
simulations are benchmarked against phantom measurements, one of the intents of this
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study was to provide a first step toward benchmarking Monte Carlo estimates and phantom
measurements against in-vivo measurements.
In order to accomplish this intent for phantoms within the parameters of this study
where internal in-vivo measurements were to be acquired during VC, the anthropomorphic
phantom had to be appropriately modified to represent patients undergoing VC. Since
patients present in a variety of sizes, and because VC at MD Anderson Cancer Center is
accomplished using a fixed technique, a patient’s girth was assumed to be the primary
determinate of the rectal dose received in VC. Therefore, efforts were made to utilize a
single anthropomorphic phantom to simulate patients of several sizes. The rectal dose
measurements obtained during the simulated VC were analyzed to ensure that the TLDs
provided adequate precision for this study such that reliable rectal dose measurements
during VC were accomplished, and a regression analysis was performed investigating the
behavior of measured rectal doses with increasing patient habitus. This model, along with
rectal dose predictions obtained from a uniform phantom, was compared to internal in-vivo
measurements in an effort to assess the legitimacy of using a phantom to estimate true
patient rectal dose during VC.

5.3.1.1 Modifications to the Anthropomorphic Phantom
The primary necessary modification to the anthropomorphic phantom was the
creation of an insufflated rectum within the phantom. Many assumptions and
approximations were requisite to determine an appropriately representative size, shape,
and location of the insufflated rectum within the phantom. The fact that each of these
approximations were based on generalizations regarding patient rectum size and shape
after gas insufflation, the bony landmarks surrounding the location of the rectal catheter,
and the focus on those patients whose size was approximately equal to that of the phantom
introduced some of the same limitations that have always plagued the use of
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anthropomorphic phantoms and therefore necessarily introduced potential rectal dose
measurement differences from those obtained within actual patients.
Confidence is gained regarding the selected size and location of the insufflated
rectum within the anthropomorphic phantom based on the population size and diverse
techniques incorporated to determine these entities. The use of anatomical measurements
from VC scans of 29 total patients when performing this analysis enabled anthropomorphic
or positional irregularities observed in one or two patients to not greatly influence decision
making (for example, a pelvis positioned in an asymmetric manner which would affect the
determination of the location of the TLDs with respect to the body landmarks). Further, due
to the fact that two separate methods were incorporated to determine the size and location
of the insufflated rectum with respect to the surrounding bony landmarks, and that each of
the two methods provided similar results, we are confident that the approximations made in
creating the insufflated rectum within the phantom were appropriate for simulated VC at MD
Anderson Cancer Center.
The decision to cut a 6.4 cm diameter bore into one section of this pricy phantom
was not made lightly, and only done with the stipulation that efforts be made to salvage as
much of the removed material as possible to plug the bore when not being used in
simulated VC. The use of “solid water” plastic material to supplement the plastic plug
where phantom material was unavoidably lost in the cutting process proved to be a good
approximation to the proprietary soft-tissue equivalent material. CT scans of the phantom
with the solid water/phantom plug in-place revealed that the solid water was sufficiently
equivalent to the surrounding phantom material that no discernable difference in contrast
was observed at any window width or level setting (see Figure 5-1). A comparison analysis
of HU values between the solid water and the surrounding phantom material was not
possible, however, because the thin size of the solid water material would not permit the
creation of a sufficiently large ROI to attain stable consecutive HU measurements.
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Figure 5-1. Visual comparison between ATOM phantom image without and with the rectal
plug (including the solid water) in place, respectively.

As a preliminary assessment of the ability of the ATOM phantom to adequately
represent a patient undergoing VC at MD Anderson Cancer Center, five ROI
measurements of rectal tissues imaged in supine VC scans of 3 true MD Anderson Cancer
Center patients (of approximately equal size to the ATOM phantom and who were chosen
at random) yielded an average of 27.09 HU. Similarly, ATOM phantom soft tissue ROI
measurements during simulated VC yielded an average measurement of 26.53 HU. This
2.06% difference in HU values represented a difference in linear attenuation coefficient of
0.05% between the actual VC patient rectal tissue and the phantom simulated soft tissue.
Therefore, based on these measurements, the ATOM phantom appeared to provide an
appropriate substitute for patient rectal tissue using the VC imaging technique.
An additional modification made to the anthropomorphic phantom involved the lowdensity Styrofoam plug that was inserted into the phantom to represent the carbon dioxide
gas within the insufflated rectum while appropriately positioning the rectal catheter away
from the posterior rectal wall. Although the location of the rectal catheter within the
insufflated rectum was not consistent among the 29 patient VC scans analyzed, none of the
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patients demonstrated rectal catheter placement against the posterior portion of the rectal
wall. The simulated VC scans of the anthropomorphic phantom with the low-density
Styrofoam plug inserted into the simulated rectum provided an average measurement of
-931.66 HUs from five averaged ROIs within the insufflated rectum. This value compares
well to true carbon dioxide ROI measurements obtained within insufflated rectums of 3
patients receiving VC scans at MD Anderson Cancer Center who were of approximately
equal size to the ATOM phantom and who were chosen at random. The average of these
measurements was -947.60 HU, which was only 1.68% larger than the HU value provided
by the low-density Styrofoam plug. Therefore it was determined that the choice of the lowdensity Styrofoam plug to support the rectal catheter appeared to be a good choice of
materials that only minimally attenuated the photons that were measured by the TLDs
within the simulated rectum.
In order to use the ATOM phantom to obtain rectal dose estimates for patients of
several sizes, fat substitutes were wrapped around the phantom in a manner that was
consistent with population anthropomorphic data. The fat materials used included porcine
adipose material (lard) and a simulated phantom fat kit manufactured by CIRS. The use of
lard as a fat substitute during diagnostic imaging procedures was not a new scientific
development (104-106). Many studies have been published that incorporated the use of
lard in dual energy x-ray absorbtiometry (DEXA) (107-117), ultrasound (118, 119) and in
magnetic resonance imaging (MRI) (120-123). A literature review did not, however, reveal
any previous research using this material for CT scans for the estimation of patient dose.
Therefore, in addition to patient rectal dose measurements, a preliminary assessment of the
use of lard as a low-cost scatter mechanism in anthropomorphic phantom VC dosimetry
studies was conducted. Due to the novel nature of this approach, this material was only
used as a scatter medium and did not attenuate the direct beam that was measured by the
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TLDs. Therefore, speculation can be made that the use of lard in this study contributed to
perhaps only 5% of each TLD reading.
An analysis of the scans that resulted from the simulated VC studies demonstrated
that the lard provided photon attenuation that was similar to that of patient adipose tissue
under VC conditions. Averaging five ROI measurements from the anthropomorphic
phantom undergoing VC and 3 randomly selected patient VC scans at MD Anderson
Cancer Center of similar size to the ATOM phantom yielded: a lard average measurement
of -156.97 HU, a CIRS manufactured simulated phantom fat measurement of -79.54 HUs,
and a true patient adipose tissue average measurement of -112.06 HUs. While these
average ROI measurements yielded a 40.08% difference in HU number between the lard
and the VC patient adipose tissue and a 29.02% difference in HU number between the
CIRS phantom fat and the VC patient adipose tissue, the measured difference in HU
numbers translated into a 5.06% difference between the linear attenuation coefficients of
the lard and the patient adipose tissue, and a 3.66% difference between the CIRS phantom
fat and the patient adipose tissue linear attenuation coefficients. This 3.66% difference
between the CIRS fat and patient fat exceeded the 1% difference in tissue equivalence
published by CIRS (83) for all diagnostic and therapeutic doses and energies.
These measurements suggest that the lard and the CIRS phantom fat provided
similar deviations in linear attenuation coefficient from actual patient adipose tissue during
VC. This fact, along with the simple advantage in cost that lard has over the CIRS phantom
fat (around $1 per lb of lard versus several thousand dollars for the CIRS simulated
phantom fat system), suggest that lard could perhaps prove to be a reasonable substitute
for patient fat in anthropomorphic phantom VC dosimetry studies. It should be stated,
however, that the packaging and use of lard as a scatter medium was a labor intensive
process. The value provided by the CIRS simulated fat material over lard was most
apparent in the ease of use of the material (especially compared to the difficulties
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encountered with the phantom set-up and packaging of the lard), the ability of the simulated
fat material to support the weight of the phantom (where the lard was pushed laterally by
the weight of the phantom), and the uniform coverage of the phantom fat material around
the circumference of the phantom provided by the structure of the gelatinous phantom
material and tapered design of the phantom fat. In contrast, the adjoining bags of lard were
abutted by duct tape and included air gaps at the juncture. This design flaw of the lard
system could be overcome with additional design efforts (such as tapering the lard within
the bags and overlapping such bags when assembling them onto the phantom).

5.3.1.2 Anthropomorphic Phantom Assembly
During simulated VC with the anthropomorphic phantom, the most difficult and time
consuming portion of the phantom irradiation process was the phantom set-up and teardown between consecutive measurements at a single phantom habitus. The most
complicated portion of this endeavor was aligning the respective sections of the phantom to
one another. This process was made difficult by the design flaws inherent within the bags
of lard as the semi-solid substance was forced laterally within the bags by the weight of the
phantom. In order to adjoin the respective phantom portions as accurately as possible to
create a uniform phantom scatter medium), supporting towels were frequently inserted
between the table and the bags of lard; most notably in the lumbar and cervical areas of the
phantom. Although the use of these towels slightly redistributed the lard within the bags, it
is unlikely this redistribution had a significant effect on the measured rectal doses; also, the
proper alignment of the respective ATOM phantom sections was considered a higher
priority than ideal lard distribution.
Two additional approximations to true patient anatomy that were made regarding
the ATOM phantom involved the phantom head and the phantom legs. The phantom head
was not used during these simulated VC scans because this structure was difficult to
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support (especially at the larger phantom sizes). It was believed that the phantom head
would only minimally contribute to the scatter dose administered to the rectum, and
therefore it is unlikely that the omission of this portion of the phantom had a significant
impact on the doses measured by the TLDs within the rectum.
Regarding the legs of the anthropomorphic phantom, true ATOM phantom legs were
not available for this study. Therefore this scatter medium was approximated by the use of
two additional phantoms: an anthropomorphic torso phantom, and a CTDI body phantom.
In order to achieve the best possible continuity in scatter material between the ATOM pelvis
and the simulated legs in the 15th percentile configuration, the CTDI body phantom was
abutted to the ATOM phantom and the anthropomorphic abdomen/pelvis phantom was
placed inferior to the CTDI body phantom. This order of was reversed, however, when the
layers of fat were applied such that the CTDI body phantom was placed inferior to the
anthropomorphic abdomen/pelvis phantom. This change was made because the bags that
were filled with lard were not large enough to wrap around the CTDI body phantom and
because the anthropomorphic pelvis phantom could be elevated with towels to mate
appropriately with the ATOM phantom pelvis once the bags of lard were wrapped around
the simulated legs. As with the head of the ATOM phantom, it is believed that the specific
geometry of the simulated phantom legs had a minimal impact on the rectal doses
measured by the TLDs since they were not subjected to the primary beam at any time
during the simulated VC (and they therefore acted solely as a scatter medium).

5.3.1.3 Phantom Measurements and Determination of Population Percentiles Represented
The determination of the percentile of US adults aged 18-64 represented by a
phantom configuration was based on circumference measurements of the phantom and the
population percentile data available in PeopleSize 2008 Pro software. The population of
US adults considered in this study was limited to those between 18-64 years of age
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because this demographic represented the population data that was most available within
the software, and it represented a reasonable approximation to the actual population that
receives VC at MD Anderson Cancer Center (which includes those older than 64 years of
age). Additionally, the demographic used in this study was not a default population
available in PeopleSize 2008 Pro software. This population was manually defined as 49%
of US males aged 18-64 and 51% of US females aged 18-64, with a “mixed adults”
correlation table. These manually defined settings were previously used in other studies
assessing US adult sizes (124).
Circumference measurements were perhaps not the ideal technique to use for the
determination of the population of US Adults represented by a phantom configuration, but it
provided the best option available. Lateral and anterior-posterior (AP) dimensions are
highly susceptible to shifts (especially in patients with a higher percentage of body fat)
when a patient is lying down (e.g. while undergoing VC) versus when the patient is standing
up (which was the posture for which data was available in PeopleSize 2008 Pro software).
Realistically, circumference measurements are also subject to redistribution based on a
patient’s posture (with dimensions shifting in a direction parallel to the CT scan table for
patients with a higher body fat percentage); but of the options available, circumference
presented the option with the least variation between the two postures and was therefore
utilized in this study. Such potential redistribution in body fat based on position may have
impacted this study’s regression analysis between measured rectal dose and effective
diameter (especially if patients were to present in this study with larger habitus), but it is
believed that any such impact was minimal and would be observed on a patient-by-patient
basis (as no two people truly have the exact same body measurements and fat distribution).
A limitation of the data contained in PeopleSize 2008 Pro software is the lack of
specific anatomical locations (i.e. anatomical landmarks) to which specific anthropometric
measurements apply. While the user interface of the software provided helpful clues, more
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specific anatomical landmarks would have made the measurement process more accurate.
As stated above, though, due to the fact that no two people yield exactly identical
anthropometric measurements at every anatomical location, this lack of specific information
likely had a minimal effect on the rectal dose to effective diameter regression analyses
contained within this study. These limitations likely had an impact, however, on the
population percentiles provided for each patient participating in this study as there
appeared to be some discrepancies between effective dose and percentiles for several
patients in Table 4-8.
Although PeopleSize 2008 Pro software did not provide specific anatomical
landmarks on which measurements should be based, the software did provide
anthropometric measurement data resolution to the millimeter. This number of significant
figures did not, however, improve the accuracy of the anthropometric measurements of the
phantom; especially with regard to the measurements that encompassed the bagged lard.
Although considerable efforts were undertaken to ensure that the lard within the bags was
correctly distributed to match the distribution within a theoretical patient characterized by a
percentile of US adults aged 18-64 (for example, ensuring that the thickness of the lard in
the abdominal portion of the 87th percentile phantom configuration was 45 mm and was 34
mm at the armpits), it was ultimately unfeasible to go to the lengths necessary to ensure
these exact measurements were obtained. Therefore, a ruler was simply used to obtain
several measurements at each end of a bag to approximate that the lard was distributed in
an appropriate manner. These measurements were complicated when the bags of lard
were attached to the phantom during the simulated VC procedures as the weight of the
phantom and the wrapping of the bags around the phantom unavoidably forced a lateral
redistribution of the semi-solid lard within the bags. Although some of this fat redistribution
realistically represented observed fat movement within patients when in a prone or supine
position, obtaining and maintaining circumference measurements to the millimeter was
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unfeasible in this study. Due to these factors in the lard redistribution, and due to the fact
that a phantom population percentile was determined by averaging the circumference
measurements at several anatomical locations, the population percentiles represented by
each phantom configuration were susceptible to some error.

5.3.1.4 Virtual Colonoscopy Simulation in an Anthropomorphic Phantom
Besides the approximations inherent within the anthropomorphic phantom and
within the population percentile represented by a phantom habitus configuration, an
approximation to a true VC scan was made in the simulated VC in that two supine scans
were performed on the anthropomorphic phantom (as opposed to a prone and a supine
scan). This modification to actual VC procedure was utilized to minimize the difficulties
associated with phantom set-up. Performing two supine CT scans was believed to be a
reasonable approximation to a true VC exam where a prone and a supine scan are
performed, but it also introduced opportunities for discrepancies between anthropomorphic
phantom measurements and in-vivo measurements. Any discrepancies caused by this
deviation from true VC protocol are believed to be minimal.

5.3.1.5 Simulated Virtual Colonoscopy Data Analysis
The trend of increasing %CoV observed in the phantom measurements with
decreasing dose was also observed in Specific Aim 1 when the TLD dose and energy
response was characterized. With the %CoV reaching 4.33% for the 99th percentile
phantom configuration (likely the largest size of patient to undergo a VC), it was determined
that TLD-100 material displays adequate precision to measure rectal doses during VC at
MD Anderson Cancer Center. Additionally, a trend of patient CT dose decreasing in an
exponential manner with an increase in patient size had been previously reported in other
studies (101, 102). This trend was observed in our TLD dose measurements within the
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anthropomorphic phantom and the calculated goodness of fit factor of R2=0.993 of the
exponential regression between the phantom effective diameter and the measured dose
supported this finding.
The 95% confidence intervals (CI) for the mean phantom TLD measurements
obtained at each patient size are admittedly difficult to observe in Figure 4-4. Although not
displayed in Figure 4-4, a few measured dose values lied outside the 95% CI at each
phantom effective diameter. This was likely due to the fact that the CIs displayed in Figure
4-4 were calculated based on a t-distribution. With only 12 data points available for each
phantom habitus, it was very difficult to determine the distribution that was appropriate to
model this data. Therefore, although some data lied outside this confidence interval range,
it is unclear whether this data should (in reality) be considered outside the 95% confidence
interval of the data.
The 95% CIs for the exponential regression equation modeling the measured rectal
doses to the phantom effective diameter are admittedly large. Based on these confidence
intervals, two patients’ effective diameter could differ by up to 5 cm and still predict the
same TLD dose within the 95% confidence interval. This large confidence interval was
attributed to the fact that TLD measurements were only obtained at three effective
diameters. If this analysis were expanded to include additional effective diameters, the
coefficients within the exponential regression equation would likely experience small
changes and the confidence intervals would likely narrow considerably toward the
regression line.
The uniform phantom-based dose predictors were included in Figures 4-4 and 4-5
for illustrative purposes. With the data presented in this manner, the reader can easily see
that all of the dose predictors, except the size specific dose estimate (SSDE), provided
equal dose estimates regardless of the size of the patient; with the SSDE dose prediction
being approximately parallel with the rectal dose regression developed by the TLD
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measurements in the anthropomorphic phantom. Obviously, the dose estimates that do not
change with patient size are not reliable prediction models of patient rectal dose as such
models only predict patient dose for those patients of one size. The reason the SSDE dose
prediction and the anthropomorphic phantom TLD measurements were not equal (and did
not overlap) was believed to be due to the fact that the SSDE is based on an average dose
distributed throughout the phantom (via the CTDIw component contained within SSDE) and
the TLD measurements were point dose measurements obtained in a position slightly
posterior to the center of a phantom. Therefore, because the dose within a phantom was
higher at the phantom’s surface than at the phantom’s center, and since such higher dose
measurements were included in the SSDE calculations and not in the TLD measurements,
SSDE values should always be higher than dose measurements obtained near the center
of a phantom.
For larger, more superficial organs in an anthropomorphic phantom that are
completely within a scan volume, SSDE may be able to provide a reasonable first
approximation to the dose administered to that phantom’s organ. However, specific organ
dose measurements would be required to verify this hypothesis. For organs not entirely
within a CT scan volume or organs irradiated using dose modulation techniques (such as
Smart mAs or automatic exposure control (AEC)), SSDE would not likely provide even
reasonable first approximation estimates of the dose to that organ in an anthropomorphic
phantom. In spite of these limitations, SSDE provides a useful adaptation to CTDIvol that
accounts for patients of various sizes and provides general patient dose estimates within
10-20% of actual doses (101), and may even provide good approximations of dose
administered to a point in the superior portion of the rectum within a typical VC patient.

5.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy
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The second phase of Specific Aim 2 included internal in-vivo rectal dose
measurements in 6 patients undergoing VC at MD Anderson Cancer Center. Based on
several literature reviews, it was believed that in-vivo dose measurements had never been
performed inside patients undergoing virtual colonoscopy or even when undergoing MDCT
scans in general. As such, significant efforts were made to define the scope of the project
and to obtain IRB approval at MD Anderson Cancer Center. This approval was granted
after the Food and Drug Adminstration (FDA) (Silver Spring, MD) determined that the study
posed a non-significant risk to patients. One of the desired outcomes associated with this
study is that more in-vivo CT dosimetric studies will be conducted in the future, not only
within the rectum but also within other anatomical locations. Such studies would be
important to validate patient or organ dose estimates produced by indirect means such as
within phantoms, by Monte Carlo simulations, or by cadaveric studies.

5.3.2.1 Maintenance of Control of TLDs during VC Procedure
No TLDs became dislodged from the rectal catheter while performing in-vivo
measurements during VC procedures. This TLD security was attributed to the fact that the
TLDs were attached to the rectal catheter by both silicone glue and suture. Disinfection of
the rectal catheter with 70% isopropyl alcohol may have negatively impacted the strength of
the silicone glue. Although no substance is known to completely dissolve silicone glue,
isopropyl alcohol is known to infiltrate the cells of silicone glue and expand them (rendering
the bonds weaker). It is for this reason that the manufacturers of silicone glue recommend
isopropyl alcohol when trying to remove the glue from surfaces. Therefore, incorporating
the additional security of the suture provided sufficient adherence of the TLDs to the rectal
catheters.

5.3.2.2 Patient Rectal Dose Determination
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As demonstrated in Figure 4-7, Patient 4 had a higher relative bone density than the
rest of patients receiving VC in this study due to the considerably younger age (and male
gender) of this patient compared to the rest of the sample population. With this relatively
high bone density, with a substantial amount of iodine contrast in the rectum, and with the
TLDs located sufficiently superior within the rectum such that the primary x-ray beam was
attenuated by the pelvis (as demonstrated in Figures 4-8 and 4-9), the measured readings
and the 95% CI were lower than those of the rest of the patients. Conversely, although
Patient 5 measured at a relatively high bone density as shown in Figure 4-7, the TLDs were
placed more inferior within the rectum than in the rest of the patients such that the primary
beam was not highly attenuated by the pelvis; but rather by the femurs and the ischia. This
explains the low percentage of highly attenuating material in the axial plane of the TLDs
observed in Figures 4-8 and 4-9. Since such relatively low amounts of highly attenuating
material interacted with the primary beam on its path to the TLDs, the measured doses in
this patient were understandably higher than in the rest of the study population.
Patient 4 had an effective diameter within 1% of that of the anthropomorphic
phantom, at a comparable percentage of highly attenuating material in the images
containing the median TLD location, and at similar measured rectal doses (within 1.7% of
one another). Although it cannot be proven with just one young male patient with a
seemingly typical amount of relative bone density, these in-vivo measurements suggest that
x-ray attenuation in younger and relatively healthy adult populations are correctly
represented by the ATOM anthropomorphic phantom; and conversely it may be implied that
the ATOM phantom under-predicts doses in older patients with lower bone density. More
patients would be required to definitively support these conclusions, however. It is
noteworthy to mention that such younger and relatively healthy adult populations are not
those typically receiving VCs, or even CT exams in general.
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Although other studies (101, 102) (as well as the anthropomorphic phantom
measurements in this study) predict a regression of patient CT dose decreasing
exponentially with increasing effective diameter, the outliers within our in-vivo dose
measurement results (Patients 4 and 5) rendered the calculation of any such regression a
statistical problem for the in-vivo measurements (since the outliers account for 1/3rd of the
total number of patients). Even though the driving factors behind these outlying
measurements were believed to be known, it would take many more patients and perhaps
even a mixed effects statistical model to create a regression of sufficient complexity to
account for these factors and accurately predict patient rectal doses. Such endeavors
would be important to undertake if adequate dose prediction models are to be developed.
It was observed in Chapter 5.3.1.5 that the simulated VC procedure within the
anthropomorphic phantom provided rectal dose measurements that were considerably
lower than those of the SSDE dose estimate. Although the two dose models decrease with
increasing patient effective diameter in a nearly parallel nature, as stated above the
differences between these dose models lies in the fact that SSDE is based on a weighted
average dose throughout a phantom and the anthropomorphic phantom is solely based on
point dose measurements in the approximate center of the phantom. It was interesting to
observe that the higher rectal doses measured in the typical VC patients (due to a lack of
relative bone density compared to the younger Patient 4 and the anthropomorphic
phantom) almost exactly coincided with those higher dose estimates provided by the SSDE
model. This coincidence is quantified by the mean square error analysis (MSE) provided in
Table 4-10 that demonstrated that the SSDE model provided the best rectal dose estimate
for 5 of 6 patients. Although the overlap of the values predicted in these models is
somewhat coincidental, it appears that when assessing dose to the superior portion of the
rectum in patients of approximately average bone density for the typical VC patient, SSDE
provided dose estimates in this study within ±5% of actual measured rectal doses.
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A close look at Table 4-9, in which in-vivo rectal dose measurements are compared
to phantom dose estimates, may suggest some inconsistencies between the listed effective
diameters and the provided percentiles of US adults aged 18-64 represented by each
patient (as stated above in Chapter 5.3.1.3). One possible source for these apparent
discrepancies is the fact that the percentiles were based on circumference measurements,
where effective diameter (calculated by obtaining the square root of the product of the AP
and lateral dimensions) was not. Secondarily, while the PeopleSize software does provide
a simple interface, it does not provide highly descriptive landmarks upon which
anthropometric measurements should be based. The dimension within this software used
to quantify the population percentile was described as “hip circumference, around buttocks”.
It is possible that the circumference measurements acquired in this study do not completely
reflect the anatomy intended in the PeopleSize software, and therefore some opportunity
existed for error in the population percentiles provided in Tables 4-6, 4-8, and 4-9.
Additionally, the observed shifts in patient habitus mentioned in Chapter 3 yielded
effective diameter measurements that were perhaps artificially inflated compared with
analogous measurements performed on the uniform phantom and compared to the
population percentiles provided. This suspicion of inflated effective diameters could
perhaps also partially explain the apparent mismatch between patient effective diameters
and population percentiles provided in Table 4-9. While it was expected that a patient’s
adipose tissue would distribute laterally as they lay either prone or supine on the CT
scanner table, the manner of this adipose tissue redistribution observed in patients provided
a different shape than that of the anthropomorphic phantom; with the actual patients’ MDCT
images yielding non-uniform lateral protrusions (where the phantom remained
approximately oval shaped). Figure 5-2 displays a comparison of the distribution of the
body mass during a simulated VC within the anthropomorphic phantom and in an actual VC
within a patient.
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A)

B)
Lateral protrusions perhaps inflating
effective diameter measurements

Figure 5-2. Visual comparison between A) non-uniform lateral adipose tissue distribution in
patients, and B) anthropomorphic phantom.

In order to be consistent across all patients when performing patient size
measurements, the lateral diameter measurements that were acquired to determine a
patient’s effective diameter were obtained at the maximum lateral distance; even when
these protrusions were observed laterally. Therefore, the lateral diameter measurements
obtained in this study were not indicative of an average lateral distance, but rather of the
maximum lateral distance. Thus, it was possible that effective diameters assigned to those
patients displaying this non-uniform distribution of adipose tissue were biased larger than
appropriate; and such measurements provided an additional opportunity for disagreement
between the data sets. It is possible that circumference measurements would have
provided a better assessment of patient size than effective diameter in such cases when
comparing anthropomorphic phantom measurement data to in-vivo patient data; however
circumference is not readily assessed on CT scanners, and many interfaces to not offer
tools to perform these measurements. Ultimately, effective diameter measurements were
selected due to their utility in AAPM Report 204 (101), which describes SSDE as a function
of effective diameter.
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In order to accurately assess the dose delivered to the rectum as a result of the CT
scans enlisted in the VC procedure, it was important to quantify the contribution to the TLD
measured doses from the survey (aka scout) scans. Each patient, before undergoing both
the supine and prone scan, received 2-3 scout scans (in both the PA and lateral directions)
in order to ensure that the patient was appropriately positioned and that the CT scan
covered all of the necessary anatomy. The results of the scout scan dose estimates are
provided in Tables 4-7 and 4-8. While these administered doses were low (estimated to be
between 0.140-0.277 mGy or 1.4-2.2% of the total VC rectal dose measurement), they
introduced an opportunity for disagreement from the TLD measurements performed within
the anthropomorphic phantom (which was not subjected to scout scans). These estimated
scout doses were subtracted from the reported CT scan doses as shown in Figure 4-5 and
Table 4-8, but as these doses are only estimates some disagreement may have been
introduced between the anthropomorphic phantom and between the in-vivo measurements.
An exact comparison between the estimated scout scan entrance exposures
calculated in this study and those results published by O’Daniel (15) is not possible; as
O’Daniel did not provide entrance exposures for a GE VCT scanner (64 channels and a 40
mm beam), for 90° (lateral) scouts, for a tube current of 80 mA, or at an equivalent
exposure measurement location (a VC patient thickness of 21.6 cm versus 22.5 cm
thickness in O’Daniel). The closest comparison with data published in this paper would be
based on a GE LightSpeed scanner (16 channels), at 10 mA and only for a 180° (PA)
scout. Under these conditions, O’Daniel published an entrance skin exposure of 24.4 mR,
while this study estimated an entrance exposure for a 180° scout at 10 mA to be 15.7 mR.
It should also be noted that the prone scout scans contributed considerably more
dose to patients than the supine scout scans. This was due an oversight in the pre-set
scanner settings that resulted in the prone scout scans being acquired at 80 mA compared
to the 10 mA tube current used for the supine scout scans. While the scout image quality
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was perhaps superior with the 80 mA technique, both imaging techniques provided images
that were of sufficient quality to perform the functions required of the CT scout scan.
Therefore, the prone scout technique could likely be decreased to 10 mA; which would
have decreased the average scout dose administered to patients participating in this study
by 59-85%.
Besides the dose contribution to the TLDs from the scout scans, additional
consideration was required regarding measured TLD doses exceeding the maximum dose
to which the TLD response was characterized. The initial estimates of rectal dose
administered during VC that were discussed in Chapter 1.3.5 and Chapter 3 were based on
Farmer chamber measurements as the midpoint dose, and 6 cm of acrylic material
mathematically subtracted from the radius of the CTDI body phantom as the approximate
upper dose limit and a simple estimate of 0.5 mGy as the lower dose limit. This initial rectal
dose estimate was calculated to range from 0.5 mGy to 11.2 mGy. In calibrating the TLDs
to this dose range, 0.7 mGy was administered at 20 mAs, and 10.8 mGy was administered
at 170 mAs.
After calculation of the in-vivo TLD dose measurements, it was obvious that the
doses administered at these mAs extremes did not completely encompass the range of
doses encountered in the 6 patient measurements. The maximum dose characterized in
Specific Aim 1 was 10.8 mGy (using an f-factor for dose to muscle), and 13 of 24 in-vivo
TLD measurements exceeded this value. Patient 2 represented the minimum sized patient
for which the TLD doses were measured in this study, and the maximum dose measured in
the study was that within Patient 5. Based on the dose measurements from Patient 5, it
can be estimated that the range of doses for which this batch of TLD-100 material should
have been characterized in the diagnostic dose range by actual Farmer chamber and TLD
measurement was 14.3 mGy (including the 95% confidence interval). This maximum dose,
along with the measured dose range of 9.86 mGy to 13.05 mGy, suggests that although the
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initial 11.2 mGy maximum dose estimate was not an entirely bad initial guess, the 11 mGy
to 18 mGy dose range published by DeMarco (59) (for the entire colon) was more accurate
for the rectum than initially expected. Based on the linearity of the administered doses to
increasing mAs established in Specific Aim 1 with a very high goodness of fit factor (R2),
the TLD dose response extrapolations performed in this study to determine the rectal doses
for those measurements exceeding the initial 11.2 mGy maximum rectal dose estimate
were believed to be appropriate and robust.
It was also observed when accomplishing Specific Aim 1 and when TLD
measurements were performed within the anthropomorphic phantom during simulated VC
that the %CoV of the TLD measurements at a single dose increased with decreasing
energy. This phenomena was not observed in the in-vivo measurements, however, as the
%CoV appeared to maintain a value of approximately 5% for four out of six patients. The
%CoV of these two outlier patients were 10% and 1.8% %CoV, even though the average
dose readings from these two patients were within 0.5 mGy of one another. It is not known
why the %CoV for these two patients varied from the others or each other, nor is it known
why the %CoV for the in-vivo measurements averaged approximately 5% while the %CoV
for the TLDs in the uniform phantom averaged 2% and the TLDs in the anthropometric
phantom averaged 3%. This increase in %CoV was driven by increases in the standard
deviations of the six patients compared to the phantom measurements, which was also
reflected in larger 95% CIs than those observed in the respective phantom measurements.
In spite of this decrease in %CoV and increase in CI, it is believed that the TLDs performed
with adequate measurement precision in this study to reliably measure patient rectal doses
during VC.
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5.4 Specific Aim 3: Compare In-Vivo Rectal Dose Measurements to Anthropomorphic
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements
from a Uniform Phantom
Since there are not yet many established methods to obtain organ dose
measurements during CT scans, it is important to understand the accuracy of any such
dose estimates provided by currently established methods. In an effort to preliminarily
assess the accuracy of such methods, the in-vivo TLD rectal dose measurements were
compared in Specific Aim 3 to dose estimates obtained from an anthropomorphic phantom,
and a uniform CTDI body phantom using the same CT scan technique. These CTDI body
phantom-based dose estimation techniques included: Farmer ionization chamber
measurements within a CTDI body phantom, CTDIvol measurements, (CTDI100)center
measurements corrected for pitch (assigned the nomenclature “CTDIvol,center“), and SSDE
dose estimates.
The Farmer chamber measurements used for comparison with the anthropomorphic
phantom and in-vivo TLD measurements were based on the same exposure measurements
used to determine the TLD KL,120 values in Specific Aim 1. A difference existed, however, in
the dose estimate used for comparison with anthropomorphic phantom and in-vivo
measurements and those used to establish TLD response. The difference observed
between these measurements was due to the fact that the f-factor that was multiplied by the
measured Farmer chamber exposure, with the f-factor for muscle (f=0.94 rad/R) being used
in Specific Aim 3 as opposed to the f-factor for acrylic (f=0.78 rad/R) that was used for the
determination of the TLD KL,120 values in Specific Aim 1.
It was necessary to use a common f-factor for both the apparent (uncorrected) TLD
measurements and the Farmer chamber in Specific Aim 1 such that both f-factors cancelled
out and were not erroneously factored into the KL,120 determination. Since the CTDI body
phantom is constructed of acrylic, this f-factor was utilized. However, TLD sensitivity (KS) is
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determined by the RPC in terms of absorbed dose to muscle. Therefore, in order to
correctly compare the TLD measurement results to the Farmer chamber measurement
dose estimate, the Farmer chamber exposure measurements were multiplied by the f-factor
for muscle instead of that for acrylic.
The uniform CTDI phantom-based dose estimates were not found to provide dose
estimates within 95% CI of the mean dose measurements within the anthropomorphic
phantom. There were two uniform phantom measurements, however, that provided dose
estimates with the 95% CI of the regression of the anthropomorphic phantom. Therefore,
there may be some (limited) circumstances in which uniform CTDI phantom-based dose
estimates may be useful in dose estimation.
Comparing the performance of the anthropomorphic and uniform phantom-based
dose estimates to in-vivo measurements by MSE calculations showed that the SSDE model
demonstrated the most consistent agreement to in-vivo measurements; providing the most
accurate dose estimation for five of six patients, and predictions within the 95% CI for two of
the patients. The remaining (younger) patient not conforming to the SSDE model was best
predicted by the anthropomorphic phantom regression due to the fact that this patient more
closely represented the phantom size and percentage of highly attenuating bone
composition. Surprisingly, in spite of the fact that the CTDIvol dose estimate model does not
change with changes in patient size, it did provide dose predictions for three patients with
MSE values less than 1 mGy. However, with a larger and more uniformly distributed
patient population, this percentage of relatively low MSE values will decrease because the
CTDIvol model does not change with patient size; which makes the model generally
unsuitable for dose predictions pertaining to a large population of individuals. Further, with
a larger patient population that would include a representation of larger patients, all of the
uniform dose predictions used in this study will predict doses for some range of patient
sizes (as displayed in Figure 4-4).
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Regarding our assessment of the variety of sizes of patients that undergo VC at MD
Anderson Cancer Center, the percent coefficient of variation (%CoV) of the mean patient
rectal doses was calculated to be 14.2%. This between-patient %CoV value was calculated
to assess whether the between-patient rectal dose %CoV was greater than 50% (as stated
in the hypothesis), which was an indirect assessment of the size distribution of patients
receiving VC at MD Anderson Cancer Center. As can be seen in Figure 4-6, however, the
distribution of patients that participated in this study was biased toward the smaller sizes of
US adults. Due to the small sample size of this pilot study, it is unclear at this time whether
this bias reflects a true bias in the population of adults receiving VC at MD Anderson
Cancer Center; or whether this size distribution is simply a function of the small population
of patients recruited for this study. If the size distribution of patients receiving VC at MD
Anderson Cancer Center is truly smaller than that of the actual population of US adults
aged 18-64, it could be a result of the fact that the typical patient receiving VC is greater
than 50 years of age (and obese patients are less likely to survive to more advanced ages);
or perhaps it could be a result of weight loss stemming from gastrointestinal issues that
prompted a VC procedure. It is anticipated that this between-patient %CoV of rectal dose
measurements would likely increase with a larger sample population.
The hypothesis of this study was: in-vivo rectal dose measurements obtained
during virtual colonoscopy will have a rectal dose coefficient of variation that will be greater
than 50%; and the differences between the anthropomorphic phantom dose measurements,
the CTDIvol-based dose estimates, and Farmer chamber measurements in a CTDI body
phantom will be outside the 95% confidence interval for in-vivo patient VC dosimetry
measurements. Based on the measurements obtained in this study, we have failed to
prove the hypothesis prediction that the between-patient rectal dose coefficient of variation
would exceed 50% based on our calculation yielding a coefficient of variation of 14.2%.
Also, we have failed to prove the hypothesis prediction that the differences between the
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anthropomorphic phantom dose measurements, the CTDIvol-based dose estimates, and
Farmer chamber measurements in a CTDI body phantom would be outside the 95%
confidence interval for in-vivo patient VC dosimetry measurements; as the SSDE and
anthropomorphic phantom provided rectal dose estimates within the 95% confidence
interval of mean patient dose measurements acquired in this study. Our data supports this
hypothesis prediction, however, for the uniform CTDIvol dose models, the CTDI phantombased CTDIvol,center, and Farmer chamber rectal dose estimates.

5.5 Potential Future Work
In addition to the in-vivo measurements obtained for the 6 patients in this study,
future work should concentrate on collecting in-vivo rectal dose measurements for a larger
population of patients. Doing so would allow for a determination of the true distribution of
rectal dose within a population of VC patients, which would allow for a better determination
of the 95% confidence intervals than those provided in Figures 4-4 and 4-5. Future studies
with a larger population of patients could also allow for an in-depth assessment of the
validity of the rectal dose regression models developed within this study, even in those
regression models such as the anthropomorphic phantom that were found to not predict
typical VC patient dose with a high degree of accuracy, but were suggested to predict rectal
doses in patients with higher relative bone density.
Future work related to this project should also focus on validating other indirect dose
estimates to determine their accuracy compared to these direct TLD dose measurements.
This could be accomplished by creating digital models of these same patients and
performing VCs in Monte Carlo simulation to estimate rectal dose administered during the
procedure. The groundwork to accomplish such dose comparisons has already been
created, with the x-ray beam quality being adequately determined for the set-up of a Monte
Carlo simulation equivalent source; and with 50 cm display field of view (DFOV)
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reconstructions already available for each of the VC scans conducted in this study.
Although it would be helpful in the development of such a Monte Carlo simulation
equivalent source if ionization chamber exposure measurements were available at a
modeled patient’s surface, entrance surface exposures could be estimated with ionization
chamber measurements at isocenter for the VC scan protocol by increasing the exposure
measurements based on inverse square corrections for a patient’s size; similarly to that
which was done to estimate patient dose from the scout images (15). Ultimately,
simulations could be performed based on the data already available without any such
measurements. A new IRB approval would be required, however, for such a study as the
IRB protocol for these measurements did not include exporting data to any other institutions
where such modeling capabilities exist (such as McNitt-Gray’s model at UCLA (44, 57-62,
102, 125)).
In addition to validating Monte Carlo models of dose administration, the techniques
described in this study could be used to validate other indirect dose estimation techniques,
such as other uniform or anthropomorphic phantom measurements or even cadaveric
measurements. In order to more completely understand the accuracy provided by these
(and Monte Carlo) dose estimates, however, dose measurements to additional organs
would need to be acquired. Admittedly, the opportunities to acquire such measurements
are primarily limited to those organs which contain accessible lumen structures (such as the
digestive tract, the urinary tract, and perhaps the circulatory system). Measurements in
each of these locations would present challenges and patient risks additional to those
contained within this study. If a solid in-vivo benchmark could be established for these
indirect measurement techniques, dose administered to many of the less accessible organs
during CT scans could potentially be reliably estimated through refined modeling that
considered patient size, anatomic composition and geometry, scan parameters, and other
factors that contribute to patient dose.
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Even if such models could be generated through a comprehensive series of direct
organ dose measurements, the “bottom line” of such measurements is the determination of
the risk to a patient. Ultimately, this determination may prove to be much more challenging
than acquiring organ dose measurements at several sites and developing well-refined
dosimetric understanding. A patient’s risk from radiation exposure is not simply a factor of
the dose that patient receives, but also a factor of many other factors; to include (as an
incomplete list): previous radiation exposure, tissues irradiated, genetic pre-disposition to
cancer, cancer history, stochastic events, deterministic thresholds, etc. Such a thorough
understanding of radiation biology does not currently exist to sufficiently determine the risk
to a patient from CT scans, even with more comprehensive organ dose measurements.
Therefore, while the performance of in-vivo organ dose measurements is a valuable step
toward understanding patient risk from a diagnostic CT procedure such as VC, such
measurements do not completely answer the fundamental question of patient risk.
Regarding the understanding of “ground truth” rectal organ dose from in-vivo rectal
dose measurements, in order to completely correlate the TLD rectal dose measurements to
actual patient rectal dose, consideration must be made regarding the amount of additional
dose deposited to the rectum as a result of the presence of the iodinated contrast agent.
Although the contrast agent acts as a highly attenuating material, photoelectric interactions
likely occur within this material, which could deposit dose in surrounding tissues.
Therefore, future work should also focus on modeling rectal dose as a function of the
relative concentration of contrast agent within the rectum at the time of the VC scan. No
such data is currently believed to be available; but a previous study (126) determined
through a combination of liquid scintillation measurements of dose increase at various
concentrations of iodinated contrast agent, HU measurements to determine the
concentration of iodinated contrast agent in a medium, and Monte Carlo modeling of organ
doses in an anthropomorphic phantom that dose to all five tissues analyzed increased with
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the presence of an iodine contrast agent. The amount of organ dose increase was
determined to be based on the concentration of the iodinated contrast agent present in the
organ and the specific organs subjected to radiation. The study showed that in some
tissues, when relatively high concentrations of iodinated contrast agents were present, the
dose administered to the organ by the CT scan increased by as much as 74%. Therefore,
an understanding of the dosimetric effects of the presence of the iodinated contrast agent
within the rectum must be attained to fully quantify the radiation dose administered to the
rectum during VC.
There are a few opportunities currently available to reduce the rectal dose resulting
from VC procedures. Some institutions have incorporated the use of automatic exposure
control (AEC) features such as GE’s “Smart mAs” technology to modulate the dose to an
appropriate level throughout the scan volume. Another potential method for reducing
radiation dose to a patient would be to eliminate one of the two CT scans within the VC
procedure. In order to eliminate one of the two CT scans (and still acquire a VC study of
sufficient diagnostic quality), better computer aided detection (CAD) of polyps, better
methods for insufflating the bowel, better methods for the removal of residual contrast agent
while obtaining necessary contrast distribution, and improved ways to identify and see
through fecal matter would have to be implemented. Although efforts have been applied to
address each of these limitations, additional progress must be achieved to eliminate one of
the two CT scans.
Radiation dose is eliminated completely when using optical colonoscopy (OC) or
MRI technology as opposed to CT for VC (known as MR Colonography or MRC) (127-132).
Although considered the “gold standard” by gastroenterologists, OC has many limitations;
including: a relative inability to know exactly where in the colon the endoscope is at a given
time, patient risks from sedation and bowel injury, and an insufficient number of qualified
endoscopists to meet demands (screening, diagnosis, treatment, and surveillance). A
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more wide-spread implementation of MRC could eliminate radiation dose. However, MRC
requires longer scan times, which contributes to additional patient discomfort; and is not as
widely accepted by clinicians as CT-based VC. Until acceptance for this modality increases
and more radiologists are adequately trained to read MRC studies, CT-based VC remains a
practical alternative to OC.
It theoretically may be possible to utilize the in-vivo dose measurements obtained in
this study along with histograms of the CT images containing the median TLD location
within the rectum to predict patient rectal dose. Based on a literature review, it is believed
that such a dose prediction technique has not been attempted previously. Since the HU
numbers upon which CT images are based is actually a measure of incident x-ray
attenuation compared with that of water, and since CT irradiates patients from all angles, a
histogram with a defined DFOV would provide data regarding the number and size of pixels
providing the various amounts of x-ray beam attenuation during the CT scan. Since
primary beam characteristics can be established with ionization chamber measurements at
isocenter, fundamentally all of the information required to estimate patient rectal dose may
be present. This technique would likely fail to accurately predict doses close to a patient’s
surface as these doses are known to vary with x-ray tube position.

5.6 Conclusions
A study was performed to acquire internal in-vivo measurements on patients
undergoing virtual colonoscopy (VC) at MD Anderson Cancer Center. Such a study
incorporating internal in-vivo measurements is not believed to have been performed
previously for virtual colonoscopy or for multi-detector computed tomography (MDCT)
scans in general. Such in-vivo measurements are important in order to benchmark the
current indirect methods that are standard for determining patient dose from computed
tomography (CT), including: measurements within a phantom, Monte Carlo simulation, and
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cadaveric measurements. Our desire is that this study will pave the way for future internal
in-vivo dose measurements in multiple organs to develop a better understanding of how
current indirect dose estimates compare to actual measurements.
TLD response was characterized for the Radiologic Physics Center (RPC)’s B09
batch of thermoluminescent dosimeter (TLD) TLD-100 powder at the doses and energies
encountered in VC at MD Anderson Cancer Center. Based on TLD measurements
obtained within a computed tomography dose index (CTDI) body phantom, TLD dose
linearity values were determined at 120 kVp (KL,120) with a percent coefficient of variation
(%CoV) less than 3.56% at all doses. A third-order polynomial regression with a goodness
of fit factor of R2=0.992 was constructed from this data, and this KL,120 regression model
was used to measure rectal doses administered to an anthropomorphic phantom and to
patients during VC at MD Anderson Cancer Center.
Mean rectal dose measurements of 8.8 mGy, 5.7 mGy, and 3.5 mGy were acquired,
respectively, during simulated VC (using the MD Anderson Cancer Center technique) within
an anthropomorphic phantom that was configured to represent the 15th, 87th, and 99th
percentile of US adult patients aged 18-64. The measured rectal doses decreased in an
exponential manner with increasing phantom effective diameter. As observed in the
measurements that were obtained to quantify the TLD response at diagnostic doses and
energies, the %CoV increased with decreasing dose. The %CoV for the 99th percentile
phantom configuration was calculated to be <5%, which implied that the TLDs were able to
provide rectal dose measurements with reasonable precision for nearly all patients that are
likely to undergo VC.
In-vivo rectal dose measurements were also acquired during VC using the MD
Anderson Cancer Center protocol within 6 patients. The average rectal doses measured in
the population of patients (of four TLD dose measurements per patient) ranged from 9.0 to
13.1 mGy. The measured rectal doses within a young adult male patient was favorably
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predicted by the exponential regression model developed from the anthropomorphic
phantom rectal dose measurements, while the typical VC patient population (older, mostly
female adults) was favorably predicted by the size specific dose estimate (SSDE) dose
model (as long as measurements were obtained sufficiently superior within the rectum). In
contrast to what was observed in the previous TLD measurements, the TLD response at
diagnostic doses and energies did not increase in %CoV with decreasing dose. The largest
TLD measurement %CoV from the in-vivo data was 10.0%, which implied that the TLDs
provided rectal dose measurements with reasonable precision for all patients in this study.
The between-patient percent coefficient of variation of the average TLD rectal dose
measurements for each patient was calculated to be 14.2%. We therefore failed to prove
our hypothesis that the between-patient percent coefficient of variation would exceed 50%.
Further, we have failed to prove our hypothesis that the anthropomorphic phantom and
uniform phantom-based rectal dose measurements would not provide dose estimates within
the 95% confidence interval of the mean patient dose measurements as the SSDE dose
model met this criteria for three patients and the anthropomorphic phantom met this criteria
for the young adult patient who does not represent the typical VC population. Our results
suggest that we may be able to accept our hypothesis for the CTDI volume (CTDIvol) dose
estimate, the CTDIvol dose estimate that disregarded the peripheral CTDI phantom
exposure measurements (CTDIvol,center) and the Farmer chamber dose estimates as each of
these techniques yielded doses that were outside the 95% confidence interval of the mean
for our initial patient population (n=6).
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